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Summary 
Knowledge from established therapeutic targets is expected to be invaluable goldmine for 
target discovery. To facilitate access to target information, publicly accessible databases 
have been developed. Information about the primary drug target(s) of comprehensive sets 
of approved, clinical trial, and experimental drugs is highly useful for facilitating focused 
investigation and discovery effort. However, none of those databases can accurately 
provide such data. Thus, a significant update to the Therapeutic Targets Database (TTD) 
in 2010 was conducted by expanding target data to include 348 successful, 292 clinical 
trial and 1,254 research targets, and added drug data for 1,514 approved, 1,212 clinical 
trial and 2,302 experimental drugs linked to their primary target(s). 
Comprehensive analysis on successful and clinical trial targets is able to reveal their 
common features. As found, analysis of therapeutic, biochemical, physicochemical, and 
systems features of clinical trial targets and drugs reveal areas of focuses, progresses and 
distinguished features. Many new targets, particularly G protein-coupled receptors 
(GPCRs) and kinases in the upstream signaling pathways are in advanced trial phases 
against cancer, inflammation, and nervous and circulatory systems diseases. The majority 
of the clinical trial targets show sequence and system profiles similar to successful targets, 
but fewer of them show overall sequence, structure, physicochemical, and system 
features resembling successful ones. Drugs in advanced trial phase show improved 
potency but increased lipophilicity and molecular weight with respect to approved drugs, 
and improved potency and lipophilicity but increased molecular weight compared to high 
thoughput screening (HTS) leads. These suggest a need for further improvement in drug-
like and target-like features. 
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Based on information from TTD and other sources, and statistical analysis results on 
successful and clinical trial targets, a collective approach combining 4 in silico methods 
to identify targets was proposed. These methods include (1) machine learning used for 
identifying physicochemical properties embedded in target primary structure; (2) 
sequence similarity in drug-binding domains; (3) 3-D structural fold of drug-binding 
domains; and (4) simple system level druggability rules. This combination identified 50%, 
25%, 10% and 4% of the phase III, II, I, and non-clinical targets as promising, it enriched 
phase II and III target identification rate by 4.0~6.0 fold over random selection. The 
phase III targets identified include 7 of the 8 targets with positive phase III results. 
Recent emergence of swine and avian influenza A H1N1 and H5N1 outbreaks and 
various drug-resistant influenza strains underscores the urgent need for developing new 
anti-influenza drugs. As an application, target discovery approach is used to identify 
promising targets from the genomes of influenza A (H1N1, H5N1, H2N2, H3N2, H9N2), 
B and C. The identified promising drug targets are neuraminidase of influenza A and B, 
polymerase of influenza A, B and C, and matrix protein 2 of influenza A. The identified 
marginally promising therapeutic targets are haemagglutinin of influenza A and B, and 
hemagglutinin-esterase of influenza C. The identified promising targets show fair drug 
discovery productivity level compared to a modest level for the marginally promising 
targets and low level for unpromising targets. Thus, the results are highly consistent with 
the current drug discovery productivity levels against these proteins. 
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Chapter 1 Introduction 
With the advent of post-genomic era, the pharmaceutical industry has been offered with 
unprecedented opportunities and challenges in drug, specifically target, discovery. On the 
one hand, the availability of human genome gives us chance to elucidate the genetic basis 
of human diseases by making overall evaluation on the druggability of all human proteins. 
On the other hand, huge amount of the genomic data requires the development of high-
throughput analysis tools and powerful computational capacity to facilitate data process. 
In face of these challenges, bioinformatics has evolved many techniques to accelerate the 
target discovery, which are based on the detection of sequence and functional similarity 
to established drug targets, motif-based drug-binding domain family affiliation, structural 
analysis of geometric and energetic features, and statistic machine learning approaches. 
In Chapter 1, I intend to give the audience a brief introduction to these popular methods. 
In order to make my illustration clear, this chapter has been organized into 5 sections. In 
Section 1.1, an overview of target discovery in current pharmaceutical research is given, 
which reviews current technologies for both target identification and validation. Section 
1.2 includes a retrospective review of efforts to distinguish established drug targets, and a 
comprehensive analysis of available drug targets databases. Then, a repetitively exposed 
concept–“druggable genome” is discussed in Section 1.3, together with an explanation of 
the difference between “druggable protein” and “therapeutic target”. In Section 1.4, four 
bioinformatics methods frequently used in target discovery have been demonstrated. Both 
their advantages and limitations have been introduced. Finally, the objective and outline 
of this thesis are presented in the last section of this chapter (Section 1.5). 
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1.1 Overview of target discovery in pharmaceutical research 
One of the most serious dilemmas encountered by current biopharmaceutical industry is 
that the output has not kept pace with the enormous increase in pharmaceutical R&D 
spending. As the very first step in drug development, target discovery is expected to play 
an important part in reducing cost and improving efficiency. In this part of my thesis, I 
intend to have a brief review on strategies currently employed for target discovery. After 
an overview of drug and target discovery in Section 1.1.1 and 1.1.2, I plan to introduce 
three popular techniques nowadays for identifying target in Section 1.1.3. In Section 
1.1.4, three in vivo loss-of-function target validation technologies will be further 
illustrated. Based on these reviews, we can have some general understanding on the 
current target discovery process, which will not only provide background knowledge for 
the main topic of this thesis but also give us some hints on the reasons and strategies of 
our research conducted for facilitating target discovery. 
1.1.1 Drug and target discovery 
Drug discovery is a difficult, inefficient, lengthy, and expensive process. As illustrated in 
Figure 01-1, the process of a typical drug discovery involves disease selection, target 
identification and validation, hit and lead identification, lead optimization, preclinical 
trial evaluation, and clinical trials. Once a candidate has shown its value in these tests, it 
will be approved by medical authorities, like Food and Drug Administration (FDA), and 
then proceed to manufacturing and marketing
1
. Despite advances in technology and 
accumulation of knowledge of biological systems, drug discovery is still time and money 
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consuming
2
. Currently, the research and development cost for each new molecular entity 
(NME) is approximately US$1.8 billion
3
, while the whole discovery process takes about 
10-17 years with less than 10% overall probability of success
2,4
. Figure 01-2 shows the 
number of new chemical entities (NCEs) in relation to pharmaceutical R&D spending 
since 1992
5
. Therefore, how to increase the efficiency and reduce the cost and time of 
pharmaceutical research and development is the major task of modern drug discovery. 
As the very early stage of drug discovery (Figure 01-1), selection and validation of novel 
molecular targets have become of paramount importance in light of the explosion in the 
number of new potential therapeutic targets that have emerged from human gene 
sequencing
6,7
. Thousands of molecular targets have been cloned and are available as 
potential novel drug targets for further investigation
8,9
. According to a brief search in the 
MEDLINE bibliographic database NCBI (http://www.ncbi.nlm.nih.gov/pubmed), a new 
potential therapeutic approach used for treating a known disease is proposed nearly every 
week, as a result of the exponential proliferation of novel therapeutic targets. Therefore, 
with thousands of potential targets available, target selection and validation has become 
one of the most critical components of drug discovery and will continue to be so in the 
future. In response to this revolution within the pharmaceutical industry, the development 
of high-throughput approaches for target discovery has been necessitated
10
. 
1.1.2 Knowledge of target and target discovery 
Before explaining the specific tools and technology used for facilitating modern target 
discovery, I would like to give a brief introduction first. As illustrated in Figure 01-1, the 
identification and validation of disease-causing target genes is an essential first step in 
 Chapter 1 Introduction  4 
drug discovery and development. A drug target is typically a key molecule involved in 
certain metabolic or signaling pathway specific to a disease condition or pathology, or to 
the infectivity or survival of a microbial pathogen. Drugs are designed to bind onto the 
active region and inhibit this key molecule, or to enhance normal pathway by promoting 
specific molecules that may have been affected in the diseased state. In addition, these 
drugs should also be designed in such a way as not to affect any other important “off-
target” that may be similar in appearance to the target molecule, since drug interactions 
with off-targets may lead to side effects
11,12
. Target discovery, thus, involves a process to 
identify key “disease-causing” molecules which can be effectively inhibited or enhanced 
by their corresponding drugs. 
In order to determine the disease-relevance of a therapeutic target to disease of interest 
and the effectiveness of target inhibition/enhancement by drugs, many key questions 
should be answered. What is the most popular technology used for determining disease-
relevance? How to measure the binding activity of drugs on the targets? If we only know 
the drug and its corresponding disease, how can we identify its primary target? In Section 
1.1.3 and 1.1.4, we attempt to answer these questions by illustrating target identification 
and validation in modern drug discovery. 
1.1.3 Target identification 
After choosing the disease of interest to study on, the next step is to identify a gene target 
or a mechanistic pathway which demonstrates correlations with the disease initiation and 
perpetuation. Target identification is to figure out disease-relevant genes and to uncover 
additional roles for genes of known functions. Many technologies now are available for 
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identifying targets, which include: expression profiling genomics, molecular genetics, 
and proteomics. 
1.1.3.1 Expression profiling genomics 
Molecular profiling has been proved as powerful tool for analyzing gene expression in 
disease and normal cells
13-17
. A good example is mRNA expression profiling using DNA 
microarray for large-scale analysis of cellular transcripts by comparing mRNA 
expression levels. By integrating knowledge of statistics and bioinformatics, gene 
expression data have been analyzed using clustering algorithms, and been used for 
detecting significant changes in gene expression levels. 
With the collaborative efforts from researchers in both biology and bioinformatics, the 
number of gene expression databases and bioinformatics tools has been dramatically 
increased which offers us new in silico strategy to discover therapeutic targets
13,16
. 
Numerous gene expression studies can be downloaded from public databases
15,18-26
. 
Table 01-1 lists examples of some well-known gene expression databases, which offer 
gold mines for target identification. However, one thing we need to keep in mind is that 
although the in silico detection of gene variants turns out to be very effective, it is 
subjected to the same limitations of all bioinformatics tools in that its results need further 
experimental validation to avoid false leads derived from noisy data. 
Discovering drug targets by analyzing pathways has been proposed as another fruitful 
approach
27
. Since pathways are known as genetic networks rather than individual genes, 
if researchers can identify them as being relevant to disease of interest, it is then possible 
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to assess the potential druggability of the individual proteins in that pathway
17
. 
Computational methods have been proposed together with mathematical models for gene 
networks
28
. These computational methods are able to reflect potential pathway alterations 
based on the expression data
29
. Thus, the analysis of pathways after gene knockout or 
drug treatment plays an important role in identifying target genes. 
1.1.3.2 Molecular genetics 
Molecular genetics is the field of biology that studies the structure and function of genes 
at molecular level, and it helps to understand genetic mutations which can cause certain 
disease. The major advantage of using molecular genetics instead of expression profiling 




One of the most extensively performed technologies available to molecular genetics is the 
forward genetic screen. The aim of this tool is to identify mutations that produce a certain 
phenotype. A mutagen N-ethylnitrosouera (ENU) is very often used to accelerate random 
mutations in the genome
31,32
. For technologies used for forward genetic screen, RNA 
interference (RNAi) based loss-of-function genetic screen is the most frequently used
33
. 
Besides forward genetic screen, a more straightforward approach is to determine disease 
phenotype that results from mutating a given gene. This is called reverse genetics. In 
some organisms, like yeast and mice, it is possible to induce the deletion of a particular 
gene, creating a gene knockout. Gene knockout model enables not only the discovery of 
target function but also possible side effects that result from the affection of the target. 
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Cellular signaling is coordinated by protein-protein interactions, posttranslational protein 
modifications, and enzymatic activities that cannot be fully described by mRNA levels. 
In the meantime, drug targets might be differentially expressed at the protein level that 
cannot be accurately predicted by mRNA expression either. Therefore, knowledge from 
protein level should be a necessary complementation to transcript analysis. Proteomics, 
the large-scale study of the proteins, is a promising technique for identifying novel drug 
targets
36
. Among the proteomics techniques, 2D gel electrophoresis, multidimensional 
liquid chromatography, mass spectrometry, and protein microarray are currently available 
for drug target identification. 
1.1.4 Target validation 
Once a potential therapeutic target is identified, the next step is to validate its critical role 
in disease initiation or perpetuation. Most diseases originate from multiple factors which 
include acquired or inherited genetic predisposition and environmental causes
37-42
. With 
the rapid accumulation of biological data and increasing understanding of disease 
mechanisms, the target validation process, however, has become more and more difficult, 
since many biological systems concerned have certain degrees of complexity
43
. In other 
words, any modification on a certain part of the system is quite possible to trigger 
additional regulation of partners in both upstream and downstream, and consequently 
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induce effects onto other interconnected pathways. Generally, diagnosis of a disease is 
based on the occurrence of characteristic pathogenic consequences, which is usually after 
the initial triggering event. The use of in vivo models, therefore, enables investigation of 
whole-organism complexity. Due to the integration of symptom parameters with target 
efficacy and side effects evaluation, in vivo target validation is essential for providing the 
most relevant information for exploring effective therapeutics. 
Currently, three in vivo loss-of-function target validation technologies are frequently used 
to specifically inactivate mammalian pathways or targets, which include: (1) DNA 
knockout validation models
44,45
, (2) mRNA knockdown validation models
46
, and (3) 
protein knockout models based on vaccination
47,48
. These three technologies cover the 
three main biological levels: gene, mRNA and protein, and provide insight into the roles 
played by the targets in both normal and pathological circumstance. 
Table 01-2 illustrates a brief description of these three loss-of-function target validation 
tools mentioned above, and illustrates their corresponding advantages and limitations. 
None of these three loss-of-function technologies is capable of answering all questions on 
complex biological systems. Animal models other than mice with similar biological 
systems to humans should be used whenever possible
44,49
, but many of which suffer from 
absence of genetic models
50
. In this circumstance, siRNA could be helpful as long as the 
target tissue is accessible via systemic or local delivery
50
. In the meantime, a functional 
protein-KO could provide a very valuable tool for secreted or receptor target. Therefore, 
siRNA and protein functional KO technologies can overcome some limitations of gene 
knockout models. Furthermore, new delivery systems, vaccination and the modulation of 
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immune response will help expand potential application of these technologies. Nowadays, 
there is a strong need to combine these techniques because individual gene manipulation 
is proved to be not enough to understand a pathway and the complex regulation of each 
biological system involved in the disease
50
. 
In summary, drug discovery is a difficult and inefficient process. As the very early step in 
drug development, target discovery plays a critical role in reducing pharmaceutical R&D 
spending and improving efficiency for drug development. As we can see, target discovery 
aims at identifying and validating genes which can be effectively inhibited or enhanced 
by their corresponding drugs. In order to achieve this goal, many techniques have been 
applied. Three most popular target identification techniques are: (1) expression profiling 
genomics, (2) molecular genetics, and (3) proteomics, while three in vivo loss-of-function 
target validation technologies are: (1) DNA knockout validation models, (2) mRNA 
knockdown validation models, and (3) protein knockout models based on vaccination. 
 Chapter 1 Introduction  10 
1.2 Knowledge of established therapeutic targets 
In contrast to the heavy spending on pharmaceutical industry, there is a surprisingly lack 
of knowledge of the set of drug targets that modern therapeutics act on. For researchers 
who try to develop predictive model for identifying new promising molecular targets, the 
number, characteristics and biological profiles of targets of approved drugs are key data 
for them to work on. However, the total number of therapeutic targets with at least one 
drug approved, which we defined here as “successful targets”, has been debated. 
1.2.1 A review of efforts on evaluating number of successful targets 
In 1996, Drews and Reiser were the first to systematically analyze the existed pool of 
therapeutic targets, and identified 483 successful targets as “the most fruitful paths for 
therapeutic development in the past”51,52. Moreover, they categorized these drug targets 
according to their therapeutic areas. Drug targets that affected synaptic and neuroeffector 
junction sites, as well as central nervous system drugs, accounted for almost 30% of the 
total. Almost half of the drug targets were divided more or less equally between drugs 
that address inflammation, renal and cardiovascular function, infectious disease, or 
hormone agonists and antagonists. The rest (26%) were targeted by drugs affecting blood 
diseases, gastrointestinal functions, uterine motility, cancer, immune-modulation, and by 
vitamins in the role of therapeutics. 
Six years later, Hopkins and Groom challenged Drews‟ conclusion by proposing “rule-of-
five” constrain as new criteria for validating successful targets and suggested that of their 
set of 399 targets with known rule-of-five-compliant agent and binding affinities below 
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10 micromole, only 120 proteins had approved or marketed drug. According to 
comparison between these 120 launched targets and 399 targets with drug-like leads, 
their overall distributions by biochemical class were similar. For launched targets, 
enzymes constituted nearly half of them (47%), whereas GPCRs accounted for 30%. The 
remaining classes included ion channels and nuclear hormone receptors which accounted 
for less than a quarter of the identified launched targets
8
. 





 proposed 14,000 targets for all approved and experimental drugs. Later, 
Wishart et al. revised the number to 6,000 on the DrugBank database website. In 2006, 
Imming et al. catalogued 218 molecular targets for approved drug substances
56
, whereas 




In late 2006, Overington et al.
59
 proposed a consensus number of 324 drug targets for all 
classes of approved therapeutic drugs (Table 01-3). Overington‟s work reconciled earlier 
publications into a comprehensive survey. Analysis of protein family distribution 
revealed that the majority of (>50%) drugs target primarily on four families: class I 
GPCRs, nuclear receptors, ligand-gated ion channels and voltage-gated ion channels. The 
targets with the largest number of drugs were glucocorticoid receptor and histamine H1 
receptor. 
In 2010, we conducted a comprehensive survey on historical researches and latest reports 
to identify “successful targets” and its corresponding drugs9. In the latest version of 
Therapeutic Targets Database (TTD, 2010)
9
 (http://bidd.nus.edu.sg/group/ttd/ttd.asp), we 
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collected information of 348 successful, 293 clinical trial and 1254 research targets, 1514 
approved, 1212 clinical trial and 2302 experimental drugs linked to their primary targets 
(3382 small molecule and 649 antisense drugs with available structure and sequence). 
Our data were consistent with previous report on the number of targets with drug 
approved. We had added a new category named “clinical trial targets” which refered to 
therapeutic targets with no drug approved but with drugs in clinical trial. According to 
the clinical trial stage of the drug, we had further defined targets as “phase III clinical 
trial targets”, “phase II clinical trial targets”, and “phase I clinical trial targets”. 
Distribution of successful and clinical trial targets with respect to biochemical classes 
was given in Figure 01-3. Biochemical classes included enzymes, receptors, nuclear 
receptors, channels and transporters, factors and regulators (factors, hormones, regulators, 
modulators, and receptor-binding proteins involved in a disease process), antigen and the 
remaining binding proteins not covered in other classes, structural proteins (non-receptor 
membrane proteins, adhesion molecules, envelop proteins, capsid proteins, motor 
proteins, and other structural protein), and nucleic acids. In Chapter 3 of this thesis, I 
will illustrate the newly updated Therapeutic Targets Database (2010) in detail. 
1.2.2 Databases providing therapeutic targets information 
In light of the extensive efforts on exploring established and potential therapeutic targets, 
many databases have been constructed to provide target information for researchers from 
various directions, like biomedicine, pharmaceutics, pharmacogenomics, comparative 
genomics, and so on. 
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Table 01-4 lists examples of well-known drug target databases which are currently web-
accessible. Each database has their distinguished features, and they are complementary 
with each other. Since these databases aim to collect target information for different 
purposes, their size of data varies dramatically. We can use the number of targets as an 
example. For some databases, such as DengueDT-DB and GTD
60
, the number of targets 
collected is below 100. This is partly because these databases are focused only on certain 
diseases, like dengue virus infection and bacterial pathogens, and the genome for these 
infectious species are relative small. In the other side of the spectrum, there are databases 
containing huge amount of targets data, such as Binding DB
61







 (2.5 million), and TDR
65
 
(10,000). The large size of these data is because of their attempts for comprehensively 
collecting target information, and majority of them do not indicate what percentage of 
their data are established therapeutic targets. 
As illustrated in its website, DrugBank
66
 collected 2,500 proteins “linked to” FDA 
approved drugs. However, according to analysis in Section 1.2.1, this number far exceeds 
those historical evaluation (300~350). This is because that “link to” may not guarantee 
that these proteins are the primary therapeutic targets for drugs. In the latest version 
Therapeutic Targets Database
9
, the total number of targets is around 1,800, with 348 
successful, 293 clinical trial and 1254 research targets. Because the number demonstrated 
in TTD is consistent with the historical exploration records, we choose to use TTD data 
to appreciate the outstanding properties of established therapeutic targets, and identify 
common features beneath those properties reflected by successful targets. This will be 
illustrated in detail in Chapter 5 and Chapter 6. 
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In conclusion, extensive efforts have been devoted into summarizing the established drug 
targets. After debates for more than two decade, researchers begin to reach an agreement 
on 300~350 successful targets established by their approved or marketed drugs. In the 
meantime, targets in clinical trial have also been identified which can be an invaluable set 
of data for evaluating the process of current target discovery. Once we get the reliable set 
of established targets, it is time for us to appreciate their properties which make them 
outstanding compared to other proteins. With the advent of post-genome era, questions 
have been frequently asked. How many genes in human genome possess the ability to be 
targeted by drug-like molecule? How many genes will be established as successful targets? 
In order to answer these questions, I would like to introduce “druggable genome” first in 
Section 1.3. 
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1.3 Therapeutic target and druggable genome 
The vast majority of successful drugs achieve their activity by binding to, and modifying 
the activity of, a protein. This limits the number of targets for which commercially viable 
therapeutics can be developed, thus leading to the concept of “druggable genome”–a 
subset of the ~30,000 genes in the human genome which express proteins able to bind 
drug-like molecules
8
. Researchers have been searching through the human genome and 
trying to identify those which are druggable, and, ideally, determine the size of druggable 
genome
67-69
. The estimated size of druggable genome from different research groups 
varies, because of the diverse sets of successful targets chosen as starting point, various 
biological hypotheses adopted, and different analysis tools applied. 
1.3.1 Efforts devoted for exploring druggable genome 
In Drews‟ historical works “Genomic sciences and the medicine of tomorrow” published 
in 1996
51
, he was the first to conclude that there could be 5,000~10,000 potential targets 
on the basis of an estimate of the number of disease-related genes. However, this analysis 
did not relate the target with its corresponding drugs. As we know, commercially viable 
molecules possess common properties that can be summarized by Lipinski “rule-of-
five”70. Since drug targets need to be able to bind compounds with shared properties, it is 
reasonable to deduce that druggable targets should share some common features. In 2001, 
Bailey et al.
71
 introduced methods by assessing the number of ligand-binding domains to 
measure the number of potential points at which small-molecules could act, and Bailey‟s 
conclusion suggests that the size of druggable genome could be even greater than 10,000. 
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However, the estimated number shrinks in Hopkins and Groom‟s publication8. A total 
number of 3,051 proteins have been predicted as druggable based on mapping proteins 
back to 130 proteins families representing the known drug targets. The estimated number 
consist ~10% of the whole human genome (30,000 genes)
72
. Hopkins further applied his 
methods onto Drosophila melanogaster, Caenorhabditis elegans, and Saccharomyces 
cerevisiae, and estimated the sizes of their druggable genome are 13,601, 18,424, and 
6,241 respectively. Their percentages of genome covered by the druggable genes are all 
around ~10% which is consistent with human genome. 
An update on Hopkins and Groom‟s work was proposed in 2005, which re-estimate the 
size by using two algorithms: optimistic and conservative. In the optimistic scenario, the 
number arrives at just over 3000 targets, the same total as Hopkins‟ reported in 2002. The 
conservative count yields a total of ~2200 druggable genes
10
. 
1.3.2 Gap between druggable protein and therapeutic targets 
Druggable does not equal therapeutic. The capacity of a protein to bind a small molecule 
at the required binding affinity might make it druggable, but it does not mean that it is a 
potential drug target. One reason for this is the protein should also be disease-related, or 





related genes, and large-scale mouse-knockout studies have revealed that only ~10% of 
all gene knockouts might have the potential to be disease modifying
75
, which is consistent 
with the lower end of this range. Therefore, the potential therapeutic targets that our 
pharmaceutical industry should exploit are in the intersection between druggable genome 
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In summary, druggable genome has long been a critical issue that attracts broad interests. 
The size of druggable genome predicted by protein family based affiliation is around 
3000. The rapid development on new computational methods has facilitated druggable 
protein identification. In the next section, I will manage to review these most popular 
approaches used for predicting druggable proteins. 
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1.4 Introduction to the prediction of druggable proteins 
As illustrated in Section 1.1.3 and 1.1.4, various target identification technologies
75,76
 
have been developed by analyzing disease relevance, functional roles, expression profiles 
and loss-of-function genetics between normal and disease states
77-84
. Computational 
methods have also been used to predict druggable proteins, the activity of which can be 
regulated by drug-like molecules
8
, from their genomic, structural and functional 
information




New and improved methods
57
 and integrated and systems-based approaches
77,78,87
 have 
been explored for identifying druggable proteins. These commonly used computational 
methods have primarily been based on the detection of sequence and functional similarity 
to known drug targets
8,85
, motif-based drug-binding domain family affiliation
8,79
, and 
structural analysis of geometric and energetic features
86
. On the other hand, machine 
learning approach takes a different strategy to identify druggability, which will be further 
illustrated in Section 1.4.4. 
1.4.1 Sequence similarity approach 
The most straightforward method of probing druggable protein from its primary structure 
is sequence alignment. Sequence alignment aims at measuring similarity to distinguish 
biologically significant relationship in evolution
88
. The rationale behind this technique is 
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Biological sequence similarity comparison started from the introduction of Needleman 
and Wunsch‟s dynamic programming algorithm90 in early 1970s, which adopted an 
iterative matrix method for global alignment of two sequences. Later, Waterman and 
Smith
91
 extended this algorithm for local alignment, in which only sub-segments of two 
sequences with the highest score were aligned. From then on, many more rigorous 
algorithms were developed
92
, but their biological meaning was difficult to formulate. All 
these dynamic programming approaches assigned some sort of penalties to insertions, 
deletions and replacements of different length and computed an alignment of two 
sequences to maximize their similarity
88
. 
However, Because of their intensive computation requirements, dynamic programming 
algorithms are impractical for searching large sequence database, which is very common 
for current biological databases, without using supercomputer
88
. Thus, various heuristic 
algorithms like FASTA
93
 with less-cost of computation resources were developed. Unlike 
dynamics algorithms, heuristic algorithms do not aim for optimal alignments between 
two sequences, but utilize strategies to find approximate solutions with human heuristics. 
A significant breakthrough was made by the invention of a heuristic algorithm–BLAST, 
which gave good balance between computation speed and sensitivity, making it the most 
popular program for sequence comparison. In order to find distantly related proteins, the 
PSI-BLAST
94
, allows to iterate BLAST search, with a position-specific score matrix 
generated from significant alignments found in previous rounds. 
Moreover, the correlations between sequence similarity and functional similarity have 
been tested
95-99
. Based on the test result, Wilson et al.
96
 concluded that for pairs of single-
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domain proteins, precise function is usually conserved for sequence identity higher than 
40%, and broad functional class is conserved for sequence identify higher than 25%. 
Thus, 40% identity seems to be an appropriate threshold to transfer the sequence 
similarity to function similarity. 
In 2002, Hopkins and Groom deduced that similar sequence can indicate similar degree 
of druggability
8
. This would suggest that if one protein was able to bind a drug, other 
proteins that are substantially similar to it are also able to bind a drug-like molecule. 
Using this algorithm, Hopkins and Groom predicted 3,051 proteins as potential drug 
targets. 
A real world example of target identification by sequence similarity comparison is the 
discovery of target candidates SNAIL3
85,100
, a potent target of pharmacogenomics in the 
field of oncology and regenerative medicine. This gene was isolated by a similarity 
search of a known database and the characteristics of the sequence, such as chromosomal 
location, phylogeny and in silico expression analysis, were investigated by BLAST and 
other bioinformatics tools. 
However, in the absence of clear sequence or structural similarities, the criteria for 
comparison of distantly-related proteins become increasingly difficult to formulate
101
. In 
the meantime, the success rate for identifying homologues with a sequence identity in the 
range of 20~30% is only approximately 50%, and the success of the searches is much 
lower for identities of less than 20%
79
. Moreover, not all homologous proteins have 
analogous functions
102
. It is thus imperative to find other solutions to assign protein 
druggability beyond sequence similarity. 
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1.4.2 Motif based approach 
Proteins with similar profiles are likely to be functionally related
103-105
. Thus, detection of 
common motifs among druggable proteins may provide important clues to targets 
identification. Motif based methods are usually more sensitive than pair wise comparison 
at detecting distant relationships between protein sequences. Moreover, motifs are easy to 
construct and use by biologists who have no training in bioinformatics
106
. A number of 
motif-based databases have been developed to facilitate the identification of short and 
well-conserved regions, such as ligand-binding sites, enzyme-catalytic sites or post-
transcriptional modifications
106
. Each is different from others in terms of nomenclature 
and the approach to pattern recognition
107
. 
One of the most widely-used motif databases is PROSITE, which consists of a large 
collection of patterns that describe biologically meaning signatures of protein families
106
. 
PROSITE was developed by manually seeking patterns that best fit particular protein 
families and functions
108
. However, one problem with PROSITE patterns is that they are 
generally too short, which causes the high false-positive occurrences in unrelated 
sequences. In addition, there is no way to evaluate the probabilities of variations at a 
particular position. In order to solve these problems, PRINTS represents protein families 
through a number of fingerprints, which could be used to characterize features of protein 
families
106
. These fingerprints consist of multiply aligned un-gapped segments derived 
from the most highly conserved regions in protein family, and they typically cover larger 
regions of the sequence than PROSITE. Moreover, PRINTS takes into account amino 
acid substitution matrices, so that it does not require exact matches to a fixed pattern
108
. 
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Beside simple motifs derived directly from protein sequences, a higher level of motifs, 
called domains, could be used to characterize parts of a protein sequence with a single 
well-defined function. ProDom database clusters related sequence segments from pair 
wise sequence comparison into domain families
109
, so that a new incoming protein could 
be compared to the domain database to identify shared domains. Another well known 
motif database is PFAM database, which collects manually curated multiple sequence 
alignments for more than 12,000 domain families
110
, and represents these families 
through hidden Markov models (HMMs). Each family contains two multiple alignments, 
one from relatively small number of representative proteins and the other one from full 
alignment of all members in the database that can be detected. InterPro is another widely 
used motif database of predictive protein “signature” used for the classification and 
automatic annotation of proteins and genomes
111
. InterPro classifies sequences at 
different levels: super-family, family and sub-family, and it is used for predicting the 
occurrence of functional domains, repeats and important sites. 
Motif based approach has been applied in finding out druggable proteins. In Hopkins and 
Groom‟s work8, they mapped the sequences of the drug-binding domain of 399 molecular 
targets into InterPro domains, and identified 130 protein families representing known 
drug targets. Since proteins with similar profiles are likely to be functionally related
103-105
, 
those proteins in the 130 protein families are regarded as potentially druggable. 
Furthermore, HMM algorithms, HMMER (profile hidden markov models)
112
 and SAM 
(sequence alignment and modeling)
113
, have been applied for detecting close and remote 
homologues of gene families that are of specific interest in target discovery
79
. As each 
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method produces overlapping but non-identical results, both algorithm were used and the 
results were combined for maximum effectiveness. 
But many motifs or domains only reflect positions for post-translational modification or 
structural signals, without any direct functional implications
114
. The presence of shared 
domain within a group of proteins does not necessarily imply that these proteins perform 
the same function
115
. Moreover, not all the protein sequences could be covered by 
currently available motifs and it is reported that the latest version of PFAM (2010) only 
covers about 75.15% of all protein sequences
110
. 
1.4.3 Structural analysis approach 
Besides sequence similarity and motif approaches, structure based approach can also 
provide valuable insights into protein druggability
86
. In the identification of homolog, 
structural approach often succeeds when sequence-alone-based methods fail
114
, since 
structure is more conserved than sequences. It is well known that proteins can function 
only when they form 3D structures in their functional environment. Due to structure-
function relationship, it is possible to correlate protein structure to function
116
. Therefore, 
knowledge of proteins sharing similar structures is a strong indication that they have 
similar functions
117,118
, and specifically similar degree of druggability
86
. Now, with the 
increasing number of protein 3D structures, databases classifying proteins into 





Successful application of structural based approaches onto druggability identification has 
been reported
86
, which uses hetero-nuclear-NMR (nuclear magnetic resonance)-based 
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screening data. The relationships between protein druggability and protein binding site 
properties have been derived. It is found that properties like polar and apolar surface area, 
surface complexity, and pocket dimensions can correctly classify 94% of the proteins 
with high-affinity, non-covalent, drug-like leads. 
Hajduk et al.
86
 demonstrate general procedures applied for identifying disease-modifying 
and druggable proteins by relying on the 3D structure of the protein target itself. The first 
step is to identify all possible binding sites on a protein surface, and followed by the 
assessment of whether the binding site can bind with high affinity and specific small 
molecule drugs. They have calculated the potential druggability of more than 1,000 non-
redundant human proteins, and predicted nearly 35% as containing at least one highly 
druggable binding site. 
The problem of a structure based approach is that only few residues are directly involved 
in the function of proteins
123
. Therefore, functions are more likely to be influenced by 
random mutations than structures. Compared with structure prediction, it is more difficult 
for computational methods to predict protein function
124
. Another problem with structure 
based approach is the limitation on available protein structures. The latest version of 
Protein Data Bank (PDB, 2010)
125
 collected 66,828 protein structures. Comparing with 
518,415 unique protein sequences in the latest sequence database
126
, only around 13% of 
the proteins have available structures. For about 34,000 human protein sequences covered 
in latest sequence database
126
, only 16,371 have been identified by conducting keyword 
search “homo sapiens” in PDB, and it is reasonable to expect the real amount of human 
protein structure will not be larger than this number. Despite progress in structural 
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genomics, most proteins encoded in newly sequenced genomes are known from their 
amino acid sequences alone
114
. Although computational methods like homology 
modeling
127-129
 may be used to an extent, however, the number of proteins with structures 
available is still far less than sequences. Thus, methods that do not require protein 
structures are needed to predict function of those proteins whose structures are 
unavailable. 
1.4.4 Machine learning methods 
Unlike sequence similarity and structure based approaches, machine learning takes a 
different strategy in predicting druggable proteins. In these methods, proteins are 
represented by digitalized descriptors instead of direct use of sequences. These 
descriptors either describe physicochemical properties of the constituent amino 
acids
130,131
 or capture both local structural motifs and longer conserved regions associated 
with specific functional properties
132
. Once we have knowledge on druggable proteins 
and non-druggable proteins, the supervised classification methods–machine learning–can 
be applied for developing an artificial intelligence system to separate proteins into two 
classes: druggable and non-druggable. 
Machine learning methods have been successfully applied to the prediction of proteins of 
specific functional class characterized by distinguished biochemical properties or 














. They also show some level of capability in predicting the functional 
class of proteins that are non-homologous to any protein of known function
140-143
. 
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Machine learning has been applied to identify druggable protein. Zheng et al.
58
 used a 
total of 1535 successful and research targets to construct the druggable class, and 12,956 
representative proteins from 6856 PFAM protein families (with all of the known target-
representing families excluded from these families) were used to construct the non-
druggable class. Their average prediction accuracy of 5-fold cross validation study is 
69.8% for druggable proteins and 99.3% for non-druggable proteins. Similarly, in a later 
report, Xu et al.
144
 reached ~72% for sensitivity and ~98% for specificity. 
However, successful machine learning process requires accurate and sufficient training 
data, but ambiguity and typos are very common in biological data. Machine learning 
methods are not applicable for proteins with insufficient knowledge about their specific 
functional profile. The searching for information about proteins known to possess a 
particular profile and for those do not possess that profile is the key to more extensive 
exploration of machine learning methods for facilitating the study of protein functional 
profiles. 
In conclusion, commonly used computational methods for druggable protein prediction 
are generally based on the detection of sequence and functional similarity to known drug 
targets
8,85
, motif-based drug-binding domain family affiliation
8,79
, structural analysis of 
geometric and energetic features
86
, and machine learning approaches
58,144
. Sequence 
similarity, motif and structure based methods are less effective in finding targets that 
exhibit no or low homology to known targets, disease proteins and proteins with available 
3D structures. However, such non-homologous and structurally unknown proteins 
constitute a substantial percentage, ~20-100%, of the open reading frames in many of the 
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completed genomes and might, therefore, be an untapped source of novel drug targets
141
. 
Hence, methods independent of sequence and functional similarity, and structural 
availability, are highly desirable. Statistical machine learning method, has recently been 




, proteins in families of 
high target concentrations
131,133,135,139,146,147
, as well as proteins of various broadly defined 
functional and structural classes
68
, from sequence-derived constitutional and 
physicochemical properties, irrespective of similarity to known proteins. This method is 
particularly useful for predicting novel targets that exhibit no or low homology to known 
targets. In Chapter 2 Section 2.3.1, I plan to describe the machine learning algorithms 
into detail. 
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1.5 Objective and outline of this thesis 
1.5.1 Objective of this thesis 
The ultimate goal of this thesis is to construct in silico target identification approaches to 
facilitate modern drug target discovery. In order to meet it, this thesis has been divided 
into three sections, each of which deals with one sub-objective. These three objectives are 
inter-connected with each other. In the following part of this section, these objectives will 
be explained step by step, which will then lead to the final goal of this thesis. 
The first objective is to construct or update pharmainformatics databases providing data 
that are pharmaceutically important but no comprehensive data have been provided in the 
publicly accessible databases. Given the demands on information about the primary drug 
target(s) of comprehensive sets of approved, clinical trial, and experimental drugs/agents 
for facilitating focused investigation and discovery, significant expansion of data and 
careful identification of primary drug target(s) for each drug are conducted in TTD 2010. 
However, it is difficult to find a place where primary targets information is provided, 
which needs additional actions on designing procedures of primary drug target(s) 
validation. Therefore, pharmainformatics databases IDAD and TVD were constructed. 
IDAD provides the activity information for each drug which acts as an essential factor for 
primary target validation, and TVD aims at giving in vitro and in vivo target validation 
data for targets covered by TTD. 
Once the target data are available, well-organized and clearly classified, it is time to reach 
the second objective: revealing common properties among drug targets by comprehensive 
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analysis on successful and clinical trial targets. The druggability of proteins varies 
according to their therapeutic, biochemical, physicochemical, and systems features, and it 
is reasonable to say that a better understanding of those common features will help to 
figure out what constitute “druggability”. Thus, analysis on protein family distribution, 
pathway affiliation, subcellular location, similarity to successful targets, drug potencies, 
and the Lipinski‟ rule of five were planned to reach this objective. 
After revealing rules guarding “druggability”, the next question would be: whether is it 
possible to develop fast approaches for identifying promising drug targets from the whole 
pool of human genome? In order to answer this question, a collective approach 
combining 4 in silico methods was proposed to facilitate target discovery. With the solid 
foundation built up by the former two objectives, the third one is reachable. Moreover, as 
an application, we also planned to extend our target discovery approach to identify 
promising targets from the genome of influenza A (H1N1, H5N1, H2N2, H3N2, H9N2), 
B and C. If this real world test is proved to be effective, it would be encouraging to apply 
the approach further. 
In summary, this thesis is to predict therapeutic targets by applying bioinformatics tools. 
In the first step, pharmainformatics databases with comprehensive and accurate data are 
constructed. With the analysis on the comprehensive targets data collected, several rules 
guarded druggability are identified. Based on reliable data and better understanding to 
drugs targets, it is finally possible to apply combinatorial bioinformatics tools to facilitate 
drug target discovery. 
1.5.2 Outline of this thesis 
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In Chapter 1, an overview of target discovery in current pharmaceutical research is given 
in the first section, which reviews current technologies for both target identification and 
validation. Then we have a retrospective review of efforts to distinguish established drug 
targets, and a comprehensive analysis of available drug targets information. As effective 
tools for target discovery, popular bioinformatics techniques are then introduced in the 
final section of this chapter. 
Chapter 2 illustrats methods used in this work. In particular, the strategy of developing 
pharmainformatics database, the methods used for validating primary therapeutic targets 
for drugs, the machine learning methods, the sequence similarity on drug-binding domain, 
the comparative study of structural fold on drug-binding domain and system-level rules 
for druggability are presented in more detail. 
In Chapter 3, construction of 3 pharmainformatics databases is demonstrated. In the first 
section, update of therapeutic targets database is shown with detailed illustration on 
significance and reliability of TTD data and many powerful new features integrated. As 
byproducts of TTD, IDAD and TVD are introduced in the following section of this 
chapter. 
Chapter 4 systematically analyzes the therapeutic, bio-chemical, physicochemical, and 
systems features of the targets and drugs in clinical trials. In the first section, an analysis 
on trends in the exploration of clinical trial targets is given. In the following two sections, 
two comparisons between characteristics of clinical trial target and that of successful one, 
and characteristics of clinical trial drug and that of approved drug and drug lead are given. 
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We conclude in the last section that it necessitates further improvement in drug-like and 
target-like physicochemical features. 
In Chapter 5, a collective approach which integrates four in silico methods is proposed 
for target identification. After a brief illustration on these four methods in the first section, 
the performances of target identification on clinical trial, non-clinical trial, difficult, and 
non-promising targets are shown. 
As an application, Chapter 6 focuses on identify promising targets from the genomes of 
influenza A (H1N1, H5N1, H2N2, H3N2, H9N2), B and C by using our target discovery 
methods. After an introduction on methods used, we illustrate the identification results 
and make further discussion on them in the rest sections of this chapter. 
Finally, in the last chapter, Chapter 7, major findings and contributions of current work 
to modern target discovery are discussed. Limitations and suggestions for future studies 
are also rationalized in this chapter. 
 
 Chapter 1 Introduction  32 
Figure 01- 1 Drug discovery process 
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Figure 01- 2 Number of new chemical entities in relation to R&D spending (1992-2006) 
 
Figure 01- 3 Biochemical class for successful and clinical trial targets in TTD 
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Table 01- 1 Examples of well-known gene expression database 
Database 
Name 




ArrayExpress Archive is a database of functional genomics experiments including gene expression where you can query and download 
data collected to MIAME and MINSEQE standards. In 2009, it contains data from over 6,000 experiments comprising approximately 




BodyMap is a human and mouse gene expression database that is based on site-directed 3'-expressed sequence tags generated at Osaka 
University. To date, it contains more than 300,000 tag sequences from 64 human and 39 mouse tissues. For the recent release, the 
precise anatomical expression patterns for more than half of the human gene entries are generated by introduced amplified fragment 
length polymorphism (iAFLP), which is a PCR-based high-throughput expression profiling method. The iAFLP data incorporated into 




CIBEX (Center for Information Biology gene Expression database) is a public database for microarray data, which is aimed at storing 





Data releases from DDBJ (DNA Data Bank of Japan) are the complete genome sequence of an endosymbiont within protist cells in the 
termite gut and Cap Analysis Gene Expression tags for human and mouse deposited from the Functional Annotation of the Mammalian 
cDNA consortium. In 2010, it contains >120 million gene expression entries and >115 billion bases. 
ExpressDB22 
ExpressDB is a relational database containing yeast and E. coli RNA expression data. Currently, it contains more than 20 million pieces of 
information loaded from numerous published and in-house expression studies. 
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GEO23 
GEO (Gene Expression Omnibus) is a public repository that archives and freely distributes microarray, next-generation sequencing, and 
other forms of high-throughput functional genomic data submitted by the scientific community. In 2009, the database holds
 
over 10,000 
experiments comprising 300,000 samples, 16 billion
 
individual abundance measurements, for over 500 organisms, submitted
 
by 5,000 
laboratories from around the world. 
GXD24 
GXD (Gene Expression Database) is a community resource for gene expression information from the laboratory mouse. GXD integrates different 
types of expression data. In 2007, it contains >56,500 entries covering
 
nearly 12,300 references analyzing nearly 8,700 genes. 
HuGE Index25 
HuGE Index (Human Gene Expression Index) aims to provide a comprehensive database to aid in understanding the expression of human genes in 
normal human tissues. Now, it provides the results
 
of 59 microarray experiments conducted using tissue from 19
 
different human organs 
from 49 different individuals. All of
 
these experiments are performed using oligo-nucleotide microarrays, which probe for mRNA from
 
approximately 7,000 genes. 
SAGEmap15 
SAGEmap is created to provide a central location for depositing, retrieving, and analyzing human gene expression data. This database uses serial 
analysis of gene expression to quantify transcript levels in both malignant and normal human tissues. Currently, this resource contains over two 




SOURCE (Stanford Microarray Database) is a web-based database that brings
 
together information from a broad range of resources, and 
provides
 
it in manner particularly useful for genome-scale analyses. 
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Table 01- 2 Brief description, advantages and limitations of loss-of-function target validation technologies 
Loss-of-function 
technologies 
Strategies of technologies Advantages Limitations 
DNA knockout 
validation models 
Genes are deleted or disrupted to 
halt their expression148 
(1) Enable the generation of relevant animal 
disease models and the determination of 
the biological functions of new targets
34,149
; 
(2) Can elucidate complex interactions in both 
normal and disease pathways150,151. 
(1) Tissue-specific transcription, insertion positioning 
and other transgenesis-related factors are not under 
full control and can alter the veracity of the 
phenotype observed50; 
(2) Potential compensatory effects during development 
may limit the validation of phenotype induction or 
suppression50; 




Synthesize RNA complementary 
to gene of interest. Introduce it 
into a cell. RNA is recognized as 
an exogenous genetic material, 
which then activate the RNAi 
pathway152-154 
(1) In theory, well-designed siRNA could be 
used to silence any gene in the body155-157; 
(2) siRNA technology can be used in vivo in 
established genetic models, humanized 
mouse models
158
 and species other than the 
mouse157. 
(1) Delivery limitations158-161; 
(2) Time frame of the silencing process is too short, 
which requires repeated or continuous delivery of 
siRNA–with the associated risk of toxicity and the 
restrictions imposed by the use of viral vectors162. 
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Protein knockout 
models based on 
vaccination 
Use of neutralizing antibodies to 
deplete proteins in vivo50. 
(1) Enable direct target validation in adult 
animals avoiding activation of 
compensatory pathways during the 
embryonic development phase50; 
(2) Applicable to circulating proteins or 
membrane-bound proteins50; 
(3) Potentially applicable to all mammalian 
species50; 
(4) Ability to derive the phenotype in pre-
existing animal models50. 
Face the immune tolerance barrier that protects 
endogenous proteins from autoimmune attacks50. 
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Table 01- 3 Molecular targets of FDA-approved drugs from Overington‟s work 




Targets of approved drugs Pathogen and human 324 
Human genome targets of approved drugs Human 266 
Targets of approved small-molecule drugs Pathogen and human 248 
Targets of approved small-molecule drugs Human 207 
Targets of approved oral small-molecule drugs Pathogen and human 227 
Targets of approved oral small-molecule drugs Human 186 
Targets of approved therapeutic antibodies Human 15 
Targets of approved biologicals Pathogen and human 76 
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Table 01- 4 Examples of well-known drug target database 
Name of target 
database 
Description 
Date of last 
update 
Most distinguished features Data statistics 
Binding DB
61 
A database of experimentally determined 
protein-ligand binding affinities. 
2010, Jul 
(1) Measured binding affinities; 
(2) Focus on the interactions of drug-targets 
with drug-like molecules. 
544,641 binding data, 782 ITC 
data, 3,056 protein targets, and 





A comprehensive database on therapeutic 
drug targets, and resource for biomedical 
and pharmaceutical researchers. 
2010, Apr 
(1) Contain targets reported in US patent or 
US/International patent applications; 
(2) Targets are classified according to specific 
drug types and disease types. 
4000 drug targets. 
DengueDT-DB 
A database about dengue virus, containing 
dengue virus genes, drugs and targets and 
aiming to facilitate dengue research from 
drug discovery, vaccine development, 
epidemiology and comparative genomics. 
2008, Jan 
(1) Focus on dengue virus only; 
(2) Include information of dengue virus genes, 
dengue virus drugs targets and drugs. 
13 dengue drugs targets, 80 
dengue virus genes, 4 drugs 
information and genome 




A bioinformatics and cheminformatics 
resource combining detailed drug data with 
comprehensive drug target information.  
2008, Aug 
(1) Comprehensive chemical, pharmacological 
and pharmaceutical data for drugs; 
(2) Detail sequence, structure and pathway 
information for targets. 
1,473 FDA-approved drugs, 71 
nutraceuticals, 3,243 agents in 
lab test. 2,500 proteins linked to 
FDA approved drugs. 





A database consisting of putative genomic 
drug targets of most common human 
bacterial pathogens. 
2009, Apr 
(1) Focus on targets from human bacterial 
pathogens; 
(2) Selected pathogens are either drug resistant 
or vaccines are yet to be developed. 
58 drug targets for 4 human 
bacterial pathogens: Aeromonas 
hydrophila ATCC-7966, 
Burkholderia pseudomallei 







A database providing a variety of resources 
of disease-causing proteins, including X-
ray, NMR and electron microscopy 
structures and pathway map. 
2010, Feb 
(1) Disease-causing proteins with X-ray, NMR 
and electron microscopy structures; 
(2) Targets information of cellular component, 
protein function, and biological process. 
395 disease associated proteins, 
256 disease-associated proteins 
with X-ray/ NMR structure; 






A dual function database associating an 
informatics database to a structural 
database of known and potential targets. 
2008, Mar 
(1) Focus only on therapeutic targets with 3D 
structure; 
(2) Integrated with TarFisDock165, a web server 
for identifying drug targets with docking. 
1,207 entries covering 841 
known and potential drug 





A central repository for genetic, genomic, 
molecular and cellular phenotype data and 
clinical information of people participated 
in pharmacogenomics research. 
2010, Jun 
(1) Pharmacokinetic and pharmacogenomic 
data in cardiovascular, pulmonary, cancer, 
pathways, metabolic domains; 
(2) Provide genetic variation differentiating 
individuals in reaction to drugs. 
20,000 genes, 3000 diseases, 
2500 drugs, 53 pathways, 470 
genetic variants (SNP data) 
affecting drug metabolism. 
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STITCH
64 
Search Tool for 
Interactions of 
Chemicals 
A database integrating information about 
interactions from metabolic pathways, 
crystal structures, binding experiments and 
drug-target relationships. 
2010 Jan 
(1) Create a network of interactions; 
(2) Incorporating BindingDB, PharmGKB and 
Comparative Toxicogenomics Database. 
74,000 small molecules and 




A one-stop data warehouse integrating 
drug-related information about medical 
indication areas, adverse drug effects, drug 
metabolization, pathways and GO terms of 
target proteins. 
2008 Jan 
(1) Information about medical indication area, 
drug adverse effects and metabolization, 
pathways and GO terms of target proteins; 
(2) Provide tools for 2D drug screening and 
sequence comparison of targets. 
2500 target proteins annotated 






A website for finding target information 
and tool for prioritizing target in genome. 
2009, Mar 
(1) Extensive genetic and pharmacological data 
related to tropical disease pathogens; 
(2) Computational assessment of target 
druggability by using weight algorithm. 
1,790, 862, 2,100, 1918 and 
5,474 target enzyme entry for 5 





A database providing information about 
known and explored therapeutic protein 
and nucleic acid targets, and their drugs. 
2010, Mar 
(1) Categorize targets into successful, clinical 
trial (phase I~III), and research target; 
(2) Identify primary target for drugs approved 
or in clinical trial by ignoring off-targets and 
targets with minor therapeutic effect. 
348 successful, 292 clinical trial 
and 1,254 research targets, and 
1,515 approved, 1,279 clinical 
trial and 2,332 drugs in lab test. 
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Chapter 2 Methods used in this thesis 
In this chapter, I intend to give the audience introductions to three methodologies applied 
to this thesis, which organize Chapter 2 into three sections. In Section 2.1, a review of 
strategy of pharmainformatics database development is given. In combination with three 
databases (TTD, IDAD and TVD) included in this work, their logical view of information 
construction is illustrated into detail. As the most critical job in TTD construction, the 
identification of primary therapeutic targets for approved drugs, drugs in clinical trial, 
and experimental agents is demonstrated in Section 2.2. In the last section of this chapter 
Section 2.3, computational approaches adopted for predicting druggable proteins are 
discussed. These approaches include: (1) physicochemical properties of drug targets 
identified by machine learning; (2) analysis on sequence similarity between drug-binding 
domain of a studied target and that of a successful target; (3) comparative study of 
structural fold of the drug-binding domains of studied and successful targets; (4) three 
simple system-level druggability rules. 
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2.1 Development of pharmainformatics databases 
Database development has shown a broad spectrum of applications in not only scientific 
research but also our everyday life. In particular, pharmainformatics databases aiming at 
providing comprehensive and systematic information for pharmaceutics-related research 
have been widely utilized. Despite their various applications in pharmaceutical research, 
the general strategy adopted for constructing these databases is similar. In Section 2.1 of 
Chapter 2, the basic strategy used for developing knowledge-based pharmainformatics 
databases is demonstrated, which is extended to construct Therapeutic Targets Database 
(TTD), Information of Drug Activity Data (IDAD) & Target Validation Database (TVD), 
which are discussed later. Generally, the development of a database is a process including 
rational architecture design, information accumulation, optimal data storage and user-
friendly data access and representation. In the following parts of Section 2.1, I will 
illustrate the strategy utilized for database construction in a stage by stage manner. 
2.1.1 Rational architecture design 
Before the construction of pharmainformatics database, designing a rational architecture 
can help us define the scope of the database, focus on relevant pharmaceutical problem, 
and pave the way for the information collection stage. So, in this stage, the objective and 
content of the database should be seriously considered. As described in Chapter 1, target 
discovery plays a very important role in drug research and development. It becomes more 
and more necessary to provide comprehensive and systematic information on therapeutic 
targets of currently available approved drugs and drugs in clinical trial, kinetic activities 
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of drugs and experimental agents, and how to validate a protein as the primary target of a 
certain drug. However, up to date, there is no such pharmainformatics database providing 
these kinds of information. Therefore, such kinds of knowledge-based pharmainformatics 
databases will provide valuable information for current pharmaceutical research. In sum, 
our databases (TTD, IDAD and TVD) are designed to afford therapeutic targets and drug 
activity related information. Following the design of the preliminary architecture of the 
whole database, a detailed description of the database development will be presented. 
2.1.2 Information mining for pharmainformatics databases 
Generally, a knowledge-based pharmainformatics database is designed to provide 
sufficient domain knowledge around a specific subject in pharmacology. Use TTD as an 
example, TTD is designed to provide some biological information for specific therapeutic 
targets, their relevant disease conditions, and drugs/ligands corresponding to this target, 
and so on. Therefore, for every entry in TTD, there are several different knowledge 
domains, some of which provide basic introduction to the entry itself, and some others 
give information derived from or relevant to this entry. 
The information planned to be integrated can be selected from a comprehensive search of 
literatures like pharmacology textbooks and research publications. In light of the diversity 
of information types, the methods used for data collection vary, but one thing in common 
is to seek data from reliable resources. At present, no ready index or library is available 
and almost all the relevant information is scattered in the huge amount of biological and 
medical literatures. Therefore, literature information extraction is considered to be one of 
the most feasible ways for information mining. It is generally agreed that literatures are 
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typically unstructured data source, and the terms used in different sources, which may be 
in synonymous name, various abbreviations, or totally different expression, are difficult 
to be recognized by automatic language processing. An automated literature information 
extraction system solely relying on computational recognition, thus, cannot be invented 
to gather information from literature both efficiently and accurately. 
In this thesis, automatic text mining methods with manual reading process was combined. 
Automated text retrieval programs developed in Perl were used to screen the literature 
that contained the key words in the local Medline abstract packages
166
. Then, the useful 
subject information was picked up manually from these matched Medline abstract. If 
necessary, the full literature was referred to facilitate information searching. Meanwhile, 
in many cases, the relevant information about the same subject could also be found in the 
same literature. Therefore, in the first step, not only subject but also relevant information 
could be obtained and recorded. In the second step, detailed biological information of 
subject was automatically selected from some general or specific biological databases, 
such as SwissProt, PDB, PubChem, KEGG, and so on, by text mining program. Likewise, 
other information derived from the subject was also extracted from the corresponding 
databases in the same way. After information collection, how to store, organize and 
manage the data using database techniques was discussed. In the next section, the 
database construction is described. 
2.1.3 Data organization and database structure construction 
A good database system enables the user to create, store, organize, and manipulate data 
efficiently. By integrating databases and web sites, users and clients can open up 
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possibilities for data access and dynamic web content. An integrated information system 
of our pharmainformatics database is constructed according to some standardization 
strategies as follows: 
1. Establishment of standardized data format and appropriate data model 
2. Database structure construction 
3. Development of Database Management System (DBMS) 
Since the original data information collected in previous section is independent, the first 
major activity of a database construction process includes creation of digital files from 
these information fragments and construction of an appropriate data model. 
2.1.3.1 The database model 
Database model is an integrated collection of concepts for describing data, relationships 
between data, and constraint on the data. In the other word, a database model is a specific 
description on how a database is structured and used. Currently, there are several 
different basic ways of constructing databases, among which have been listed as follow: 
1. The flat file model 
2. The hierarchical model 
3. The network model 
4. The relational model 
5. The object-oriented model 
The flat-file model is the simplest data model, which is essentially a plain table of data. 
Each item in the flat file, called a record, corresponds to a single, complete data entry. A 
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record is made up by data elements, which is the basic building block of all data models, 
not just flat files. The flat-file data model is relatively simple to use; however, it is 
inefficient for large databases. 
The hierarchical data model organizes data in a tree structure (Figure 02-1). It has been 
used in many well-known database management systems. The basic idea of hierarchical 
systems is to organize data into different groups, which can be divided into different 
subgroups. In a subgroup, there may be some sub-subgroups, and so on. That is to say, 
there is a hierarchy of parent and child data segments. In a hierarchical database the 
parent-child relationship is one-to-many. The hierarchical data model will be convenient 
to use and run very efficiently only if the nature of the application remains strictly 
hierarchical. Actually, in real world application, few database management problems 
remain strictly hierarchical. It is the major failing of this kind of data model. 
In most cases, the relationships of data would be arbitrarily complex (Figure 02-2). In 
this model, some data are more naturally modeled with multiple parents per child. So, the 
network model permits the modeling of many-to-many relationships in data. This model, 
thus, can handle varied and complex information while remaining reasonably efficient. 
Even so, the biggest problem with the network data model is that databases can get 
excessively complicated. 
The relational model was formally introduced in 1970 and has been extensively used in 
biological database development (Figure 02-3). The model is a much more versatile form 
of database. On the basis of this kind of data model, a novel system named relational 
database management system is established. A relational database allows the definition of 
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data structures, storage and retrieval operations and integrity constraints. In such a 
database the data and relations between them are organized in tables. 
Every relational database consists of multiple tables of data, related to one another by 
columns that are common among them. Every table is a collection of records and each 
record in a table contains the same fields. Therefore, if the database is relational, we can 
have different tables for different information. And the common columns, such as entry 
ID, can be used to relate the different tables. Relational database is the predominant form 
of database in use today, especially in biological research field. 
The object-oriented database (OODB) paradigm is “the combination of object-oriented 
programming language (OOPL) systems and persistent systems”167. “The power of the 
OODB comes from the seamless treatment of both persistent data, as found in databases, 
and transient data, as found in executing programs”167. The database functionality is 
added to object programming languages in object database management systems, which 
extend the semantics of the C++, Smalltalk and Java object programming languages to 
provide full-featured database programming capability. The combination of the 
application and database development with a data model and language environment is a 
major advantage of the object-oriented model. As a result, applications require less code, 
use more natural data modeling, and code bases are easier to maintain. 
2.1.3.2 Construction of relational database structure 
The relational model has been used in our pharmainformatics databases. It represents 
relevant data in the form of two-dimension tables. Each table represents relevant data 
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collected. The two-dimensional tables (Figure 02-4) for the relational database include 
the entry ID list table, the main information table, which contains a record for the basic 
information of each entry, data type table, which demonstrates the meaning represented 
by different number, and reference information table, which gives the general reference 
information following by different PubMed ID in Medline
166
. 
Figure 02-4 is a general logical view of databases (TTD, IDAD and TVD) we developed. 
It shows the organization of relevant data into relational tables. In these tables, certain 
fields may be designated as keys, by which the separated tables can be linked together to 
facilitate searching specific values of that field. Commonly, in relational table, the key 
can be divided into two types. One is primary key, which uniquely identifies each record 
in the table. Here it is a normal attribute that is guaranteed to be unique, such as entry ID 
in entry ID list table with no more than one record per entry. The other is foreign key, 
which is a field in a relational table that matches the primary key column of another table. 
The foreign key can be used to cross-reference tables. For example, in tables of our 
databases, there are two foreign keys: Data type ID and Reference ID. According to 
Figure 02-4, a connection between a pair of tables is established using a foreign key. The 
two foreign keys make three tables relevant. Generally, there are three basic types of 
relationships of related table: one-to-one, one-to-many, and many-to-many. In our case, 
these databases belong to one-to-many relationships. 
2.1.3.3 Development of Database Management System 
By using relational database construction software (e.g. Oracle, Microsoft SQL Server) or 
even the personal database systems (e.g. Access, Fox), the relational database can be 
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organized and managed effectively. This kind of data storage and retrieval system is 
called Database Management System (DBMS). An Oracle 9i DBMS is used to define, 
create, maintain and provide controlled access to our pharmainformatics databases and 
the repository. All entry data from the related tables described in previous section are 
brought together for user display and output using SQL queries. 
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2.2 Methodology for validating therapeutic targets 
In the development of TTD, the most critical job is to identify primary therapeutic targets 
for approved drugs, drugs in clinical trial, and experimental agents. In our analysis, the 
primary targets and their corresponding drugs/agents were initially collected from the 
company websites and publications or review articles in reputable journals (e.g. Nature 
Reviews Drug Discovery, Drug Discovery Today, Current Opinion in Pharmacology, 
Current Drug Targets, Current Topics in Medicinal Chemistry, Science, Mini-Reviews in 
Medicinal Chemistry, Anti-Cancer Agents in Medicinal Chemistry, and so on), 2008 
Report of Medicines in Development biotechnology, and 2008 Report of Medicines in 
Development for HIV/AIDS, cancer, children, diabetes, neurological disorders, women, 
and rare diseases, which explicitly mentioned the targets and theirs corresponding drugs. 
These targets are expected to be well defined based on solid in vitro and in vivo target 
validation studies. However, in order to double check and have an overall understanding 
on the status of these targets, we have searched from literatures of reported IC50/EC50 
values against the target/targets and cell-lines and the reports of in vivo studies to confirm 
that the reported primary targets are accurate. 
For those drugs/agents without explicitly reported targets in the above mentioned sources, 
we conducted additional literature search to first identify proteins or nucleic acid targets 
explicitly reported to be inhibited or activated by the drug and the interaction reported in 
the same or different papers to be directly responsible for the claimed therapeutic effect. 
We again check their IC50/EC50 values against the targets, cell-lines and in vivo data. A 
target was confirmed if, in addition to the mentioned reports above, the corresponding 
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drug acts on the target with IC50/EC50 values < 100nM or with IC50/EC50 values < 1 μM 
but acts on relevant cell-lines with IC50/EC50 < 1 μM. 
Based on the target collection method and the results of conformation study on randomly 
selected targets, the collected target data is reasonably accurate. None-the-less, only 
~20% of the clinical trial targets have IC50/EC50 data, it would be better to have the 
relevant data for more comprehensive sets of targets. Hence, further search was 
conducted to collect IC50/EC50 values against targets, cell-lines, and in vivo and knock-
out studies for more comprehensive sets of clinical trial targets and corresponding clinical 
trial drugs. 
For multi-target kinase inhibitors, not all drug targets with IC50 < 100nM are necessarily 
primary targets. The primary targets of these kinase inhibitors were identified as follows: 
Step 1, all the targets of the multi-target kinase inhibitor were identified based on explicit 
literature report and IC50 < 100 nM (< 1 μM if cell-line IC50 < 1 μM), most kinase 
inhibitors are multi-target and have IC50 values; Step 2, check literature report about each 
target to determine if in specific disease or disease subtype (e.g. NSCLC lung cancer), the 
inhibition of this target will produce a response (i.e. they can be the main target against 
the disease), or whether it is a bypass gene directly contributing to the resistance of the 
drug against the main target, then check whether the target is up-regulated or have 
sensitizing mutation or amplified in the specific disease cell-lines or tissues; Step 3, the 
primary targets are selected from those targets that are the main target or bypass genes 
with the right expression, mutation or amplification profile against the clinical trial 
disease or disease subtype (e.g. NSCLC lung cancer). Typically, the number of primary 
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targets of multi-target kinase inhibitors are in the range of 2-4, with a very small number 
of them has 5~6 primary targets. 
For multi-target GPCR binders, the methods for determining their primary targets are 
similar to those of multi-target kinase inhibitor. The specific steps are: Step 1, identify all 
the targets of the multi-target GPCR binder based on explicit literature report and 
IC50/EC50 < 100 nM (< 1 μM if cell-line IC50/EC50 < 1 μM); Step 2, check literature 
report about each target to determine in which disease or disease subtype, binding to 
(agonizing or antagonizing) this target will produce a response, and whether the target is 
up-regulated or amplified in the specific disease cell-lines or tissues. Step 3, select the 
primary targets from those targets reported to be effective and have the right expression 
and amplification profile against the clinical trial disease or disease subtype as one of the 
primary target. Typically, the number of primary targets of multi-target GPCR binders is 
in the range of 2-3, with a very small number of them has 4-5 primary targets. 
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2.3 Computational methods for predicting druggable proteins 
In Chapter 1 Section 1.4, several commonly used computational methods for predicting 
druggable proteins have been introduced. In Chapter 5, I will utilize four in silico 
methods to facilitate target identification. In the following four sections, these approaches 
will be illustrated in detail, which include: physicochemical property of drug targets 
identified by machine learning (Section 2.3.1); sequence similarity in drug-binding 
domains (Section 2.3.2); structural fold comparison of drug-binding domains (Section 
2.3.3); and simple system level druggability rules (Section 2.3.4). 
2.3.1 Physicochemical properties of drug targets identified by machine 
learning methods 
The term “machine learning” refers to algorithms and techniques that allow computers to 
extract information from past experience. Although it emerges as a separate research field 
in the early 1980s, the study of machine learning can be traced back to the 1960s
168
. Over 
the past 50 years, various machine learning methods have been developed and applied in 
a wide spectrum of fields, such as k-nearest neighbor algorithms in text categorization, 
decision tree methods in pharmaceutical research, artificial neural network in stock 
market analysis and prediction, support vector machine in bioinformatics and 
cheminformatics. 
Machine learning uses computational and statistical methods to build mathematical 
models, and makes inference from training samples
169
. Machine learning is a branch of 
artificial intelligence (AI), and it is closely related to statistics and pattern recognition, 
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since they all study the analysis of data. However, unlike statistics and pattern 




In order to be learnt by computational methods, all the samples, or instances, should be 
represented by feature vectors, which could be categorical, binary or continuous. 
Machine learning could be divided into two categories: if samples are given with known 
classes, it is called supervised learning; otherwise, it is called unsupervised learning
171
. In 
supervised learning, the learning process is to optimize an objective function and predict 
the value of the function for any valid input object after having learnt experience from 
training examples. This category includes well known machine learning methods like k-
nearest neighbors, support vector machines, and decision trees. On the other hand, 
unsupervised learning is never given the answer set, and all the answers are assumed to 
be latent variable. All data under investigation are allowed to speak for themselves and 
they are treated evenly. This category includes self organization map and clustering 
methods. 
The machine learning method used in this work is support vector machines (SVM). We 
used our own developed SVM code. Websites for the freely downloadable codes of SVM 
and other machine learning methods are given in Table 02-1.  
2.3.1.1 SVM Algorithm 
Support vector machine (SVM) is one of newest members in supervised learning 
family
172
. It was first officially proposed by Vapnik in 1995
172
, and then further 
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explained by Dr. Burges in 1998
173
. A special property of SVM is that it simultaneously 
minimizes the empirical classification error and maximizes the geometric margin. Over 
the past 20 years, SVM has been successfully applied to a wide range of real-world 







, as well as broad fields in biology, such as protein function 
prediction
133,134
, protein-protein interaction prediction
180
, protein remote homology 
detection
181,182
, and classification for discriminating coronary heart disease patients
183
. 
SVM is the primary method used in our study, and its algorithm will be discussed with 
more details in following sections. 
2.3.1.1.1 Linear SVM 
In two-class problems, SVM aims to separate examples of two classes with the maximum 
hyper plane (Figure 02-5). Mathematically, the data is composed of n examples of two 
classes, denoted as 1 2{( , ), , ( , )}n nx y x y  , where 
N
ix R  is a vector in feature space 
and { 1, 1}iy     denotes its class. A hyper plane could be drawn to separate examples of 
one class (positive examples) from those of the other one (negative examples). The hyper 
plane is represented by 0w x b   , where w  is slope and b is bias. Thus the objective 
function of SVM changes to minimize Euclidean norm
2
w  with following limitations:  
1iw x b     for 1iy         (positive examples)                        (1) 
1iw x b     for 1iy         (negative example)                         (2) 
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According to which side those new instances locate, we can easily determine which class 
they belong to. So the decision function becomes , ( ) ( , )w bf x sign w x b    . 
Geometrically, all the points are divided into two regions by a hyper plane H. As shown 
in Figure 02-6, there are numerous ways through which a hyper plane can separate these 
examples. The objective of SVM is to choose the “optimal” hyper plane. As all new 
examples are supposed to be located under similar distribution as training examples, the 
hyper plane should be chosen such that small shifts of data do not result in fluctuations in 
prediction result. Therefore, the hyper plane that separates examples of two classes 
should have the largest margin, which is expected to possess the best generalization 
performance. Such hyper plane is called the Optimal Separating Hyper plane (OSH)
172
. 
Examples locating on the margins are called support vectors, whose presentation 
determines the location of the hyper plane. OSH could be thus represented by a linear 
combination of support vectors. The margin ( , )i w b of a training point ix is defined as 
the distance between H and ix : 
( , ) ( )i iw b y w x b                                                      (3) 
and the margin of a set of vectors 1{ , , }nS x x is defined as the minimum distance 
between the hyper plane H to all the vectors in S : 
{ | 1} { | 1}
( , ) ( , )min min max
i
S i
x S x y x y
w x w x





                             (4) 
So the OSH is the solution to the optimization problem
184,185
: 
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Maximize: ( , )w b                                                        (5) 
Subject to: 
( , ) 0w b                                                                (6) 
2
1w                                                                   (7) 




w                                                            (8) 
Subject to: 
1iw x b     for 1iy                                                       (9) 
1iw x b     for 1iy                                                     (10) 
This optimization problem could be efficiently solved by the Lagrange method. With the 
introduction of Lagrangian multipliers 0( 1,2,..., )i i n   , one for each of the inequality 
constraints, we obtain the Lagrangian: 
1
1




P i i i
i
L w b w w y w x b 

                                   (11) 
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This is a Quadratic Programming (QP) problem. We would have to minimize ( , , )PL w b   
with respect to w , b and simultaneously require that the derivatives of ( , , )PL w b   with 




























                                                 (12) 
By substituting these two equations into equation (11), the QP problem becomes the 
Wolfe dual of the optimization problem: 
1 , 1
1
( , , ) ( )
2
n n
D i i j i j i j
i i j
L w b y y x x  
 
                                    (13) 








  and 0i  , 1, 2, ,i n . 
The corresponding bias 0b  can be calculated as: 
 0 0 0{ | 1} { | 1}
1
( ) ( )
2
min max
x y x y
b w x w x
 
                                      (14) 
This QP problem could be efficiently solved through several standard algorithms like 
Sequential Minimization Optimization
186
 or decomposition algorithms
187
.  
Once 0w and 0b  are determined, the hyper plane is readily drawn. The points for which 
0i   are called support vectors, which lie on the margin
173
. 
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2.3.1.1.2 Nonlinear SVM 
Many real-world problems are usually too complicated to be solved with linear classifiers. 
With the introduction of kernel techniques, input data could be mapped to a higher-
dimension space, where a new linear classifier can be used to classify these examples 
(Figure 02-7). 
Let   denotes an implicit mapping function from input space to feature space F . Then 
all the previous equations are transformed by substituting input vector ix  and inner 
product ( , )ix x  with ( )ix  and kernel ( , )iK x x  respectively, where 
( , ) ( ) ( )i iK x x x x                                                     (15) 
Equation (13) is then replaced by 
1 1 1
1
( , , ) ( )
2
n n n
D i i j i j i j
i i j
L w b y y K x x  
  









  and 0i  , for 1, 2, ,i n . The bias 0b  becomes  
0
{ | 1} { | 1}
1
[ ( , )] [ ( , )]
2
min maxi i i i i i
SV SV
x y x y
b y K x x y K x x 
 
 
   
 
                     (17) 
and the decision function becomes 
0 0
1
( ) [ ( , ) ] [ ( , ) ]
n n
i i i i i i
i SV
f x sign y K x x b sign y K x x b 

                      (18) 
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Note that the mapping function   is never explicitly computed, which would 
significantly reduce the computation load. Another advantage is that the feature space 
may be infinitely dimensional, such as in the case of Gaussian kernel
188
, where mapping 
function cannot be explicitly represented. A function could be used as a kernel function if 
and only if it satisfies Merce‟s condition189. Followings are well-known kernel functions: 
Polynomial ( , ) ( , 1) pk x z x z     
Sigmoid ( , ) tanh( , )k x z x z      
Radial basis function (RBF) 
2 2( , ) exp( / 2 )k x z x z     
In this work, RBF kernel is used due to its many advantages demonstrated in previous 
studies. Different SVM models could be developed by using different   values. It is thus 
necessary to scan a number of   values to find the best model, which is evaluated by 
their performance on classification tasks. In our work, SVM models with value in the 
range of 1~100 were developed for each classification task. Figure 02-8 illustrates the 
schematic diagrams of the process of training and prediction of drug targets by SVM. 
Sequence-derived feature hi, pi, vi… represents such structural and physicochemical 
properties as hydrophobicity, polarizability, and volume. 
2.3.1.1.3 Performance evaluation 
The performance evaluation aims to find out whether an algorithm is able to be applied to 
novel data that have not been used to develop the prediction model, or measure the 
generalization capacity to recognize new examples from the same data domain
190
. 
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In this study, several statistical measurements were explored, including sensitivity (SE), 
specificity (SP), positive prediction value (PPV), and overall prediction accuracy (Q). 
The formulas to calculate these measurements are listed as following: 
)/( FNTPTPSE   
)/( FPTNTNSP   
)/( FPTPTPPPV   
)/()( FNFPTNTPTNTPQ   
where TP, FN, TN, and FP represent correctly predicted positive data, positive data 
incorrectly predicted as negative, correctly predicted negative data, and negative data 
incorrectly predicted as positive respectively. Another measurement named as Matthews 
correlation coefficient (MCC) was also used to evaluate the randomness of the prediction. 
))()()((/)( FNTNFPTNFPTPFNTPFNFPTNTPMCC   
where MCC is within the range of -1 to 1. Negative values of MCC indicate the 
disagreement between prediction and measurement, while positive values of MCC 
indicates the agreement between prediction and measurement. A zero value means the 
prediction is no better than random guess. 
2.3.1.2 Structural and physicochemical descriptors of proteins 
A number of descriptors have been introduced to represent protein
133,180,191-195
, the post-
translational modifications and localization features
196-198
. The sequence-derived 
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structural and physicochemical descriptors include amino acid composition, dipeptide 
composition, sequence autocorrelation descriptors, sequence coupling descriptors, and 
descriptors for composition, transition and distribution of hydrophobicity, polarity, 
polarizibility, charge, secondary structures, surface tension, and Van der Waals volume. 
Servers such as PROFEAT
199
 (http://jing.cz3.nus.edu.sg/cgi-bin/prof/prof.cgi) and the 
ProtParam
200
 (http://au.expasy.org/tools/protparam.html) have also appeared for 
facilitating the computation of these descriptors, and other sequence derived features such 
as the cleavage sites, the nuclear export signals, and the subcellular localization can be 
computed from CBS Prediction (http://www.cbs.dtu.dk/services/). 
Three groups of widely-used protein descriptors were combined into a single set of 
protein descriptors for predicting targets. The first group is physicochemical descriptors 
used for predicting druggable proteins
201
 that include amino acid composition and the 
composition, transition and distribution of such structural and physicochemical properties 
as hydrophobicity, polarity, polarizibility, charge, secondary structures, surface tension, 
and normalized Van der Waals volumes
202
, the second is normalized Moreau-Broto 
autocorrelation, and the third is pseudo amino acid descriptors. 
2.3.1.2.1 Amino acid composition and composition, transition and distribution 
Each feature vector is constructed from the encoded representations of tabulated residue 
properties including amino acid composition, hydrophobicity, normalized Van der Waals 
volume, polarity, polarizability, charge, surface tension, secondary structure and solvent 
accessibility 
180,202
. For each of these properties, amino acids are divided into three 
groups such that those in a particular group are regarded to have the same property. For 
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instance, amino acids can be divided into hydrophobic (CVLIMFW), neutral 
(GASTPHY), and polar (RKEDQN) groups. The groupings of amino acids for each of 
the properties are given in Table 02-2. Three descriptors, composition (C), transition (T), 
and distribution (D), are used to describe global composition of each of the properties. C 
is the number of amino acids of a particular property (such as hydrophobicity) divided by 
the total number of amino acids in a protein sequence. T characterizes the percent 
frequency with which amino acids of a particular property is followed by amino acids of 
a different property. D measures the chain length within which the first, 25%, 50%, 75% 
and 100% of the amino acids of a particular property is located respectively.  
Overall, there are 21 elements representing these three descriptors: 3 for C, 3 for T and 15 
for D
180,202
. The feature vector of a protein is constructed by combining the 21 elements 
of all of these properties and the 20 elements of amino acid composition in sequential 
order. In this study, totally 188 elements are used as feature vector for each protein 
shown in Table 02-3. The following is a hypothetical protein sequence: 
AEAAAEAEEAAAAAEAEEEAAEEAEEEAAE 
As shown in Figure 02-9, which has 16 alanines (n1=16) and 14 glutamic acids (n2=14). 
The compositions for these two amino acids are: 
n1×100.00/(n1+n2)=53.33 and n2×100.00/(n1+n2)=46.67 respectively 
There are 15 transitions from A to E or from E to A in this sequence and the percent 
frequency of these transitions is (15/29)×100.00=51.72. The first, 25%, 50%, 75% and 
100% of alanines are located within the first 1, 5, 12, 20, and 29 residues respectively. 
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The D descriptor for alanines is therefore 1/30 ×100.00=3.33, 5/30×100.00=16.67, 
12/30×100.00=40.0, 20/30×100.00=66.67, 29/30×100.00=96.67. Likewise, the D 
descriptor for glutamic is 6.67, 26.67, 60.0, 76.67, and 100.0. Overall, the amino acid 
composition descriptors for this sequence are C=(53.33, 46.67), T=(51.72), and D=(3.33, 
16.67, 40.0, 66.67, 96.67, 6.67, 26.67, 60.0, 76.67, 100.0) respectively. Descriptors for 
other properties can be computed by a similar procedure. Table 2-4 gives the computed 
descriptors of the cellular tumor antigen p53 (Swiss-Prot AC P04637). The feature vector 
of a protein is constructed by combining all of the descriptors in sequential order. 
2.3.1.2.2 Normalized Moreau-Broto autocorrelation 
Normalized Moreau-Broto autocorrelation features describe the level of correlation 
between two protein sequences in terms of their specific structural or physicochemical 
property
203
, which are defined based on the distribution of amino acid properties along 
the sequence
204
. There are eight amino acid properties used for deriving these auto-
correlation descriptors. The first is hydrophobicity scale derived from the bulk 
hydrophobic character for the 20 types of amino acids in 60 protein structures
205
. The 
second is the average flexibility index derived from the statistical average of the B-
factors of each type of amino acids in the available protein x-ray crystallographic 
structures
206
. The third is the polarizability parameter computed from the group molar 
refractivity values originally provided by Hansch et al
207
. The fourth is the free energy of 
amino acid solution in water measured by Hutchins
207
. The fifth is the residue accessible 
surface areas taken from average values from folded proteins
208
. The sixth is the amino 
acid residue volumes measured by Fisher
209
. The seventh is the steric parameters derived 
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from the van der Waals raddi of amino acid side-chain atoms
210
. The eighth is the relative 
mutability obtained by multiplying the number of observed mutations by the frequency of 
occurrence of the individual amino acids
211
. Each of these properties is centralized and 
standardized such that ' ( ) /r rP P P    , where P  is the average of the property of the 20 






























which has been used for predicting transmembrane protein types
213
 and protein secondary 
structural contents
214
 at accuracy levels of 82%~94% and 91%~94% respectively. Here d 
is the lag of the autocorrelation, Pi and Pi+d are the amino acid property at position i and 
i+d respectively. The normalized Moreau-Broto autocorrelation is defined as: 
( ) ( ) /( )ATS d AC d N d   where d=1, 2, 3 … 30. 
2.3.1.2.3 Pseudo amino acid  
Pseudo amino acid descriptor is made up of a 50-dimensional vector in which the first 20 
components reflect the effect of the amino acid composition and the remaining 30 
components reflect the effect of sequence order, only now, the coupling number d is now 
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replaced by the sequence order correlation factor 
215
.The set of sequence order 


















where  is the first-tier correlation factor that reflects the sequence order correlation 
between all of the -most contiguous resides along a protein chain (=1,…30) and N is 
the number of amino acid residues. (Ri, Rj) is the correlation factor and is given by: 
      2222211 )()()()()()(
3
1
),( ijijijji RMRMRHRHRHRHRR   
where H1(Ri), H2(Ri) and M(Ri) are the hydrophobicity, hydrophilicity, and side-chain 
mass of amino acid Ri, respectively. Before being substituted in the above equation, the 








































This sequence order correlation definition introduces more correlation factors of 
physicochemical effects as compared to the coupling number, and has been shown to be 
an improvement on the way sequence order effect information is represented. Thus, for 
each amino acid type, the first part of the vector is defined as: 



















where r = 1, 2, …, 20, fr is the normalized occurrence of amino acid type i and w is a 













2.3.1.3 Computational implementation 
In this work, a nonlinear SVM with kernel function: 
2 2/ 2




x x  
was used. SVM prediction system was developed using feature vectors of 
physicochemical and structural properties of 348 successful targets and it was used to 
screen the clinical trial and research targets for identifying potential promising targets by 
the procedures illustrated in Figure 02-8. 
2.3.1.4 Sources of druggable and non-druggable proteins 
Sufficiently diverse sets of druggable and non-druggable proteins are needed for training 
and testing a SVM prediction model. There are 1,894 successful (commercialized) and 
research targets in the therapeutic target database
216
 with available sequence information, 
which together form the druggable class. Some viral and microbial targets have multiple 
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sequence entries, as there are significant sequence variations across strains. Based on 
their family distribution pattern, targets are expected to be represented by < 800 protein 
families including 460 covered by the known targets
58,217
. There are 11,912 protein 
families in the protein family PFAM database
218
 that contain no known target at present. 
Protein families in PFAM database are defined based on domain affiliations or sequence 
clustering. Therefore, without substantially reducing SVM prediction performance, 
putative non-druggable proteins can be tentatively derived from these non-target families, 
which produces a maximum possible “wrong” family representation rate of <7% even 
when all of the < 340 unidentified target families are misplaced
201
. Representative 
proteins of these non-target families form the non-druggable class. Importantly, inclusion 
of the representative of a “wrong” family into the non-druggable class does not preclude 
other family members from being classified as druggable. Statistically, a substantial 
percentage of druggable members can be located on the druggable side of the SVM 
hyper-plane even if its family representative is on the non-druggable side. Therefore, in 
principle, a reasonably good SVM prediction model can be derived from these putative 
non-druggable proteins for predicting druggable ones rather than PFAM family members, 
as confirmed by the case studies described. The quality of the non-druggable class and 
performance of SVM can be further improved along with the discovery of new targets. 
2.3.2 Method for analyzing sequence similarity between the drug-
binding domain of a studied target and that of a successful target 
Sequence similarity between the drug-binding domain of a studied target and that of a 
successful target is obtained by using BLAST
219
 to scan the sequence of the drug-binding 
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domain of the studied target against those of 168 successful targets with identifiable 
drug-binding domain. We used BLAST program downloaded from the National Centre 
for Biotechnology Information (NCBI) (http://blast.ncbi.nlm.nih.gov/Blast.cgi). A stricter 
BLAST cut-off, E-value=0.001, was used for determining the similarity domains. The 
drug-binding domain of the successful target with the smallest E-value that is smaller 
than 0.001 was selected. This E-value has been reported to give reliable predictions of the 
homologous relationships
220
 and it can be used to find 16% more structural relationships 
in the SCOP database than when using a standard sequence similarity with a 40% 
sequence-identity threshold
221
. The majority of protein pairs that share 40~50% (or 
higher) sequence-identity differ by <1 Å RMS deviation
222,223
, and a larger structural 
deviation probably alters drug-binding properties. Therefore, the adopted E-value seems 
to be reasonable for selecting similarity protein domains relevant to the binding of a 
common set of drug-like molecules. None-the-less, low percentages of protein pairs of 
higher sequence-identity have been found to differ by larger RMS deviations
223
 and some 
protein pairs of lower sequence-identity might also have high structural similarity, which 
probably affects the accuracy of our analysis to some extent. 
2.3.3 Comparative study of structural fold of the drug-binding domains 
of studied and successful targets 
The rationale and procedure for comparative study of structural fold of the drug-binding 
domain of two proteins are similar to general strategies adopted by popular structural fold 
databases such as SCOP
224
, and are described below: 
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2.3.3.1 The ligand-sensing core of domain 
The ligand-binding or catalytic sites are the most relevant subsets of a domain from the 
point of view of development of small-molecule binders, which are normally located 
within the so-called ligand-sensing core of the domain where the actual catalytic 
conversion of enzymes, or the binding event of small-molecule ligand, occurs. It has been 
suggested to confine structural similarity considerations to these distinct parts of a 
domain and grouping ligand-sensing cores, instead of whole domains, according to 3D 
similarities into so-called protein structure similarity clusters
225
. 
2.3.3.2 Protein structure similarity clustering 
Clustering of ligand-sensing or catalytic cores of two domains is based on visual 
inspection and structural superimposition and alignment tools in SYBYL (SYBYL® 6.7 
Tripos Inc., St. Louis, Missouri, USA). and Insight II (Insight II® Accelrys Software Inc, 




2.3.4 Simple system-level druggability rules 
2.3.4.1 Druggability rules 
Based on the systems characteristics of therapeutic targets described in earlier 
studies
87,226,227
, systems-level druggability rules have been proposed for guiding the 
search of druggable proteins
227
, a revised version is as follows: 
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1) Protein preferably has less than 15 human similarity proteins outside its family. 
While existence of a larger number of human similarity proteins doesn‟t rule it out as a 
druggable protein, it generally increases the chance of un-wanted interferences and thus 
the level of difficulty for finding viable drugs. (78% of the successful targets with 
identifiable drug-binding domain have less than 15 human similarity proteins). 
2) Protein is preferably involved in no more than three pathways in human. While 
association with a larger number of human pathways doesn‟t rule it out as a druggable 
protein, it generally increases the chance of un-wanted interferences with other human 
processes and thus the level of difficulty for finding a viable target. (87% of the 
successful targets with pathway information are associated with no more than 3 
pathways). 
3) For organ or tissue specific diseases, protein is preferably distributed in no more than 
five tissues in human. While distribution in a higher number of tissues doesn‟t rule it out 
as a druggable protein, it generally increases the chance of un-wanted interferences with 
other tissues unless the disease-relevant targets are located within blood vessels or cells 
lining the arteries where they have higher priority to bind drugs than targets in other 
tissues. The un-wanted interferences increase the level of difficulty for finding a viable 
target. (79% of the successful targets with tissue distribution information are distributed 
in no more than 5 tissues). 
In this work, these rules were applied to those studied targets with sufficient information 
about their systems-related profiles for identifying potential promising targets. 
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2.3.4.2 Number of human similarity proteins of a target 
Human similarity proteins of a target are those human proteins whose drug-binding 
domain is similar to that of the studied target by using the same BLAST method
219
 as that 
described in Section 1 of this supplementary material. 
2.3.4.3 Number of affiliated human pathways of a target 
Information about the affiliated pathways of a target was obtained from KEGG 
database
228
 (see: http://www.genome.jp/kegg/). 
2.3.4.4 Number of human tissues of a target is distributed 
In estimating the number of human tissues where each target is distributed, relevant data 
from the Swissprot database were used. We were able to find the published literature for 
92% of these data, and a random check of these publications confirmed the quality of the 
data. We also used the level-4 tissue-distribution data from another database, 
TissueDistributionDBs (http://genome.dkfz-heidelberg.de/menu/tissue_db/index.html), to 
derive the tissue distribution pattern of the same set of 158 successful targets. A target is 
assumed to be primarily distributed in a tissue if no less than 8% of the total protein 
contents are distributed in that tissue. Approximately 28, 24, 19, 10, 6, 6, 5, and 1% of 
these targets were found to be affiliated with 1 to 8 tissues, respectively, which are 
roughly similar to those derived from Swissprot data
227
, although the definition and 
content of these databases are somehow different. Thus, our estimated tissue distribution 
profiles are quite stable even though the exact percentages may differ by some degrees. 
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Figure 02- 1 The hierarchical data model 
 
 
Figure 02- 2 The network data model 
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Figure 02- 3 The relational data model 
 
Figure 02- 4 Logical view of the database 
 
 
Figure 02- 5 Architecture of support vector machines 
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Figure 02- 6 Different hyper planes could be used to separate examples 
 
 
Figure 02- 7 Mapping input space to feature space 
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Figure 02- 8 Diagrams of the process for training and predicting targets 
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Figure 02- 9 Illustration of derivation of the feature vector* 
 
* Sequence index indicates the position of an amino acid in the sequence. The index for each type 
of amino acids in the sequence (A or E) indicates the position of the first, second, third, … of 
that type of amino acid (The position of the first, second, third, …, A is at 1, 3, 4, …). A/E 
transition indicates the position of AE or EA pairs in the sequence. 
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Table 02- 1 Websites that contain freely downloadable codes of machine learning methods 







k Nearest Neighbor demo http://www.cs.cmu.edu/~zhuxj/courseproject/knndemo/KNN.html 
PERL Module for KNN http://aspn.activestate.com/ASPN/CodeDoc/AI-Categorize/AI/Categorize/kNN.html 





NeuralWorks Predict http://www.neuralware.com/products.jsp 
NeuroShell Predictor http://www.mbaware.com/neurpred.html 
SVM 
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Table 02- 2 Division of amino acids into 3 different groups by different physicochemical properties 
Property  Group 1 Group 2 Group 3 
Hydrophobicity 
Type Polar Neutral  Hydrophobic 
Amino acids RKEDQN GASTPHY CVLUMFW 
Van der Waals volume 
Value 0~2.78 2.95~4.0 4.43~8.08 
Amino acids  GASCTPD NVEQIL MHKFRYW 
Polarity 
Value 0~0.456 0.6~0.696 0.792~1.0 
Amino acids  LIFWCMVY PATGS HQRKNED 
Polarizability 
Value 0~0.108 0.128~0.186 0.219~0.409 
Amino acids  GASDT CPNVEQIL KMHFRYW 
Charge 
Type Positive Neutral Negative 
Amino acids  KR ANCQGHILMFPSTWYV DE 
Surface tension 
Value -0.20~0.16 -0.3~ -0.52 -0.98~ -2.46 
Amino acids  GQDNAHR KTSEC ILMFPWYV 
Secondary structure 
Type Helix Strand Coil 
Amino acids  EALMQKRH VIYCWFT GNPSD 
Solvent accessibility 
Type Buried Exposed Intermediate 
Amino acids  ALFCGIVW RKQEND MPSTHY 
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Table 02- 3 List of features for proteins 
Feature Description Number of Dimensions 
Amino acid composition 20 
Hydrophobicity 21 




Surface tension 21 
Secondary structure 21 
Solvent accessibility 21 
Total 188 
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Table 02- 4 Characteristic descriptors of cellular tumor antigen p53 
Property Elements of Descriptors 
Amino acid 
composition 
A C D E F G H I K L 
6.11 2.54 5.09 7.63 2.80 5.85 3.05 2.04 5.09 8.14 
M N P Q R S T V W Y 
3.05 3.56 11.45 3.82 6.62 9.67 5.60 4.58 1.02 2.29 
Hydrophobicity 
31.81 44.02 24.17 26.02 16.58 19.39 0.51 33.33 58.02 81.17 
100.0 1.02 22.39 43.26 74.55 99.75 0.25 24.68 46.31 65.39 
97.96  
Van der waals 
volume 
46.31 29.77 23.92 23.98 17.10 14.29 1.02 20.87 42.24 70.74 
100.0 0.51 24.68 51.14 72.77 98.73 0.25 34.10 59.29 81.68 
98.22  
Polarity 
26.46 38.68 34.86 18.62 19.90 24.23 0.25 27.74 47.84 64.89 
97.96 1.02 21.12 39.44 74.55 99.75 0.51 34.61 58.02 81.17 
100.0  
Polarizability 
32.32 43.77 23.92 28.57 13.52 17.86 1.53 22.40 46.82 76.84 
100.0 0.51 19.59 48.35 69.97 99.24 0.25 34.10 59.29 81.68 
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98.22  
Charge 
11.70 75.57 12.72 16.07 2.30 18.37 6.11 44.27 71.76 85.24 
98.22 0.25 23.66 45.55 69.97 99.74 0.51 12.98 52.67 74.81 
100.0  
Surface tension 
34.10 30.53 35.37 19.90 25.77 20.92 1.27 27.99 52.67 75.57 




43.51 20.87 35.62 17.86 27.30 11.22 0.25 25.70 51.40 81.17 




33.08 31.81 35.11 22.45 25.0 20.15 2.54 24.68 47.84 69.72 
98.98 0.51 33.33 58.02 81.17 100.0 0.25 22.14 43.00 68.45 
99.75  
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Chapter 3 Pharmainformatics databases construction 
Three pharmainformatics databases have been constructed and described in detail in this 
thesis. They are Therapeutic Targets Database (TTD), Information of Drug Activity Data 
(IDAD), and Target Validation Database (TVD). TTD was first constructed in 2002 as a 
pioneer for providing pharmaceutical information on therapeutic target. After progress in 
the past 8 years on target discovery, TTD still acts as reliable knowledge base providing 
information on successful therapeutic target. However, the profile of drugs under clinical 
developing keeps changing in the past decade, and many new drugs have been approved 
for acting on novel targets. So it is time to update information into TTD by adding novel 
targets approved and identifying clinical trial targets. The identification of primary targets 
for approved, clinical trial, and experimental drugs partly relies on literature data mining, 
but sometimes target for a drug is not clearly indicated. In both situations, the validation 
of the target is very critical not only for double confirm the reliability of information got 
from those reputable journal but also for identifying reliable primary target for drugs with 
no target information provided. Thus, IDAD for evaluating drug potency on its target(s) 
and TVD for validating primary target(s) for drugs have been developed. In Section 3.1, 
therapeutic target database 2010 update has been shown. I have spent most of this chapter 
to demonstrate its data structure and new features. In Section 3.2 and Section 3.3, IDAD 
and TVD have been introduced respectively. Although there are three databases, they are 
interrelated to each other and aiming at the same goal to provide useful information for 
modern target, and finally contribute to drug, discovery. 
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3.1 Therapeutic targets database, 2010 update 
Pharmaceutical drugs or agents generally exert their therapeutic effects by binding to and 
subsequently modulating the activity of particular protein, nucleic acid or other molecular 
(like membrane) targets
6,34
. Target discovery efforts have led to the discovery of 
hundreds of successful targets (targeted by at least one approved/marketed drug), several 
hundred clinical trial targets (targeted by drug in clinical trial but not any 
approved/marketed drug) and more than 1,000 research targets (targeted only by 
experimental drugs only)
53,56,58,59
. Rapid advances in genomic, proteomic, structural, 
functional and systems studies of the known targets and other disease proteins
79,81,229-233
 
enable the discovery of drugs, multi-target agents, combination therapies and new drug 
targets
56,58,81,234,235
, analysis of on-target toxicity
236
 and pharmacogenetic responses
237
, 
and development of discovery tools
238-241
. 
To facilitate the access of therapeutic targets information, publicly accessible databases 
such as Drugbank
66
, Potential Drug Target Database (PDTD)
164
 and our own Therapeutic 
Target Database (TTD)
216
 have been developed. As illustrated in Chapter 1 Section 
1.2.2, a detail list of these therapeutic target related databases is provided (Table 01-4). 
These databases complement each other to provide target and drug profiles. DrugBank is 
an excellent source for comprehensive drug data with information about drug actions and 
multiple targets
66
. PDTD contains active-sites as well as functional information for the 
potential targets with available 3D structures
164
 in PDB. TTD provides information about 
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While drugs and agents typically modulate the activities of multiple proteins
242
 and up to 
14,000 drug-targeted-proteins have been published
55
, the reported number of primary 
targets directly related to the therapeutic actions of approved drugs is limited to 324
59
. 
Information about the primary targets of more comprehensive sets of approved, clinical 
trial and experimental drugs is highly useful for facilitating focused investigations and 
discovery efforts against the most relevant and proven targets 
56,81,234,236,237,240
. Therefore, 
we updated TTD by significantly expanding the target data to include 348 successful, 292 
clinical trial, and 1,254 research targets, and added drug data for 1,514 approved, 1,212 
clinical trial and 2,302 experimental drugs linked to their primary targets (3,382 small 
molecule and 649 antisense drugs with available structure and sequence). 
We collected a slightly higher number of successful targets than the reported number of 
320 targets
59
 due to the identification of protein subtypes as the targets of some approved 
drugs and the inclusion of multiple drug targets of approved multi-target drugs and non-
protein/nucleic acid targets of anti-infectious drugs (e.g. bacterial cell wall and membrane 
components). Clinical trial drugs are based on reports since 2005 with the majority since 
2008, their corresponding clinical trial phase is specified. We also added new features for 
data access by drug mode of action, sequence and tanimoto similarity search of targets 
and drugs, customized and whole data download, and standardized target ID. TTD is now 
available online, and can be accessed at http://bidd.nus.edu.sg/group/cjttd/TTD.asp. 
3.1.1 Target and drug data collection and access 
Additional information about the approved, clinical trial and experimental drugs and their 
primary targets were collected by comprehensive search of literatures, FDA Drugs@FDA 
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webpage (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/) with data about FDA 
approved drugs, latest reports from 17 pharmaceutical companies that describe clinical 
trial and other pipeline drugs (Astrazeneca, Bayer, Boehringer Ingelheim, Genentech, 
GSK, Idenix, Incyte, ISIS, Merck, Novartis, Pfizer, Roche, Sanofi Aventis, Schering-
Plough, Spectrum, Takeda and Teva). Literature search was conducted by combinational 
searching the PubMed database by using keyword “therapeutic” and “target”, “drug” and 
“target”, “clinical trial” and “drug”, “clinical trial” and “target”, and by comprehensively 
searching reputable review journal like Nature Reviews Drug Discovery, Drug Discovery 
Today, Current Opinion in Pharmacology, Current Drug Targets, Current Topics in 
Medicinal Chemistry, Science, Mini-Reviews in Medicinal Chemistry, Anti-Cancer 
Agents in Medicinal Chemistry, and so on. In the meantime, we also extracted data from 
2008 Report of Medicines in Development biotechnology, and 2008 Report of Medicines 
in Development for HIV/AIDS, cancer, children, diabetes, neurological disorders, women, 
and rare diseases, which explicitly mentioned the targets and theirs corresponding drugs. 
In particular, these searches identified 198 recent papers reporting approved and clinical 
trial drugs and their targets. As many of the experimental antisense drugs were described 
in US patents, we specifically searched US patent databases to identify 745 antisense 
drugs targeting 104 targets. Primary targets of 211 drugs and drug binding modes of 79 
drugs were not specified in our collected documents. Further literature search was 
conducted to find the relevant information for these drugs. The criteria for identifying the 
primary target of a drug or targets of a multi-target drug is based on the developer or 
literature reported cell-based or in vivo evidence that links the target to the therapeutic 
effect of the drug. These searched documents are listed in the respective target or drug 
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entry page of TTD and many cross links are provided for the respective PubMed abstracts, 
US patents, or developer web-page. 
However, in order to double check and have an overall understanding on the status of 
these targets, we have searched from literatures of reported IC50/EC50 values against the 
target/targets and cell-lines and the reports of in vivo studies to confirm that the reported 
primary targets are accurate. For detailed information about how primary target is 
identified, please refer back to Chapter 2 methodology Section 2.2. 
3.1.2 Ways to access therapeutic targets database 
TTD data can be accessed by both whole database (Figure 03-1) and customized (Figure 
03-2) keyword search, and by target sequence similarity (Figure 03-3) and drug 
Tanimoto similarity search (Figure 03-4). Full TTD data download is also provided 
(Figure 03-5). Two optional whole database searches are provided: one is to search by 
target name, and another is by drug name. Different whole database search options will 
list search results in different manners, which are designed to facilitate users with 
different initial searching information. Customized search fields include target name, 
drug name, disease indication, target biochemical class, drug mode of action, and drug 
therapeutic class. In current TTD, 112 disease indications, 61 target biochemical classes, 
20 drug mode of actions, and 157 drug therapeutic classes are available for customized 
selection. 
After input keywords and search in TTD database, the intermediate searching results will 
be displayed for user to choose from. For example, if we input “Dopamine receptor” into 
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the search box–“List search results by targets” in the home page, the intermediate search 
results page (Figure 03-6) will display Dopamine D1 receptor, D(1B) dopamine receptor, 
D(2) dopamine receptor, D(3) dopamine receptor, and D(4) dopamine receptor for users 
to make further selection. Another example is: if we input “influenza virus infection” into 
the search box–“List search results by drugs”, the intermediate results page (Figure 03-7) 
will display approved drugs Oseltamivir, Zanamivir, Rimantadine, phase III clinical trial 
drugs Peramivir and CS-8958. In the intermediate search results page, hyper-links linking 
to detailed target or drug information pages are provided. 
Target detail information page (Figure 03-8) lists target name, target status (successful, 
clinical trial and research), synonyms, disease, corresponding drugs, target bio-chemical 
class, pathway involved, target uniprot accession number, PDB structure, protein function, 
sequence information, US patents, drug mode of action, references, and so on. Moreover, 
further information about each target can be accessed via crosslink to external databases, 
like SwissProt/UniProt, PDB, KEGG, OMID, and Brenda database. 
Drug detail information page (Figure 03-9) lists drug name, drug synonyms, trade name, 
company information, disease indication, 3D drug structure displayed, 2D&3D structural 
MOL files for download, target therapeutic class, CAS number, formula, PubChem ID, 
ChEBI ID, SuperDrug ATC & CAS IDs, primary therapeutic target(s), references, and so 
on. Further drug information can be accessed via cross links to the external databases, 
such as PubChem, DrugBank, SuperDrug, and ChEBI 
Related target or drug entries can be recursively searched by clicking a disease or drug 
name. Similarity targets of an input protein sequence in FASTA format can be searched 
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by using the NCBI BLAST sequence alignment tool
94
. Similarity drugs of an input drug 
structure can be searched by using molecular descriptor based Tanimoto similarity 
searching method
243,244
. Target and drug entries are assigned standardized TTD IDs for 
easy identification, analysis and linkage to other related databases. The whole TTD data, 
target sequences along with Swissprot and Entrez gene IDs, and drug structures can be 
downloaded via the download link (Figure 03-5). A separate downloadable file contains 
the list of TTD drug ID, drug name and the corresponding IDs in other cross-matching 
database PubChem, DrugBank, SuperDrug, and ChEBI. The corresponding HGNC name 
and Swissprot and Entrez gene ID of each target is provided in the target page. The 
SMILES and InCHI of each drug is provided in the drug page. 
3.1.3 Target and drug similarity searching 
Target similarity search (Figure 03-3) is based on BLAST 
94
 algorithm to determine the 
similarity level between the sequence of an input protein and the sequence of each of the 
TTD target entries. The NCBI website (http://blast.ncbi.nlm.nih.gov/Blast.cgi) is used for 
downloading BLAST program. The result of similarity targets searched out are ranked by 
E-value and BLAST score
94
. E-value has been reported to give reliable predictions of the 
homologous relationships
220
 and a cutoff of 0.001 can be used to find 16% more 
structural relationships in the SCOP database than when using a standard sequence 
similarity with a 40% sequence-identity threshold
221
. The majority of protein pairs 
sharing ~50% (or higher) sequence-identity differ by < 1 Å RMS deviation
222,223
. A larger 
structural deviation alters drug-binding properties probably. 
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Drug similarity search (Figure 03-4) is based on the Tanimoto similarity search 
method
243
. An input compound structure in MOL or SDF format is converted into a 
vector composed of molecular descriptor by using MODEL
245
. These molecular 
descriptors are quantitative representations of structural and physicochemical features of 
molecules, which have been extensively used in deriving structure-activity relationships, 
quantitative structure-activity relationship and virtual screening tool for drug 
discovery
246,247
. Based on the results of our earlier studies
244
, a total of 98 1D and 2D 
descriptors are used as the components of the compound vector, which include 18 
descriptors in the class of simple molecular property, 3 descriptors in chemical property, 
35 descriptors in molecular connectivity and shape, and 42 descriptors in electro-
topological state. The vector of an input compound i then compared to drug j in TTD by 
























where l is the total number of molecular descriptors. Tanimoto coefficient of similarity 
compounds are typically in the range of 0.8 to 0.9
248,249
. Hence compound i is considered 
to be very similar, similar, moderately similar, or un-similar to drug j if  sim(i,j) > 0.9, 
0.85< sim(i,j) <0.9, 0.75< sim(i,j) <0.85, or sim(i,j) > 0.75 respectively. 
In conclusion, TTD 2010 update is intended to be a more useful resource in complement 
to other related databases by providing comprehensive information to the primary targets 
and other drug data for the approved, clinical trial, and experimental drugs. In addition to 
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the continuous update of new target and drug information, efforts will be devoted to the 
incorporation of more features into TTD. Increasing amounts of data about the genomic, 
proteomic, structural, functional and systems profiles of therapeutic targets have been and 
are being generated
79,81,229-233
. Apart from establishing crosslink to the emerging sources, 
some of the profiles extracted or derived from the relevant data
58
 may be further 
incorporated into TTD. Target data has been used for developing target discovery 
methods
238-240
, and some of these methods may be included in TTD in addition to the 
BLAST tool for similarity target searching. As in the case of PDTD
164
, some of the 
virtual screening methods and datasets may also be included in TTD for facilitating target 
oriented drug lead discovery. 
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3.2 Information of Drug Activity Data 
The initial idea of building a drug activity database is to provide activity information for 
the primary targets of drugs and clinical trials compounds in TTD. With the development 
of this database, we feel that the scope shall not be limited only to drugs and clinical trials 
compounds. Compounds like natural products, promising compounds developed by the 
pharmaceutical companies as lead compound or preclinical candidates shall be included 
too. Currently, there are several similar databases that provide activity information for 
compounds, like BindingDB61, DrugBank66, MDDR
250
, et al. (Table 03-1). BindingDB is 
a public, web-accessible database of measured binding affinities, focusing chiefly on the 
interactions of protein targets with small drug-like molecules. DrugBank is also a unique 
bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, 
pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, 
structure, and pathway) information. MDDR is a database covering the patent literature, 
journals, meetings and congresses produced by Symyx and Prous Science. As compared 
to those databases, IDAD is mainly focusing on in vitro activity of drugs, clinical trial 
compounds and preclinical candidates while BindingDB collects data of all kinds of 
compounds binding to the targets, which are not limited to therapeutic targets. IDAD can 
currently be accessed at http://bidd.nus.edu.sg/group/IDAD/IDAD_Home.asp. 
3.2.1 The data collection of IDAD information 
Information collection was conducted by literature search on PubMed database by using 
keyword combinations of “therapeutic” and “target”, “drug” and “target”, “clinical trial” 
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and “drug”, and “clinical trial” and “target”, and by comprehensive search of such review 
journals as Journal of medicinal chemistry, Journal of European journal of medicinal 
chemistry, Current topics in medicinal chemistry, Nature Reviews Drug Discovery, 
Trends of Pharmaceutical Science, Drug Discovery Today, Oncogene and so on. In 
particular, these searches identified 198 recent papers reporting approved and clinical 
trial drugs and their targets. 
3.2.2 The construction of IDAD database 
IDAD is a relational database, which represents the drug-target interaction database in the 
form of two-dimension tables. The two-dimensional tables include IDAD ID-Drug Name 
pair ID table, IDAD ID-Activity ID pair main information table, Activity ID, Protein ID, 
Activity, Normalized Activity, Reference ID table,  Protein ID–TTDID and Swiss-Prot 
ID information table and Reference information table. In these tables, IDAD serves as 
primary key; Activity ID, Protein ID, reference ID are considered as foreign keys. 
TTDID and Swiss-Prot ID are used to cross-link to external database like TTD and 
Swiss-Prot. 
3.2.3 Way to accession IDAD database 
Entries of IDAD are searchable by several methods. These methods include the search by 
compound name or ID, search by target. Case-insensitive keyword-based text search and 
wildcards are also supported. In a query, one can specify full name or part of the name in 
a text field. For instance, wild characters of '*' and '?' are allowed in the text field. In this 
case, '?' represents any single character, and '*' represents a string of characters of any 
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length. As an example, input of „HDAC‟ in the field of target name enables the search of 
all entries containing the target name of „HDAC‟ such as HDAC1, HDAC8, HDAC4, etc. 
In IDAD interface, all entries that satisfy search criteria are listed along with IDAD ID, 
target name, activity, and references. More detailed information of a compound can be 
obtained by clicking the corresponding TTD target ID and TTD drug ID. For a systematic 
comparison of compound activities, all activity values are normalized. For completeness, 
the relevant references are provided in the interface. 
In summary, IDAD is designed to provide activity information for approved drugs, drugs 
in clinical trial, and important experimental agents, such as the natural product, promising 
compounds developed by the pharmaceutical companies as lead compound or preclinical 
candidates. This information will act as an informative data source to support research in 
pharmaceutical sciences. 
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3.3 Therapeutic targets validation database 
In the development of TTD, the most critical job is to identify primary therapeutic targets 
for approved drugs, drugs in clinical trial, and experimental agents. In our analysis, the 
primary targets and their corresponding drugs/agents were initially collected from the 
company websites and publications in reputable journals, which explicitly mentioned the 
targets and theirs corresponding drugs. These drug targets were expected to be well 
defined based on solid in vitro and in vivo target validation studies. Because of this, we 
came up with the idea of constructing Target Validation Database (TVD) for collecting 
supporting information of the primary target(s) for approved drugs, drugs in clinical trial, 
and the experimental agents (such as natural products, promising compounds developed 
by the pharmaceutical companies as lead compound or preclinical candidates). 
3.3.1 Pharmaceutical demands for target validation information 
As illustrated in Chapter 1 Section 1.1.4, target validation is important in selecting right 
targets for drug discovery, which evaluates multiple profiles including the expression and 
relevance of targets in disease models, the potency of drugs in modulating target activity 
and disease model, and the correlation of these activities to the claimed therapeutic effect. 
Therefore, target validation data, particularly those of successful and clinical trial targets, 
is expected to be invaluable data which provide historical “model” for facilitating target 
discovery, validation and analysis. Our TVD aims at collecting in vitro and in vivo target 
validation data for therapeutic targets covered by TTD. These data include the potencies 
of drugs against their efficacy targets, and potencies of drugs against the disease relevant 
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cell-lines expressing these targets (potencies are measured in IC50, Ki, and EC50), and the 
effects of target knock-out or variation in target sequence, expression and activity in 
disease models. TVD can be accessed at http://bidd.nus.edu.sg/group/TVDtest/TVD.asp. 
3.3.2 The data collection of TVD information 
Therapeutic target validation data was collected by combinational keywords search in 
PubMed database by using “validation” and “target”, “drug” and “potency”, “cell line” 
and “potency”, “cell line” and “activity”, “knock-out” and “target”, “target” and “IC50”, 
and by comprehensively searching literatures and research articles in reputable research 
journals such as Annual Review of Pharmacology and Toxicology, Annual Review of 
Physiology, Nature Reviews Drug Discovery, Nature Reviews Cancer, Nature Reviews 
Neuroscience, Trends in Pharmacological Sciences, Pharmacology & Therapeutics, 
Drug Discovery Today, Clinical Pharmacology & Therapeutics, Current Opinion in 
Pharmacology, and so on, which explicitly mentioned techniques validating targets. In 
particular, these searches identified 218 recent papers offering target validation data. 
Currently, there are 243 successful, 233 clinical trial, and 154 research targets covering 
1,006 approved, 573 clinical trial, and 311 investigative drugs. With TTD data, the 
majority of successful (243 out of 348) and (233 out of 292) clinical trial targets have 
been covered. On the other hand, only 154 out of 1254 research targets have validation 
information. Furthermore, TVD is an ongoing project, which aims at covering all 
successful and clinical trial targets, and exploring validation information for as many 
research targets as possible. In order to integrate target validation data into TTD, links to 
the relevant data in TVD will be shown in the corresponding target page in TTD. 
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3.3.3 Explanation on target validation data 
Generally, our target validation data collected for TVD provided evidences from three 
different aspects: (1) the potencies of drugs against their primary efficacy targets; (2) the 
potencies of drugs against the disease relevant cell-lines expressing these targets; (3) the 
effects of drug target knock-out and variance in target sequence, expression and activity 
in disease models; and additional evidences of actions on target from drug-like molecules. 
TVD is constructed based on explaining and validating a target from those data. 
Take CDK2 as an example. CDK2 is a clinical trial target inhibited by many drugs in 
clinical trial, such as Flavopiridol (Phase III, CLL), SCH 727965 (Phase II, NSCLC), 
Seliciclib (Phase II, CLL), R-roscovitine (Phase I/II, NSCLC), AT7519 (Phase I/II, NHL), 
R547 (Phase I, solid tumors), AT7519 (Phase I, solid tumors), Ro 31-7453 (Phase I, solid 
tumors), SCH 727965 (Phase I, NHL and CLL), ZK 304709 (Phase I, solid tumors), and 
SNS-032 (Phase I, B-lymphoid malignancy). Table 03-2 shows potency of drugs against 
their primary efficacy target CDK2. Their kinetic activities are all <500 nM and majority 
of them are below 50 nM, which indicate CDK2 is very promising in light of its binding 
potency. Table 03-3 listed potency of drugs against disease relevant cell-lines expressing 
CDK2. As shown, the cell-line activities are around 200~300 nM, which is a very potent 
value compared to cell-line activities of other drugs
251,252
. Finally, the effects of target 
knock-out and variance in CDK2 sequence, expression and activity in disease models and 
additional evidences have been illustrated in Table 03-4. CDK2 in vivo knock-out study 
correlates CDK2 with the tumor development, and identifies it as tumor-causing target. 
Addition evidences focus on information of drug-like action on their primary target(s). 
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Figure 03- 1 Screenshot of home page of TTD 2010 
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Figure 03- 2 Screenshot of customized search page of TTD 2010 
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Figure 03- 3 Screenshot of sequence similarity search page of TTD 2010 
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Figure 03- 4 Screenshot of drug tanimot similarity search page of TTD 2010 
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Figure 03- 5 Screenshot of full database download page of TTD 2010 
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Figure 03- 6 Intermediate search results of “dopamine receptor” listed by targets 
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Figure 03- 7 Intermediate search results of “influenza virus infection” listed by drugs 
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Figure 03- 8 TTD target main information page 
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Figure 03- 9 TTD drug main information page 
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Table 03- 1 Main drug-binding databases available online 
No Database Address 
1 BRENDA http://www.brenda-enzymes.info/ 
2 DrugBank  http://www.drugbank.ca/ 
3 eMolecules  http://www.emolecules.com/  
4 MDDR http://www.symyx.com/products/databases/index.jsp  
5 PNPDB  http://azevedolab.net/14.html  
6 PubChem  http://nihroadmap.nih.gov  
7 SCOWLP  http://www.scowlp.org/  
8 ShikiPDB  http://azevedolab.net/14.html  
9 SuperNatural  http://bioinformatics.charite.de/supernatural/  
10 SuperHapten  http://bioinformatics.charite.de/superhapten/  
11 WOMBAT http://www.sunsetmolecular.com  
12 ZINC  http://zinc.docking.org/  
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Table 03- 2 Potencies of drugs against their efficacy targets CDK2 
Drug Name Potency Status Disease indication 
Flavopiridol IC50: 100 nM 
Phase III Chronic lymphocytic leukemia (CLL) 
Phase II Acute myeloid and lymphoblastic leukemia 
Discontinued Hepatocellular carcinoma 
SCH 727965 IC50: < 5 nM 
Phase II Advanced breast cancer, NSCLC, and acute leukemia 
Phase I Advanced solid tumors, NHL, multiple myeloma and CLL 
Seliciclib IC50: 220 nM Phase II NSCLC, lymphoid leukemia, and multiple myeloma 
R-roscovitine IC50: 220 nM Phase I/II completed NSCLC 
AT7519 IC50: 47 nM 
Phase I/II Non-Hodgkin's Lymphoma 
Phase I Solid Tumors 
R547 IC50: 1~3 nM Phase I completed Advanced solid tumors 
SNS-032 IC50: 48 nM Phase I B-lymphoid malignancies and advanced solid tumors 
ZK 304709 IC50: 4 nM Phase I Advanced solid tumors 
AG-024322 IC50: 1~3 nM Discontinued Advanced cancer 
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Table 03- 3 Potencies of drugs against the disease relevant cell-lines expressing CDK2 
Drug Name Effect and potency against cell line 
AG-024322 
Arrested multiple stages of the cell cycle and induced apoptosis in various human tumor cell lines (IC50 = 30~200 nM). 
Displayed dose-dependent antitumor activity in mice bearing human tumor xenografts. 
AT7519 
Potent anti-proliferative activity in various human tumor cell lines, a lower activity in non-transformed fibroblasts and no 
activity in non-cycling cells; promoted tumor growth inhibition or regression in human ovarian and colon carcinoma xenogra 
Flavopiridol 
Induced G1–S phase and G2–M phase arrest and apoptosis at 200~300 nM concentrations in many tumor cells. Significant 
clinical activity in refractory CLL; clinical studies ongoing to determine efficacy of combination with anti-neoplastic agents. 
R547 
Induced G1–G2 arrest and apoptosis in tumor cell lines independently of RB1 or p53 status (IC50 < 0.60 mM); induced 
significant tumor growth reduction in human tumor xenografts and efficacious with daily oral dosing and weekly intravenous 
dosing. Early 
R-roscovitine Induces S–G2 arrest and apoptosis. 
SCH 727965 Induced apoptosis in tumor cell lines and growth inhibition or regression in xenograft models. 
SNS-032 
In vitro; high CDK selectivity over a panel of 12 unrelated kinases (IC50 > 25 mM); induced tumor growth reduction in a 
human ovarian carcinoma xenograft. Sensitized radioresistant NSCLC cells to ionizing radiation. 
ZK 304709 
Blocked growth of human tumor cell lines at IC50 = 317 nM, by inducing a dose-dependent G1–S arrest followed by 
apoptosis. Superior efficacy over standard chemotherapy in human tumor xenografts and orthotopic mouse models of human 
pancreatic cancer. 
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Table 03- 4 Effects of target knock-out in CDK2 sequence, expression and activity in disease models and additional evidences 
Effects of target knock-out or variation in target sequence, expression and activity in disease models 
Target Alteration Type Remarks Effects on disease model 
Genotype: Cdk2-/- Loss-of-function strains Sterility due to defective meiosis; no effect on mitotic cells 
Genotype: Cdk2-/-; Cdkn1b-/- Target validation strains 
Develop tumors with similar incidence and latency to those in Cdkn1b-deficient 
mice, suggesting the function of p27 (encoded by Cdkn1b) is independent of CDK2 
Additional Evidences 
Drug Name Drug-like Action Remarks 
Purvalanol B Inhibition IC50: 6 nM 
AG-024322 Inhibition Phase I, advanced cancer: NCT00147485 sponsor: Pfizer 
AT-7519 Inhibition Phase I/II, advanced or metastatic tumours: NCT00390117; sponsor: Astex 
Ro-4584820 Inhibition Phase I, advanced solid tumours: NCT00400296; sponsor: Hoffmann-LaRoche 
Roscovitine Inhibition 
Phase II, non-small cell lung cancer, nasopharyngeal cancer, haematological tumours: 
NCT00372073; sponsor: Cyclacel 
SNS-032  Inhibition 
Phase I, B-lymphoid malignancies: NCT00446342; 
Phase I, solid tumours: NCT00292864; sponsor: Sunesis 
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Chapter 4 Therapeutic targets in clinical trials 
Most drugs produce their therapeutic effect by interacting and modulating the activity of 
selected protein targets
6,253,254
. Based on data from TTD
9
, intensive drug exploration and 
target discovery efforts
56,226,227,255
 have sent 1,164 drugs to clinical trial, 690 of which 
direct at 292 new targets. These clinical trial drugs and targets are fruits and bear marks 
of past decades‟ application of drug discovery technologies (combinatorial chemistry256, 









, system biology and multi-target drug discovery
254
, 
and progresses in genomics, structural genomics and proteomics
262-265
. 
By analyzing the therapeutic, biochemical, physicochemical, and systems features of the 
clinical trial targets and drugs with respect to successful targets, approved drugs and drug 
leads, useful information can be gained regarding general trends of past decades‟ drug 
discovery efforts
56,59,255
, areas of focus, progress and difficulty
201,227
, and distinguished 
features guiding the enhancement of specific properties in the target exploration and drug 
discovery
56,59,70,240,255,266-271
. Given the key role played by target selection in clinical 
successes of drugs and the unique role of clinical trials in target validation in human and 
in evaluation of drug efficacy and safety, we systematically analyzed physicochemical, 
therapeutic, biochemical, and systems features of targets and drugs in clinical trials. We 





 and the high-throughput 
screening derived drug leads
255,269,271
. 
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4.1 Trends in the exploration of clinical trial targets 
The areas of progress in the exploration of new targets for disease treatment can be partly 
revealed by evaluating the distribution of clinical trial targets in different trial phases with 
respect to different disease classes, which are given in Table 04-1. Every target is 
assigned to the highest trial phase in which a target-directed drug has been or is being 
tested. The way of dividing disease classes is based on the international statistical disease 
classification of the World Health Organization (WHO, 1992). Neoplasm, inflammation, 
nervous system and sense organs disorders, diseases of circulatory system, and nutritional 
and metabolic diseases constitute the classes with the largest number of targets in all 
clinical trial phases, which include 133, 70, 57, 52 and 47 targets respectively. For phase 
III trial targets, the classes with the largest number of targets are neoplasm, nervous 
system and sense organs disorders, inflammation, diseases of circulatory system, and the 
nutritional and metabolic disease with 33, 21, 20, 18 and 14 targets respectively. In 
comparison, the disease classes with highest number of successful targets are neoplasm, 
infectious and parasitic diseases, nervous system and sense organs disorders, circulatory 
system diseases, mental disorders, and respiratory system diseases with 78, 78, 56, 54, 46, 
and 35 targets respectively
227
. Thus, in clinical trial pipelines, there is an increased pool 
of novel targets for inflammation and nutritional and metabolic diseases, and a steady 
stream of fresh drug targets for neoplasm, circulatory system diseases, and nervous 
system and sense organs disorders. On the other hand, a relatively decreased pool of 
novel targets for mental disorders, respiratory system diseases, and infectious and 
parasitic diseases is also observed. 
 Chapter 4 Therapeutic targets in clinical trial  114 
The areas of progress in target exploration may be further revealed by evaluating the top 
protein families and biological pathways that contain high number of clinical trial targets. 
Figure 04-1 and Figure 04-2 show the top-10 PFAM protein families and top-20 KEGG 
pathways with a large number of phase I, II, and III clinical trial drug targets. A large 
number of targets are concentrated in the GPCR and kinase protein families and 
distributed in the upstream or upstream-linked signaling pathways, such as the 
neuroactive ligand-receptor, cytokine-cytokine receptor, chemokine, Jak-STAT, toll-like 
receptor, neurotrophin, ErbB, and VEGF signaling pathways. Evaluation of the sub-
cellular distribution of the phase I, II, and III targets, in Figure 04-3, further demonstrates 
that the majority of these targets are associated with membrane or in extracellular 
locations. 
Figure 04-4 shows the top-10 PFAM protein families that contain a large number of 
targets in clinical trial in comparison with the top-10 PFAM families containing a large 
number of successful targets. There appears to be continued progress in exploring new 
targets in the highly successful GPCR, kinase, trypsin, and hormone receptor families. 
Progresses have also been made in the exploration of new targets in new protein families 
such as matrixin (matrix metalloproteinase), TNFR/NGFR, and eukaryotic porin families. 
However, there is a substantial reduction in the number of new targets in the ion transport 
protein, nuclear hormone, immunoglobulin, cytochrome P450, and ABC transporter 
families. 
Figure 04-5, Figure 04-6 and Figure 04-7 show the specific clinical trial and successful 
targets with a largest  number of phase II, III and all clinical trial drugs respectively. Most 
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of the drugs in phase III trials target successful GPCR receptors D2, 5HT-2, 5HT-1, D3, 
adrenoceptor beta 2, and opioid receptor sigma 1, and successful anticancer kinase targets 
VEGFR2, Her2, and c-kit. But there are a fair number of drugs targeting a number of new 
targets such as D4, voltage-gated K channel kv1.5, VEGFR3 and endothelial nitric oxide 
synthase. Significantly larger number of drugs, particularly multi-target kinase inhibitors, 
in phase II trials target new kinase targets such as P38, VEGFR3, aurora-A and -B, Jak2, 
PI3K, c-Met and CDK2. Successful kinase targets such as VEGFR2, EGFR, PDGFR and 
VEGFR1 are also targeted by a large number of phase II drugs, and other heavily 
explored targets in phase II are histone deacetylase, substance-P, TNF, adrenoceptor 
beta2, and the adenosine A2a receptor. Overall, the new targets with the largest number 
of clinical trial drugs are kinases aurora-A and –B, PI3K, VEGFR3, Akt, c-met, CDK2 
and P38, and the successful targets with largest number of clinical trial drugs are GPCR 
receptors like D2, substance P, 5HT-2, adrenoceptor beta 2 and D3, kinases VEGFR2, 
Her2 and EGFR, and histone deacetylase (HDAC). 
The level of difficulty in target exploration is partly reflected by the time spent so far for 
developing target-directed drugs that enter specific stage of clinical trials. We crudely 
estimated the exploration time of clinical trial targets by using the number of years from 
the year the target was first reported in the literature to the current year. Figure 04-8 and 
Figure 04-9 shows the distribution of all clinical trial targets and clinical trial targets in 
individual trial phases with respect to their exploration time respectively. For comparison, 
the distribution of innovative successful targets approved by FDA from 1995 to 2008 
with respect to target exploration time is also included in Figure 04-8. Here innovative 
successful targets refer to the successful targets that have no other subtype of the same 
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protein as a successful target before the first FDA approval of these targets. The target 
exploration time for these innovative successful targets was crudely estimated by using 
the number of years from the year the target was first reported in the literature to the year 
of FDA. The average exploration time of phase I, II, III and all clinical trial targets is 18, 
16, 20, and 18 years respectively, which is compared to the average target exploration 
time of 20 years for the innovative successful targets. Thus it remains a very slow and 
difficult process for moving drugs into clinical trial and through the three trial phases, 
which is also reflected by the low productivity rates of innovative successful targets
227
. 
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4.2 Comparison of the characteristics of clinical trial targets 
with successful targets 
Comparison of the characteristics of clinical trial targets with those of successful targets 
provide useful hints about both the common and distinguished features of clinical trial 
targets that can be retained, enhanced, or improved. Figure 04-10 shows the distribution 
of phase I, II and III clinical trial targets and discontinued clinical trial targets in different 
similarity ranges with respect to successful targets. The levels of similarity to successful 
targets are classified into very similar, marginally similar, and un-similar based on Blast 
E-values in the range of ≤ 0.001, 0.001 ~ 0.1 and ≥ 0.1 respectively. The majority of the 
clinical trial targets (68%, 63%, 56%, and 50% of the phase III, II, I and discontinued 
clinical trial targets) are very similar in sequence to these successful targets. Non-the-less, 
substantial percentages of the clinical trial targets (26%, 32%, 35%, and 44% of the phase 
III, II, I and discontinued clinical trial targets) are un-similar in sequence to successful 
targets. Furthermore, target failure is not necessarily associated with the dissimilarity to 
successful targets, as there are comparable numbers of discontinued clinical trial targets 
that are very similar and un-similar to successful targets. 
Figure 04-11, Figure 04-12 and Figure 04-13 respectively show the distribution of all 
clinical trial targets and successful targets with respect to the number of human similarity 
proteins outside the target family, number of pathways the target is associated with, and 
the number of tissues the target is distributed in. The distribution profiles of the clinical 
trial targets are comparable to those of successful targets
201,227
. Similar to successful 
targets, most of the clinical trial targets have less than 15 human similarity proteins 
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outside their respective target family. The vast majority of the clinical trial targets, at 
slightly reduced percentage compared to the successful targets, are associated with no 
more than 3 human pathways and distributed in no more than 5 human tissues. Therefore 
the systems profiles of vast majority of clinical trial targets appear to be very similar to 
those of successful targets
240
. 
Apart from similarity of sequence
226,227
 and systems profiles
201,227,270,272-274
, the similarity 
or the resemblance of other features such as drug binding-site structural 
conformations
275,276
 and physicochemical properties
144,227,241
 are also important in protein 
overall druggability. Table 04-2 shows the reported distribution of the phase I, II, and III 
targets that are similar or resemble the properties of successful targets in sequence, drug-
binding domain structural fold, physicochemical features, and the systems profiles
240
. In 
Chapter 5, this distribution will be further illustrated. In particular, the comparison of 
physicochemical features of clinical trial and successful targets has been conducted by 
inputting the physicochemical features of a specific clinical trial target into a machine 
learning classification model to evaluate whether that target can be classified into the 
successful target class
144,227,241
. Few percentages of the clinical trial targets, 2.4%, 8.3%, 
and 10% of phase I, II, and III targets, have all four profiles similar to or resemble those 
of successful targets, and 9.8%, 25%, and 50% of the phase I, II, and III targets have 
three of the four profiles similar to or resemble those of successful targets. This profile-
combinatory method will be explained in detail in Chapter 5. 





 of the sequence similarity, drug-binding domain structural fold analysis, 
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the physicochemical features recognized by machine learning methods, and systems 
profiles with respect to successful targets for in silico target prediction. In particular, it 
has been proposed that a promising target likely has at least three of the four profiles 
similar to or resemble those of successful targets
240
. This proposed method recognized 7 
of the 8 targets with positive phase III results, and dropped 89% of the 19 discontinued 
clinical trial targets and 97% of the 65 targets failed in HTS or knockout studies
240
. 
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4.3 The characteristics of clinical trial drugs with respect to 
approved drugs and drug leads 
The effectiveness and trends of clinical trial targets as well as successful targets targeted 
by clinical trial drugs may be revealed by analyzing the potencies and physicochemical 
properties of their targeted drugs with respect to those of approved drugs and drug leads. 
Recent analyses of clinical trial drugs and patented agents with respect to approved drugs 
have revealed marked differences in median values of key physicochemical properties 
between approved oral drugs and clinical trial drugs and patented agents
269,277
. Another 
analysis of recently developed drug leads and drug hits with respect to approved drugs 
has further shown that recently developed drug leads generally have good potencies but 
their median values of key physicochemical properties are substantially different from 
those of approved drugs primarily due to the nature of high-throughput screening hits and 
hit-to-lead optimization practices
255
. We extended this type of analysis to a significantly 
higher number of 656 clinical trial drugs and by profiling the potencies of clinical trial 
drugs with respect to those of approved drugs. 
Figure 04-14 and Figure 04-15 show the distribution of clinical trial and approved drugs 
by potency, and the distribution of phase I, II, and III drugs by potency respectively. The 
distribution pattern of the approved drugs is very similar to that of FDA approved drugs 
reported in the literature
278
. As shown in Table 04-3, the median potency of clinical trial 
drugs (32.2nM) is substantially improved against approved drugs (74.6nM), particularly 
for phase III drugs (19.5nM), and it very similar to that of HTS drug leads (30nM)
255
. It 
appears that new technologies such as HTS and virtual screening
257,258
 has enabled the 
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identification or design of more drug candidates with higher potencies by more extensive 
exploration of chemical space. Good potency seems to be one of the important factors for 
the advancement of some drugs into higher phases. Clinical trial drugs targeting the novel 
targets appear to show higher median potency (25.5nM) than clinical trial drugs targeting 
successful targets (39.9nM) and clinical trial targets with protein subtype as successful 
target (32.9nM). One possible reason for this discrepancy is that highly potent agents 
may be more easily identified or designed against novel targets by the ability to explore 
new as well as existing chemical space with reduced possibility of potential conflict with 
existing drugs and potential obstacles of patent protection. 
Figure 04-16, Figure 04-17 and Figure 04-18 show the distribution of clinical trial drugs 
and approved drugs by molecular weight, the distribution patterns for drugs in different 
trial phases, and the distribution patterns for drugs targeting different types of targets 
(novel clinical trial targets, clinical trial targets with protein subtype as successful target, 
and successful targets). Figure 04-19, Figure 04-20 and Figure 04-21 show distribution 
of clinical trial drugs and approved drugs by ALogP, the distribution pattern for drugs in 
specific trial phases, and the distribution pattern for drugs targeting different types of 
targets. As shown in Table 04-3, the median molecular weight, ALogP and the number 
of non-terminal rotatable bonds of all clinical trial drugs (403.4Da, 3.9 and 5.6), are 
substantially higher than the median values of 342.4Da, 2.8 and 4.6 of approved drugs. 
The molecular weight and flexibility level (represented by the number of non-terminal 
rotatable bonds) of phase I, II and III drugs show apparent descending trend, with the 
median values of phase III drugs closest to those of approved drugs. In contrast, AlogP of 
phase I, II and III drugs show no apparent trend and small variations. It seems that phase 
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I, II and III trials are increasingly selective towards drugs with drug-like molecular 
weight and flexibility level, while phase I and II trials are far less selective and phase III 
trials are very selective towards drugs with drug-like lipophilicity. Against HTS drug 
leads
255
, clinical trial drugs show slightly improved molecular weight and lipophilicity 
(represented by CLogP for HTS drug leads and ALogP for clinical trial drugs). Against 
WOrld of Molecular BioAcTivity database compounds with potency better than 1nM
277
, 
clinical trial drugs show significantly improved molecular weight and flexibility level and 
comparable lipophilicity. Moreover, as show in Figure 04-22, the percentage of approved 
drugs obeying Lipinski‟s rule of five70 is substantially higher than phase III clinical trial 
drugs, and the percentage of phase III drugs is substantially higher than that of phase I 
and II drugs. 
The higher value in key physicochemical properties has been considered to be one of the 
important factors for the high attrition rates of clinical trial drugs
255,269
. To some extent, 
preclinical and phase I trials appear to be less discriminative than phase II and III trials in 
selecting drugs with higher values of these two key physicochemical properties. Other 
factors are likely to be equally important in determining the advancement of clinical trial 
drugs. For instance, the key physicochemical properties of the ligands of different target 
protein families have been found to be substantially different
266
. Thus, there might be 
different ranges of good physicochemical properties for different target classes. Moreover, 
clinical trial drugs are more complex than approved drugs, with the computed molecular 
complexity level of phase I, II and III drugs showing descending trend
277
. 
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4.4 Perspectives 
Intensive drug discovery efforts have led to a steady stream of pipeline drugs in clinical 
trials directed at new targets, particularly GPCRs and kinases in upstream signaling 
pathways for high-impact diseases that need more treatment options or more-effective 
drugs. Many successful targets or protein subtypes of successful targets have been 
heavily explored in clinical trials. Majority of clinical trial targets appear to have one or 
more of the sequence, structure, physicochemical and systems profiles similar to or 
resemble those of successful targets. In particular, targets of positive phase III results 
have multiple profiles similar to or resemble those of successful targets. Thus, the search 
of novel drugs directed at new targets with some form of similarity or resemblance to 
successful targets has been and will likely continue to be considered as a „good bet‟ by 
the pharmaceutical industry. 
There is another reason for the high number of clinical trial drugs against targets that are 
similar in sequence to successful targets. By taking advantage of the progress in genome 
sequencing and in the more extensive understanding of disease mechanisms, exploration 
of new targets has become increasingly subtype-specific and, for some diseases, 
pathogen-species-specific. It is expected that this trend will continue, and more subtype-
specific and pathogen-species specific targets will be explored. Non-the-less, rapid 
progress in genomics, structural genomics,  proteomics
262-265
, systems biology and multi-
target drug discovery
254
 will enable the discovery of more novel targets, and the 
secondary targets of multi-target agents that previously cannot be explored as a primary 
target of single-target drugs. 
 Chapter 4 Therapeutic targets in clinical trial  124 
Comparative analysis of multiple profiles of clinical trial targets with respect to 
successful targets provides useful clues to the quality of clinical trial targets and to the 
identification of promising targets
240
. In silico target identification methods have been 





 of the sequence, structure, physicochemical, and systems profiles with 





, ligand-protein inverse docking
279
, machine learning of 
druggability characteristics
227
, system-related druggability profiles
201,227
 and 
combinations of these four profiles
240
 for recognizing target-like and druggable proteins. 





 enable the development of efficient tools for identifying 
innovative targets of new therapies and personalized medicine. In exploring and 
validating a new target, one also needs to pay attention to the capability in the 
identification of drug candidates with good drug-like physicochemical properties, such as 
lipophilicity and molecular weight, as well as other desirable features such as potency, 
ADME and toxicity. 
In conclusion, over 1,164 drugs have entered clinical trials, 690 of which target 283 new 
targets. Analysis of the therapeutic, biochemical, physicochemical, and systems features 
of these clinical trial targets and drugs reveals areas of focuses, progresses and 
distinguished features. Many new targets, particularly GPCRs and kinases in upstream 
signaling pathways, are in advanced trial phases against cancer, inflammation, nervous 
and circulatory systems diseases, and nutritional and metabolic disorders. Majority of the 
new targets show sequence and systems profiles similar to those of successful targets, but 
 Chapter 4 Therapeutic targets in clinical trial  125 
fewer of them show overall sequence, structure, physicochemical, and systems features 
resembling those of successful targets. Drugs in advanced trial phases show improved 
potency but increased lipophilicity and molecular weight with respect to approved drugs, 
and improved potency and lipophilicity but increased molecular weight (particularly for 
novel targets) compared to HTS leads. These suggest a need for further improvement in 
drug-like and target-like physicochemical features. 
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Table 04- 1 Number of clinical trial targets in different disease classes* 
Index Disease Class 
Number of Targets in All Trial 
Phases, Phase III, II, and I 




This Disease Class 
a b c d e f g h i j k l m n o p 
a Blood and blood-forming organ disease 14, 3, 6, 5 3, 0, 2, 1  7 0 0 0 1 1 0 0 0 0 3 0 3 2 0 
b Circulatory system diseases 52,18,24,10 7, 3, 3, 1 7  2 1 2 13 0 4 4 5 2 20 2 21 9 0 
c Digestive system diseases 7, 4, 3, 0 0, 0, 0, 0 0 2  1 1 2 0 0 2 1 1 1 0 2 4 0 
d Genitourinary system diseases 7, 3, 4, 0 0, 0, 0, 0 0 1 1  1 2 0 2 0 2 0 1 1 0 2 0 
e 
Musculoskeletal system and connective 
tissue diseases 
12, 3, 9, 0 0, 0, 0, 0 0 2 1 1  4 0 1 0 2 1 4 0 6 0 1 
f Nervous system and sense organ disease 57,21,24,12 16, 5, 7, 4 1 13 2 2 4  0 3 4 2 3 14 7 14 9 0 
g Respiratory system diseases 10, 3, 7, 0 0, 0, 0, 0 1 0 0 0 0 0  1 0 1 2 8 1 2 0 0 
h Skin and subcutaneous tissue disease 17, 2,13, 2 1, 1, 0, 0 0 4 0 2 1 3 1  0 5 2 9 1 5 2 0 
i Endocrine disorders 20, 8, 8, 4 2, 0, 0, 0 0 4 2 0 0 4 0 0  0 1 1 0 7 14 0 
j Immunity disorders 34, 5,22, 7 6, 1, 3, 2 0 5 1 2 2 2 1 5 0  3 20 2 9 4 0 
k Infectious and parasitic diseases 26, 4,16, 6 12, 0, 9, 3 0 2 1 0 1 3 2 2 1 3  2 0 7 1 0 
l Inflammation 70,20,22,10 8, 2, 3, 1 3 20 1 1 4 14 8 9 1 20 2  4 26 6 0 
m Mental disorders 22,10, 7, 5 8, 2, 4, 2 0 2 0 1 0 7 1 1 0 2 0 4  4 4 0 
n Neoplasm 133,33,66,34 70,12,37,21 3 21 2 0 6 14 2 5 7 9 7 26 4  6 1 
o Nutritional and Metabolic diseases 43,14,24, 5 7, 4, 3, 0 2 9 4 2 0 9 0 2 14 4 1 6 4 6  0 
p Congenital anomalies 2, 0, 1, 1 1, 0, 0, 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0  
Total clinical trial therapeutic targets in all trial 
phases based on disease classes 
516 (duplicate); 
286 (distinct) 
141 Redundancy of therapeutic targets = 145; non-redundancy of therapeutic targets = 141 
* The total number of non-redundant clinical trial targets in all trial phases is 286, 145 of which are for more than one disease classes. Because of this redundancy of 
targets, the sum of the number of targets in these classes is greater than 286. The number of targets shared between different disease classes is also given in the table. 
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Table 04- 2 Distribution of the phase III, II, and I targets that are similar or resemble the properties of successful targets in sequence (A), drug-binding 
domain structural fold (B), physicochemical features (C), and systems profiles (D) 
Similarity in combinations of sequence (A), structural (B), physicochemical (C), and 
systems (D) profiles 
No and Percentage of the 
30 Phase III Targets in 
This Catagory 
No and Percentage of the 
84 Phase II Targets in This 
Catagory 
No and Percentage of the 
41 Phase I Targets in This 
Catagory 
Similarity in all four profiles A, B, C, D  3     (10.0%) 7     (  8.3%) 1     (  2.4%) 
Similarity in any 3 profiles of A, B, C, D  15   (50.0%) 21   (25.0%) 4     (  9.8%) 
 Combination of A, B, C 5     (16.7%) 10   (11.9%) 1     (  2.4%) 
 Combination of A, B, D 7     (23.3%) 11   (13.1 %) 4     (  9.8%) 
 Combination of A, C, D 9     (30.0%) 14   (16.7%) 1     (  2.4%) 
 Combination of B, C, D 3     (10.0%) 7     (  8.3%) 1     (  2.4%) 
Similarity in any one profile of A, B, C, D  28   (93.3%) 51   (60.7%) 25   (61.0%) 
 Only A 18   (60.0%) 39   (46.4%) 17   (41.5%) 
 Only B 11   (36.7%) 26   (31.0%) 8     (19.5%) 
 Only C 13   (43.3%) 21   (25.0%) 3     (  7.3%) 
 Only D 23   (76.7%) 31   (36.9%) 13   (31.7%) 
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Table 04- 3 Median potency, molecular weight, AlogP, the number of H-bond donor and H-bond acceptor, and the number of 
rotatable bond of approved, all clinical trial, phase , II and III drugs, and clinical trial drugs targeting novel clinical trial targets, 
clinical trial targets protein subtype as a successful target, and successful targets. 



























Approved drugs 74.608 342.386 2.787 2.190 5.847 4.554 
All clinical trial drugs 32.210 403.352 3.915 2.177 6.827 5.620 
Phase III clinical trial drugs 19.475 387.637 3.831 1.962 6.445 4.829 
Phase II clinical trial drugs 29.587 406.791 3.993 2.195 6.802 5.725 
Phase I clinical trial drugs 46.365 416.812 3.865 2.422 7.379 6.441 
Clinical trial drugs targeting novel clinical 
trial targets 
25.485 412.756 4.018 2.200 7.174 5.613 
Clinical trial drugs targeting clinical trial 
targets with protein subtype as successful 
targets 
32.973 412.090 3.826 2.559 7.126 6.216 
Clinical trial drugs targeting successful 
targets 
39.910 394.768 3.878 2.047 6.518 5.444 
HTS drug leads255 30 406 4.1 (CLogP) NA NA NA 
WOrld of Molecular BioAcTivity database 




1 5 10 
WOrld of Molecular BioAcTivity database 




1 4 6 
Inactives277 NA 260.2 
2.00 
(CLogP) 
0 3 4 
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Figure 04- 1 Top-10 PFAM protein families that contain high number of phase I (yellow), II (green), and III (orange) 
clinical trial targets along with the number of targets in each family 
 
Figure 04- 2 Top-20 KEGG pathways that contain high number of phase I (yellow), II (green), and III (orange), and all 
clinical trial targets (brown) along with the number of targets in each pathway 
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Figure 04- 3 Number of phase I (yellow), II (green), and III (orange) targets distributed in various sub-cellular locations 
 
Figure 04- 4 Top-10 Pfam protein families that contain high number of clinical trial (orange) and successful (red) targets 
along with the number of targets in each family 
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Figure 04- 5 Top-10 clinical trial (orange) and successful (red) targets targeted by phase II clinical trial drugs 
 
Figure 04- 6 Top-10 clinical trial (orange) and successful (red) targets targeted by phase III clinical trial drugs 
 
Figure 04- 7 Top-10 clinical trial (orange) and successful (red) targets targeted by all clinical trial drugs 
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Figure 04- 8 Distribution of all clinical trial targets (orange) and the innovative successful targets (approved by FDA 
from 1995 to 2008) (red) by crudely estimated target exploration time 
 
Figure 04- 9 Distribution of phase I (yellow), phase II (green), and phase III (orange) clinical trial targets by crudely 
estimated target exploration time 
 
Figure 04- 10 Distribution of phase I (yellow), phase II (green), and phase III (orange) clinical trial targets and 
discontinued clinical trial targets (blue) by level of similarity to successful targets* 
 
* The level of similarity to successful targets is classified into very similar, marginally similar, and un-similar with Blast 
E-values in the range of ≤ 0.001, 0.001~0.1 and ≥0.1 respectively.
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Figure 04- 11 Distribution of all clinical trial targets and successful targets with respect to the number of human 
similarity proteins outside the target family 
 
Figure 04- 12 Distribution of all clinical trial targets and successful targets with respect to the number of human 
pathways the target is associated with 
 
Figure 04- 13 Distribution of all clinical trial targets and successful targets with respect to the number of human tissues 
the target is distributed in 
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Figure 04- 14 Distribution of clinical trial drugs (orange) and approved drugs (red) by potency (IC50, EC50, Ki etc in 
units of nM) 
 
Figure 04- 15 Distribution of phase I (yellow), II (green), and III (orange) clinical trial drugs and discontinued clinical 
trial drugs (blue) by potency (IC50, EC50, Ki etc in units of nM) 
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Figure 04- 16 Distribution of clinical trial drugs (orange) and approved drugs (red) by molecular weight 
 
Figure 04- 17 Distribution of phase I (yellow), II (green), and III (orange) clinical trial drugs by molecular weight 
 
Figure 04- 18 Distribution of clinical trial drugs targeting novel clinical trial targets (green), clinical trial targets with 
protein subtype as successful target (brown), and successful targets (pink) by molecular weight 
 
 Chapter 4 Therapeutic targets in clinical trial  136 
 
Figure 04- 19 Distribution of clinical trial drugs (orange) and approved drugs (red) by ALogP 
 
Figure 04- 20 Distribution of phase I (yellow), II (green), and III (orange) clinical trial drugs and discontinued clinical 
trial drugs (blue) by ALogP 
 
Figure 04- 21 Distribution of clinical trial drugs targeting novel clinical trial targets (green), clinical trial targets with 
protein subtype as successful target (brown), and successful targets (pink) by ALogP 
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Figure 04- 22 Percentage of phase I (yellow), II (green), III (orange) clinical trial drugs and approved drugs (red) 
obeying Lipinsky‟s rule of five (dark color), with one violation of rule of five (medium color) and the others (light color). 
The numbers in this figure refer to number of drugs. 
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Chapter 5 Identification of next generation innovative 
therapeutic targets: an application to clinical trial targets 
The majority of clinical drugs achieve their therapeutic effects by binding and modulating 
activity of protein targets
6,253,281
. Intensive efforts in searching for target
75,76,227,282,283
 have 
discover > 1,000 research targets (targeted by investigational agents only)
227
. These 
targets have been derived from analysis of disease relevance, functional roles, expression 
profiles and loss-of-function genetics of normal & disease state
272,273,284-289
. Many targets 
have been targeted by target-selective lead
227,290
. Despite heavy spending and exploration 
of techniques
291
, fewer innovative targets have emerged
272
. It typically takes 8~20 years 
to derive a marketed drug against these innovative targets
227
. Innovative targets refer to 
the targets with no other sub-type of the same protein successfully explored before. 
Low productivity of innovative targets
272
 has been attributed to problems in target 
selection and validation
148,272,273
. A particular problem is inadequate physiological and 
clinical investigations
272,273,292
. Drug effects are due to interactions with various sites of 
human physiological systems and pathways as well as its intended target, which 
collectively determine the success of target exploration
227
. Current efforts have been 
focused on target-selective agents minimally interacting with other human members of 
the target family
6,293
. However, their possible interactions with other human proteins, 
pathways and tissues have not been fully considered, leading to frequent failures in 
subsequent development stages. Therefore, a target cannot be fully validated by 
considering disease relevance and target-selectivity alone
272,273
. 
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Integrated target and physiology-based approaches have been proposed for target 
identification and validation
272,273
. Different in silico approaches have been explored for 
target prediction based on sequence similarity
226,227
, structural similarity and binding-site 
geometric and energetic features
275,276
, target physicochemical and other characteristics 
detected by machine learning
144,227,241
, and systems-profiles (similarity to human proteins, 
pathway and tissue distribution)
227,270,274
. We evaluated whether target prediction can be 
improved by combinations of these approaches, which were tested against 155 clinical 
trial targets (Data are collected from CenterWatch Drugs in Clinical Trials Database 2009 
http://www.centerwatch.com/drug-information/pipeline/), 864 non-clinical trial research 
targets
294
, 19 difficult targets currently discontinued in clinical trials (with clinical trial 
drug discontinued and no new drug entered clinical trial at the moment) (Data from 
CenterWatch Drugs in Clinical Trials Database 2009), and 65 non-promising targets 
failed in large-scale HTS campaigns
295
 or found non-viable in knockout studies
296
. 
In summary, low target discovery rate has been linked to inadequate consideration of 
multiple factors collectively contributing to druggability. These factors include sequence, 
structural, physicochemical and systems profiles. Methods individually exploring each of 
these profiles for identifying target have been developed but have not been collectively 
used. In the following sections of the chapter, we evaluated the collective capability of 
these methods in identifying promising targets from 1,019 research targets based on the 
multiple profiles of up to 320 successful targets. As shown by the results, the collective 
consideration of multiple profiles demonstrated promising potential in identifying the 
innovative therapeutic targets. 
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5.1 Summary on materials and methods applied for drug target 
identification 
As shown in Chapter 2 Section 2.3, four in silico approaches have been applied for the 
identification of drug targets, which include: physicochemical property of drug targets 
identified by machine learning; sequence similarity in drug-binding domains; structural 
fold comparison of drug-binding domains; and simple system level druggability rules. 
5.1.1 Target classification based on characteristics of successful targets 
detected by a machine learning method 
Promising targets can be separated from other proteins based on the structural and 
physicochemical characteristics of successful targets detected by a machine learning 
method. By using sequence-derived structural and physicochemical descriptors of the 
successful targets and those of other proteins, a machine learning algorithm attempts to 
separate successful targets from other proteins by searching for a projection function that 
maps the descriptors of successful targets and those of other proteins into separate 
regions in a high-dimensional feature space, and these regions are separated by easily 
defined borders. A research target is classified as promising if it is located in the region 
of successful targets, which is not necessarily similar in sequence to any successful target 
because the mapping to the feature space is typically nonlinear and the proteins are 
characterized by structural and physicochemical descriptors rather than sequence. 
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The machine learning method used in this work is support vector machines (SVM), 
which is a supervised learning methods used for classification of objects (e.g. proteins) 
into two classes (e.g. promising targets and other proteins) and has been applied to target 
prediction
227
. Details of SVM can be found in Chapter 2 Methodology Section 2.3.1. In 






                                                    (1) 
The non-linear SVM projects feature vectors into a high-dimensional feature space using 
the kernel function defined above.  The linear SVM was then applied to produce a single 
hyper-plane that separates targets from non-targets. A SVM prediction system was 
developed by using the feature vectors of the structural and physicochemical properties of 
320 successful targets and 24066 putative non-targets generated by a procedure described 
in our earlier study
241
, which was used to screen the 1,019 research targets for identifying 
potential promising targets. The sequence-derived structural and physicochemical 
descriptors used in SVM include amino acid composition, dipeptide composition, 
sequence autocorrelation descriptors, sequence coupling descriptors, and the descriptors 
for the composition, transition and distribution of hydrophobicity, polarity, polarizibility, 
charge, secondary structures, surface tension, and normalized Van der Waals volumes
191
. 
5.1.2 Sequence similarity analysis between drug-binding domain of 
studied target and that of successful target 
BLAST
219
 was applied to determine the level of similarity between sequence of the drug-
binding domain of each studied research target and the sequence of drug-binding domain 
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of each of the 168 successful targets with identifiable drug-binding domains. The BLAST 
program was downloaded from NCBI (ftp://ftp.ncbi.nlm.nih.gov/blast/executables/). A 
stricter BLAST cut-off, E-value = 0.001, was used for selecting research targets which 
are similar to a successful target, i.e., the E-value of the drug-binding domains is ≤ 0.001. 
The detail strategy utilized by this analysis is described in Chapter 2 Methodology 
Section 2.3.2. 
5.1.3 Structural comparison between drug-binding domain of studied 
target and that of successful target 
The ligand-binding or catalytic sites are the most relevant subsets of a domain, which are 
normally located within the so-called ligand-sensing core where actual catalytic 
conversion of enzyme substrates, or the binding event of small-molecule ligands, occurs. 
It has been suggested that structural similarity considerations should be confined to 
ligand-sensing cores, instead of whole domains, according to 3D similarities with respect 
to so-called protein structure similarity clusters
225
. In this study, ligand-sensing or 
catalytic cores of drug-binding domain of the studied research target were clustered 
against those of 129 successful targets with available 3D structure based on visual 
inspection and structural superimposition and alignment tools in SYBYL (SYBYL® 6.7 
Tripos Inc., St. Louis, Missouri, USA). and Insight II (Insight II® Accelrys Software Inc, 
San Diego, CA) following the same procedure used for generating SCOP structural 
folds
224
. For details information of structural comparison, please refer back to Chapter 2 
Methodology Section 2.3.3. 
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5.1.4 Computation of number of human similarity proteins, number of 
affiliated human pathways, and number of human tissues of a target 
These quantities are needed for determining whether or not a studied target obeys the 
simple systems-level druggability rules. Human similarity proteins of a target are those 
human proteins whose drug-binding domain is similar to that of the studied target by 
using the same BLAST method as that for analyzing sequence similarity between drug-
binding domain of studied target and that of successful target
219
. Information about the 
affiliated pathways of a target was obtained from KEGG
228
 (http://www.genome.jp/kegg/). 
In estimating the number of human tissues of each target is distributed, relevant data from 
the Swissprot database were used. We were able to find the published literature for 92% 
of these data, and a random check of these publications confirms the quality of the data. 
We have also used the level-4 tissue-distribution data from another database, 
TissueDistributionDBs (http://genome.dkfz-heidelberg.de/menu/tissue_db/index.html), to 
derive the tissue distribution pattern of the same set of 158 successful targets. A target is 
assumed to be primarily distributed in a tissue if no less than 8% of the total protein 
contents are distributed in that tissue. Approximately 28, 24, 19, 10, 6, 6, 5, and 1% of 
these targets were found to be affiliated with 1 to 8 tissues, respectively, which are 
roughly similar to those derived from Swissprot data
227
, although the definition and 
content of these databases are somehow different. Therefore, our estimated tissue 
distribution profiles are quite stable even though the exact percentages may differ by 
some degrees. Please refer back to Chapter 2 Methodology Section 2.3.4 for detail 
information. 
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5.2 Target identification by collective analysis of sequence, 
structural, physicochemical, and system profiles of successful 
targets 
Each in silico target prediction approach has its unique advantages and limitations. 
Sequence similarity to the drug-binding domain of a successful target may indicate 
druggability, which has been extensively explored for target identification
226,275
. However, 
it cannot fully capture druggable features not reflected by homology
275
 and tend to 
indiscriminately select homologous proteins. Targets can be identified by structural 
similarity to drug-binding domain and binding-site geometric and energetic features
275
, 
which are less effective for covering proteins of unknown structure and for describing 
systems profiles. 
Druggability is collectively determined by target structural and physicochemical 
properties, ability to conduct certain interactions and functions, and patterns of pathway, 
sub-cellular and tissue distributions
227
. Many of these individual properties can be 
predicted by machine learning
68
 which have been explored for target 
prediction
144,201,227,241
. This approach cannot fully capture such systems profiles as 
pathway affiliation and may disproportionately interpret certain physicochemical 
properties due to biases in protein descriptors or training datasets. Simple systems-level 
druggability rules have been derived
227
, which are summarized as follows: targets are 
similar to fewer (<15) human proteins of non-target family and associated with fewer (≤3) 
human pathways tend to bind drugs with reduced side-effects, and high efficacy drugs 
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may be more easily derived from targets expressed in fewer tissues (≤5) or located within 
blood vessels or cells lining the arteries where they have higher priority (P) to bind drugs 
than targets in other tissues. These systems-level rules are not intended for describing 
structural, physicochemical, and functional aspects of druggability. 
These limitations may be reduced if those approaches are combined. Four in silico 
methods were developed from the relevant profiles of up to 320 successful targets in TTD 
database
294
. Method A measures drug-binding domain sequence similarity against those 
of 168 successful targets with identifiable drug-binding domains. Method B studies drug-
binding domain structural similarity against those of 129 successful targets with available 
structures. Method C predicts druggable proteins from a machine learning model trained 
by 320 successful targets
241
. Method D evaluates whether the systems-level druggability 
rules
227
 are satisfied. More detailed descriptions about these methods are given in 
Chapter 2 Methodology. 
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5.3 Performance of target identification on clinical trial, non-
clinical trial, difficult, and non-promising targets 
The collective predictive performance of the four methods was tested against clinical trial 
(from CenterWatch Drugs in Clinical Trials Database) and non-clinical trial research 
targets
294
. Clinical trial targets that have drugs in multiple phases are only included in the 
highest phase category. The best overall performance was produced by the combination 
of at least three methods, which maximize the collective predictive capability of the 
methods and minimize the impact of limited structural availability. This combination 
identified 50% of the 30 phase III (Table 05-1), 25% and 10% of the 84 phase II and 41 
phase I (Table 05-2), and 4% of the 864 non-clinical trial research targets as promising. 
We were unable to find a report about target success rates in different development stages. 
It is noted that the reported probabilities of successes in developing systemic broad-
spectrum antibacterials are 67%, 50%, 25%, and 3% in phase III, phase II, phase I, and 
preclinical stages
295
. The percentages of the identified promising clinical trial targets are 
lower than but roughly follow a similar descending trend as the reported drug 
development rates. The overall performance of different combinations is given in Table 
05-3. These combinations enriched Phase II and phase III target identification rate by 
4.0~6.0 fold over random selection, with the combination of all four methods producing 
the highest enrichment. 
The 15 identified promising phase III targets include 7 of the 8 targets with positive 
phase III results. These include 5 innovative targets without a protein-subtype as a 
successful target (BK-2 receptor, C1 esterase, CCK-A receptor, NK-2 receptor and 
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plasma kallikrein) and 2 conventional targets having a different protein-subtype as a 
successful target (5HT3 receptor and CXCR4). Overall, 60%, 43%, and 50% of the 
predicted phase III, phase II, and phase I targets are innovative, which seems to indicate 
substantial level of successes in exploring novel targets. Most of the identified promising 
clinical trial targets are from the highly successful GPCR, tyrosine kinase, serine protease 
and ABC transporter families for the treatment of cancers, cardiovascular diseases, neural 
disorders, arthritis, diabetes and obesity, which suggests that these families continue to be 
attractive sources for target discovery
59,227,253
. 
The 15 phase III targets dropped by the combination method (Table 05-4) include MMPs, 
kinases of CMGC, AGC and DAGK classes, farnesyltransferases, oxygenase, 
phospholipase and others. Only one of these, heme oxygenase, has a positive phase III 
result reported in 2004. It is noted that this protein is important for attenuating oxidative 
stress and inflammation and its inhibition may lead to some adverse effects
297
. The 
difficulty in exploring some of these targets has been reported
227
. MMP inhibitors have 
been explored since the early 1990s but their trials have not yielded good results due 
primarily to the lack of subtype selectivity, bioavailability and efficacy as well as 
inappropriate study design
298
. Despite successes in developing several tyrosine kinase 
inhibitors, kinase inhibitor discovery remains difficult particularly for non-tyrosine kinase 
classes partly due to broad promiscuity that causes off-target side effects
299




The combination method dropped 17 of the 19 difficult targets currently discontinued in 
clinical trials (Table 05-5) and 63 of the 65 non-promising targets failed in HTS 
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campaigns or found non-viable in knockout studies (Table 05-6). 12 of the 17 un-
predicted difficult targets have been discontinued since 2004 without another drug 
entering clinical trial. In the HTS campaigns for testing 70 antibacterial targets, up to 
~500,000 compounds have been screened at a concentration of 10 µM, 33 of which have 
yielded no hit and can thus be considered to be highly un-promising
295
. Target knockout, 
extensively explored for target validation, has been applied to the validation of 55 targets 
in Mycobacterium tuberculosis, 32 of which have been found to be non-viable for 
developing drugs
296
. The low rate in selecting these difficult and unpromising targets 
suggests that combinations of target prediction methods are capable of eliminating 
unpromising as well as selecting promising ones. As a supplementary data, Table 05-7 
shown the definitions and structures (if available) of drugs and compounds used in this 
chapter. 
In conclusion, collective use of multiple in silico methods is capable of identifying high 
percentages of phase III targets including most of the targets of positive phase III results, 
and of eliminating difficult and un-promising ones. Our study suggests that comparative 
analysis of multiple profiles of successful targets provides useful clues to the 
identification of promising targets. Overall, 71 targets were predicted as promising from a 
pool of 1,019 targets. This number is likely constrained by the limited knowledge from 
the 320 known successful targets and limited structural information for large percentage 














, various in silico methods are being developed. These 
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protein inverse docking
279





 for recognizing target-like and druggable 
proteins. These progresses combined with increased molecular understanding of 
diseases
280
 and their corresponding targets
227
 enable the development of efficient tools for 
identifying innovative targets of new therapies and personalized medicine. 
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Target Exploration Status 
(Tested Drug)  
Positive Results in Phase III Trial 




of A, B, C, D 





Favourable topline results in patients 
with constipation–predominant Irritable 
Bowel Syndrome (2007) 
Coagulation factor IIa* 
Combination 
of A, B, C, D 








of A, B, C, D 
3 6 2 
Acute Myeloid 
Leukemia 
Phase II/III (lestaurtinib)  
5HT 3 receptor 
Combination 
of A, C, D 
1 0 2 
Irritable Bowel 
Syndrome 
Phase III (cilansetron) 
Positive data for treating irritable bowel 




of A, C, D 
2 0 2 
Hepatocellular 
Cancer 
Phase III (PI-88)  
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MDR 3 
Combination 
of A, C, D 
1 0 3 
Acute Myeloid 
Leukemia 




of A, C, D 
1 0 2 Sleep Disorders Phase III (almorexant)  
Somatostatin receptor 1 
Combination 
of A, C, D 




Phase III (Pasireotide), 




of A, C, D 
2 0 3 Depression Phase III (Saredutant) 
Overall statistically significant efficacy 
versus placebo, well tolerated (2007) 
BK-2 receptor* 
Combination 
of A, B, C 





Phase III (icatibant), 
Phase II (anatibant) 
Positive results for the treatment of 
hereditary angioedema (2006) 
Thrombin receptor* 
Combination 
of A, B, C 
4 0 5 
Cardiovascular 
Disorders 
Phase III (SCH-530348)  
CXCR4 
Combination 
of A, B, D 
3 2 P 
Non-Hodgkin's 
Lymphoma, Late-
stage Solid Tumors 
Phase III (AMD-3100), 
Phase I/II (AMD-070), 
Phase I (MSX-122) 
Positive results for the treatment of 
multiple myeloma (2007) 
C1 esterase* 
Combination 
of A, B, D 
1 3 P 
Hereditary 
Angioedema 
Phase III (C1-INH) 
Positive results for treating hereditary 
angioedema, significantly decreases the 
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number of attacks in patients (2007) 
NPYR5 
Combination 
of A, B, D 
1 0 2 Obesity Phase III (CGP71683A)  
Plasma kallikrein* 
Combination 
of A, B, D 
1 0 5 
Hereditary 
Angioedema 
Phase III (DX-88) 
Positive top-line results for treating 
hereditary angioedema, well tolerated 
(2007) 
Targets marked by* are innovative targets without a protein-subtype as a successful target. Tissue distribution “P” represents cases where target is distributed in 
>5 tissues but the disease relevant targets are located within blood vessels or cells lining the arteries where they have higher priority to bind drugs. 
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of A, B, C, D 
1 0 1 Rheumatoid Arthritis, Multiple Sclerosis Phase II (INCB3284), Phase I (CCX915) 
ErbB-4 
Combination 
of A, B, C, D 
3 4 2 Breast Cancer Phase II (CI-1033) 
FGFR-3 
Combination 
of A, B, C, D 
3 0 4 Solid Tumors, Multiple Myeloma Phase II (XL999), Phase I (CHIR-258) 
Guanylate cyclase B* 
Combination 
of A, B, C, D 
3 0 1 Heart Disease Phase I a (CD-NP), Preclinical (guanilib) 
HDAC4 
Combination 
of A, B, C, D 
1 1 P Basal Cell Carcinoma, Melanoma, Cancer 
Phase II (Avugane, romidepsin, MS-275, 
PXD101) 
Neuropeptide Y Combination 1 0 4 Obesity Phase II (Obinepitide) 
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of A, B, C, D 
1 0 3 Schizophrenia, Schizoaffective Disorders Phase I/II (TM30339) 
Toll-like receptor 3 
Combination 
of A, B, C, D 
1 0 2 Human Papillomavirus Infections Phase II (HspE7) 
FGFR-1 
Combination 
of A, B, C 
5 0 >10 Coronary Heart Disease, Solid Tumors Phase II (XL999), Phase II (FGF-1) 
PKC-gamma 
Combination 
of A, B, C 
16 0 4 Acute Myocardial Infarction 





of A, B, C 
1 4 >10 Lung Cancer, Solid Tumors Phase II (XL647) 
Histamine H3 receptor 
Combination 
of A, C, D 
1 0 4 
Attention-deficit hyperactivity disorder, 
Alzheimer's disease, Schizophrenia 




of A, C, D 
1 0 4 Cancer, Renal Cell Carcinoma Phase II (LY293111), Phase I (Biomed 101) 
Motilin receptor* 
Combination 
of A, C, D 
1 0 1 
Irritable Bowel Syndrome, Gastrointestinal 
Disorders 




of A, C, D 
2 0 1 Schizophrenia, Schizoaffective Disorders Phase II b (osanetant), Phase II (talnetant) 




of A, C, D 
1 2 3 Solid Tumors Phase II (CAP-232) 
Tissue kallikrein-2* 
Combination 
of A, C, D 
1 0 2 Atopic Dermatitis Phase II (Dermolastin) 
Toll-like receptor 8 
Combination 
of A, C, D 
1 0 5 
Genital Warts, Systemic Lupus 
Erythematosus 
Phase II (resiquimod), Phase I (CPG 52364) 
CDK7 
Combination 
of A, B, D 
1 1 P B-cell malignancies Phase I (SNS-032) 
Coagulation factor IX* 
Combination 
of A, B, D 
1 5 1 Thrombosis, Venous Thromboembolism 




of A, B, D 




of A, B, D 





of A, B, D 
3 0 P Obesity Phase II (MBX-8025), Phase I (KD3010) 
Serine/threonine-
protein kinase Chk2 
Combination 
of A, B, D 
2 0 4 Solid Tumors Phase I (XL844), Phase I (UCN-01) 
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Serine/threonine-
protein kinase PLK* 
Combination 
of A, B, D 
1 1 P 
Pancreatic, prostate and a number of other 
cancers 
Phase I (HMN-214) 
Targets marked by* are innovative targets without a protein-subtype as a successful target. Tissue distribution P represents cases where target is distributed 
in >5 tissues but the disease relevant targets are located within blood vessels or cells lining the arteries where they have higher priority to bind drugs. 
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Table 05- 3 Statistics of promising targets selected from the 1,019 research targets by combinations of methods A, B, C and D, and clinical trial target enrichment factors 
Method or Combination 
No and Percentage 
of the 30 Phase III 
Targets Predicted 
by Method 
No and Percentage 
of the 84 Phase II 
Targets Predicted 
by Method 
No and Percentage 
of the 41 Phase I 
Targets Predicted 
by Method 
No and Percentage of 
the 864 Non-Clinical 
Trial Targets Predicted 
as Target by Method 
Target Prediction 
Enrichment 
Factor for Phase 
II and III Targets 
Target Prediction 
Enrichment Factor 
for All Clinical Trial 
Targets 
Combination of A, B, C, D  3     (10.0%) 7     (  8.3%) 1     (  2.4%) 4     (  0.5%) 6.0 4.8 
Any 3-combination of A, B, C, D  15   (50.0%) 21   (25.0%) 4     (  9.8%) 31   (  3.6%) 4.5 3.7 
 Combination of A, B, C 5     (16.7%) 10   (11.9%) 1     (  2.4%) 8     (  0.9%) 5.6 4.4 
 Combination of A, B, D 7     (23.3%) 11   (13.1 %) 4     (  9.8%) 18   (  2.1%) 4.0 3.6 
 Combination of A, C, D 9     (30.0%) 14   (16.7%) 1     (  2.4%) 14   (  1.6%) 5.4 4.2 
 Combination of B, C, D 3     (10.0%) 7     (  8.3%) 1     (  2.4%) 6     (  0.7%) 5.3 4.3 
Any of A, B, C, D  28   (93.3%) 51   (60.7%) 25   (61.0%) 283 (32.8%) 1.8 1.8 
 A 18   (60.0%) 39   (46.4%) 17   (41.5%) 125 (14.5%) 2.6 2.4 
 B 11   (36.7%) 26   (31.0%) 8     (19.5%) 95   (11.0%) 2.4 2.1 
 C 13   (43.3%) 21   (25.0%) 3     (  7.3%) 75   (  8.7%) 2.7 2.2 
 D 23   (76.7%) 31   (36.9%) 13   (31.7%) 138 (16.0%) 2.4 2.1 
Targets that have drugs tested in multiple phases are only included in the highest phase category. 
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Targeted Disease Conditions Target Exploration Status (Tested Drug) 
AKT 
Combination 
of A, B 
25 1 P 
Non-Hodgkin's Lymphoma, Multiple 
Myeloma, Renal Cell Carcinoma 
Phase III (enzastaurin), Phase II (perifosine), Phase 




of A, B 
4 0 P 
Lymphocytic leukemia, Lung Cancer 
(NSCLC), Non-Hodgkin's Lymphoma 
Phase III (flavopiridol), Phase II completed 
(seliciclib), Phase I/II (AT7519), Phase I (SNS-
032), Preclinical (capridine-beta) 
Alpha-glucosidase 
Combination 
of A, D 
2 0 P Cardiovascular Disorders Phase III (acarbose), Phase II (celgosivir) 
Squalene synthetase 
Combination 
of C, D 
2 0 4 Hyperlipidemia Phase III (TAK-475) 
Arachidonate 5-
lipoxygenase-activating 
Only D 1 0 1 
Coronary Artery Disease, Heart 
Attack, Cardiovascular Disorders 
Phase III (DG031), Phase I (AM803, AM103) 
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protein 
Heme Oxygenase # Only D 1 0 1 Neonatal Hyperbilirubinemia, Jaundice Phase III (stannsoporfin) 
Farnesyl protein 
transferase 
Only D 2 0 P Myeloid Leukemia Phase III (R115777) 
Lipoprotein-associated 
phospholipase A2 
Only D 1 0 P 
Atherosclerosis, Cardiovascular 
Disorders 
Phase II/III (darapladib), Phase I (659032) 
MMP-12 Only D 1 0 4 Lung Cancer (NSCLC) Phase III (AE-941) 
Myophosphorylase Only D 2 0 1 
Lymphocytic Leukemia, Diabetes 
Mellitus 
Phase III (flavopiridol), Phase IIa (PSN357) 
Neutral endopeptidase Only D 3 0 P 
Hypertension, Congestive Heart 
Failure 
Phase II/III (Ilepatril), Phase II (SLV 306) 
Sphingosine kinase Only D 3 0 4 Ovarian Cancer Phase III (phenoxodiol) 
Heat shock protein HSP 
90 
Only C 1 0 >10 
Multiple Myeloma, Metastatic Breast 
Cancer, Prostate Cancer 
Phase III (tanespimycin), Phase II (alvespimycin 
hydrochloride, IPI-504), Phase I (CNF1010, SNX-
5422, STA-9090), IND filed (AT13387) 
Cathepsin K None No-Info 0 4 Osteoporosis, Bone Metastases 
Phase III (odanacatib), Phase II (relacatib), Phase 
I/II (MIV-701), 
MMP-2 / MMP-9 None 3 0 6 Lung Cancer (NSCLC), Osteoarthritis Phase III (Neovastat), Phase II (PG-530742) 
The target marked by # has a positive phase-III result reported in 2004, but since then there has been no report about the further progress of the phase III drug. 
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of A, B, C, D 




Prolactin receptor (PRLR) 
Combination 




February of 2004 Not Clear 
B-cell surface antigen 
CD40 
Combination 
of A, B 
Cancer/Tumors Avrend (Amgen) January of 2002 
In 1998, phase I results showed few changes in 
circulating leukocyte subsets after a five-day course of 
treatment. In January 2002, Immunex announced that it 
was no longer developing Avrend. 
C3/C5 convertase 
Combination 















In November 2005, Eisai stated that ravuconazole had 
been superceded, hence development was discontinued. 
Cytochrome P450 24A1 Only A Prostate Cancer RC-8800 (Sapphire) August of 2006 Not Clear 
Alpha-mannosidase 2 Only D Cancer/Tumors GD0039 (Inflazyme May of 2002 In May 2002, GlycoDesign discontinued the phase II 
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Pharmaceuticals) clinical trials of GD0039 for the treatment of metastatic 
renal cancer, due to the fact that tumor response and 















April of 2003 
In April 2003, Medigene terminated phase II trials for 
etomoxir based on data suggesting an increase in side 
effects in treated subjects. 
MMP-7 Only D 






June of 2003 
Before 2006 
Results of a phase I trial in cancer subjects showed that 
it caused musculoskeletal pain like marimastat did. At 
its maximum tolerated dose of 20 mg twice daily, BB-
3644 does not show any advantage over marimastat. 
















March of 2007 Not Clear 
 Chapter 5 Identification of innovative targets: an application to clinical trial targets 162 
Cell surface glycoprotein 
MUC18 
None Melanoma ABX-MA1 (Amgen) March of 2005 Not Clear 




July of 2006 
In July 2006, Threshold reported negative results from 
both a phase II and phase III trial of lonidamine for the 
treatment of benign prostatic hyperplasia (BPH). Then, 
Threshold announced its discontinuatioin. 
MMP-8 None 






In June 2003, Celltech and Bristol Meyers Squibb 
announced they were discontinuing the development of 
BMS 275291 in it's current indications due to a general 
lack of efficacy in phase II. 
Pyruvate dehydrogenase 
kinase 









Various Types of 
Cancer 
Tezacitabine (Chiron) March of 2004 
In March 2004, Chiron announced they were 
discontinuing development of tezacitabine due to a lack 
of efficacy in phase II. 
Sodium/hydrogen 
exchanger 1 
None Cardiac Surgery 
Cariporide (Sanofi-
aventis) 








January of 2007 Not Clear 
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Table 05- 6 List of unpromising targets failed in HTS campaigns or found non-viable in knockout studies, and the prediction results 
Target Failed in HTS campaigns or found 
non-viable in knockout studies 
Predicted as Promising by 
Method or Combination 
Exploration 
Results 
Target Failed in HTS campaigns or found 
non-viable in knockout studies 
Predicted as Promising by 
Method or Combination 
Exploration 
Results 
DNA gyrase subunit A Combination of A, C, D Not viable MabA Combination of A, B, D Not viable 
Acyl carrier protein synthase Combination of A, D No hits L tRNA synthetase Combination of A, D No hits 
Penicillin-binding protein-2' Combination of A, D No hits Ribonucleotide reductase Combination of A, D Not viable 
V tRNA synthetase Combination of A, D No hits AccD5 Combination of B, D Not viable 
Alanine racemase Combination of C, D Not viable AroA Combination of C, D Not viable 
D-Ala-D-Ala ligase Combination of C, D Not viable FabH Combination of C, D Not viable 
Thymidine monophosphate kinase Combination of C, D Not viable A tRNA synthetase Only D No hits 
AcpM Only D Not viable AftA Only D Not viable 
AroB Only D Not viable AroC Only D Not viable 
AroE Only D Not viable ArgF Only D Not viable 
AroG Only D Not viable AroK Only D Not viable 
AroQ Only D Not viable Biotin ligase(BirA) Only D Not viable 
Branched-chain amino acid 
aminotransferase 
Only D Not viable C tRNA synthetase Only D No hits 
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Chorismate synthase Only D No hits CoA(PanK) Only D Not viable 
D tRNA synthetase Only D No hits DNA polymerase IIIalpha Only D No hits 
E tRNA synthetase Only D No hits FtsH ATP-dependent protease Only D No hits 
G tRNA synthetase Only D No hits Galactofuraosyl transferase Only D Not viable 
GlmU Only D No hits GlnE Only D Not viable 
H tRNA synthetase Only D No hits IdeR Only D Not viable 
K tRNA synthetase Only D No hits LigA Only D Not viable 
LS, riboflavin synthase Only D Not viable MenA Only D Not viable 
MenB Only D Not viable MenC Only D Not viable 
MenD Only D Not viable MenE Only D Not viable 
MenH Only D Not viable MtrA Only D Not viable 
MurB Only D No hits N tRNA synthetase Only D No hits 
P tRNA synthetase Only D No hits Peptidyl tRNA hydrolase Only D No hits 
Phosphopantetheine adenylyl 
transferase 
Only D No hits R tRNA synthetase Only D No hits 
Ribonuclease P Only D No hits S tRNA synthetase Only D No hits 
Signal peptidases Only D No hits T tRNA synthetase Only D No hits 
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Transketolase Only D No hits 
UDP-N-acety muramyl:L-alanine 
ligase(MurC) 
Only D No hits 
UMP kinase inhibitor Only D No hits 
Undecaprenyl(UDP) pyrophosphate 
synthase 
Only D No hits 
Metallo beta-lactamase Non No hits SecA subunit of preprotein translocase Non No hits 
Serine beta-lactamase Non No hits    
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Table 05- 7 Definitions and structures (if available) of drugs and compounds in this chapter 
Drug Name Definition 
AE-941 
AE-941 (Neovastat®; Aeterna Laboratories, Quebec City, Quebec, Canada) is a novel standardized water-soluble extract derived from shark cartilage 
that represents less than 5% of the crude cartilage. It is a multifunctional antiangiogenic product that contains several biologically active molecules 
being studied for its ability to prevent the growth of new blood vessels to solid tumors. However, the chemical characterization of the standardized 
water-soluble extract derived from shark cartilage has never been performed. United States Patent: 5,618,925. 
References: (Dupont, E, Brazeau, P, and Juneau, C (1997) Extracts of shark cartilage having an antiangiogenic activity and an effect on tumor 
regression; process of making thereof. United States Patent 5,618,925.)301,302 
AM103 
AM103 (Amira Pharmaceuticals, Inc., San Diego, California, USA), 2-[2-(2-Oxo-propyl)-5-(quinolin-2-ylmethoxy)-pyrrolo[2,3-b]pyridin-1-yl]-









References: (Hutchinson JH, Prasit PP, Moran M, Evans JF, Zunic JE and Stock NS (2008) 5-lipoxygenase-activating protein (FLAP) inhibitors. 
United States Patent 7,405,302.)303 (http://www.amirapharm.com/pipeline.html) 
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AM803 
AM803 (Amira Pharmaceuticals, Inc., San Diego, California, USA), [3-Hydroxy-2-methylsulfanylmethyl-5-(pyridin-2-ylmethoxy)-pyrrolo[2,3-
b]pyridin-1-yl]-acetaldehyde, is a novel inhibitor of 5-lipoxygenase-activating protein (FLAP). Information about AM803 and related compounds can 











References: (Hutchinson JH, Prasit PP, Moran M, Evans JF, Zunic JE and Stock NS (2008) 5-lipoxygenase-activating protein (FLAP) inhibitors. 
United States Patent 7,405,302.) (http://www.amirapharm.com/pipeline.html) 
C1-INH 
C1-INH (Lev Pharmaceuticals, New York, USA), also known as C1-inhibitor or C1 esterase inhibitor, has a 2-domain structure including a C-terminal 
serpin domain and an N-terminal tail domain. 
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CAP-232 
CAP-232 (Thallion Pharmaceuticals, Alexander-Fleming Montreal, Quebec, Canada), (1R,4S,7R,10S,13R)-4-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-
hydroxy-1-oxobutan-2-yl]-13-[[(2R)-2-amino-3-phenylpropanoyl]amino]-10-[(4-hydroxyphenyl)methyl]-7-(1H-indol-3-ylmethyl)-3,6,9,12-tetraoxo-





























CPG 52364 (Coley Pharmaceutical Group, Wellesley, Massachusetts, USA), N'-[6,7-Dimethoxy-2-(4-phenyl-piperazin-1-yl)-quinazolin-4-yl]-N,N-
dimethyl-ethane-1,2-diamine, is a small molecule, first-in-class TLR antagonist designed to specifically inhibit TLRs 7, 8, and 9. Information about 
CPG 52364 and related compounds can be obtained from United States Patent: 7,410,975. 
Structure: 











References: (Lipford GB, Forsbach A and Zepp C (2004) Small molecule toll-like receptor (TLR) antagonists. United States Patent 7,410,975.) 
(http://www.medicalnewstoday.com/articles/87013.php) 
INCB3284 
INCB3284 (Incyte Corporation, Wilmington, Delaware, USA), 1-Hydroxy-4-[3-isopropyl-3-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridine-6-
carbonyl)-cyclopentylamino]-cyclohexanecarbonitrile, is a small molecule CCR2 antagonist. Information about INCB3284 and related compounds can 
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References: (Xue CB, Zheng C, Cao G, Feng H, Xia M, Anand R, Glenn J and Metcalf B (2005) 3-(4-
heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors. United States Patent 7,307,086.)308,309 
KAI-9803 
KAI-9803 (KAI Pharmaceuticals Inc., South San Francisco, California, USA), also known as delta-V1-1, is a novel peptide derived from the first 





























































References: 310-312 (http://www.kaipharmaceuticals.com/index.php?option=com_content&task=view&id=18&Itemid=40) 
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KOS-2187 
KOS-2187 (Kosan Biosciences, Hayward, California, USA), 7,10,12,13-Tetrahydroxy-6-[3-hydroxy-4-(isopropyl-methyl-amino)-6-methyl-tetrahydro-
pyran-2-yloxy]-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyl-14-phenyl-oxacyclotetradecan-2-one,  is a 
novel erythromycin-based second-generation motilides, a non-peptide derivative of a natural motilin agonist which demonstrates capacity in addressing 
the serious limitations of first-generation erythromycin analogs. Information about KOS-2187 and other related compounds can be obtained from 
















References: (Santi DV, Metcalf B, Carreras C, Liu Y, McDaniel R and Rodriguez EJ (2005) Motilide compounds. United States Patent 6,946,482.)313 
(Sandham DA (2008) Recent developments in gastrointestinal prokinetic agents. Expert Opinion on Therapeutic Patents 18: 501-514.) 
(http://www.kosan.com/pipeline.html) 
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MBX-8025 
MBX-8025 (Metabolex, Hayward, California, USA), formerly RWJ-800025, is a potent, selective PPAR-delta agonist regulating fatty acid 
degradation, lipid storage/transport and insulin sensitivity, under Phase II clinical development 314. Information about MBX-8025 and other related 













References: (Zhu Y, Ma J, Cheng P, Zhao Z, Gregoire FM and Rakhmanova VA (2005) Substituted triazoles as modulators of PPAR and methods of 
their preparation. United States patent 7,323,480.) (http://www.metabolex.com/MBX-8025.html) 
MLN2222 
MLN2222 (Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA), also known as CAB-2, is a novel proprietary chimeric recombinant 
protein that blocks C3 and C5 convertases. It encodes amino acid residues I to 254 of membrane cofactor protein MCP (excluding the signal sequence) 
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PSN357 
PSN357 (OSI Pharmaceuticals, Melville, New York, USA), 5-Chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid [2-[4-(2-dimethylamino-ethyl)-
piperazin-1-yl]-1-(4-fluoro-benzyl)-2-oxo-ethyl]-amide, is a glycogen phosphorylase inhibitor (GPI). Information about PSN357 and other related 















References: (Bradley SE, Krulle TM, Murray PJ, Procter MJ, Rowley RJ, Sambrook Smith CP and Thomas GH (2005) Pyrrolopyridine-2-carboxylic 
acid amide inhibitors of glycogen phosphorylase. United States patent 7,405,210.)317 (http://www.osip.com/) 
RC-8800 
RC-8800 (Speedel Pharmaceuticals, Bridgewater, New Jersey, USA), 5-(2-{1-[3-(3,4-Dichloro-benzenesulfonyl)-1-methyl-propyl]-7a-methyl-
octahydro-inden-4-ylidene}-ethylidene)-4-methylene-cyclohexane-1,3-diol, is a small molecule acting on the vitamin D (calcitriol) metabolic pathway. 
Information about RC-8800 and other related compounds can be obtained from United States Patent: 7,166,585. 











References: (Posner GH, Crawford K, Yang HW, Jeon HB, Hatcher M, Suh BC, White J and Jones G (2005) 24-Sulfur-substituted analogs of 
1.alpha.,25-dihydroxy vitamin D.sub.3. United States patent 7,166,585.) (http://www.helsinn.com/) 
REG1 
REG1 (Regado Biosciences, Durham, North Carolina, USA) is a two-component system, consisting of an aptamer-based anticoagulant and its matched 
reversal agent. The REG1 anticoagulant component, RB006, is a single-stranded, nucleic acid aptamer. RB006 selectively and potently binds to and 
inhibits factor IXa, a protein that is critical to blood coagulation. The reversal agent, RB007, is a complementary nucleic acid that binds to and 
neutralizes RB006. The amount of RB007 administered allows physicians to fine tune the pharmacodynamic effect of RB006, from slight reduction in 
anticoagulation all the way to complete reversal. United States Patent for REG1 and related nucleic acids is 7,304,041. 
Structure: 
the following is the structure of RB006, while RB007 is the complementary nucleic acid of RB006 

























References: (Rusconi C (2005) Modulators of coagulation factors. United States patent 7,304,041.)318-320. (http://www.regadobiosciences.com/) 
SR-123781A 
SR-123781A (SanofiAventis, Paris, France) is a synthetic hexadecasaccharide comprising an antithrombin (AT) binding domain, a thrombin binding 















































































































Antithrombin (AT) binding domain Neutral domain Thrombin binding domain  
References:321 
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TM30339 
TM30339 (7TM Pharma, Hørsholm, Hørsholm Municipality, Denmark) is an analogue of the natural hormone, Pancreatic Polypeptide, PP. Its 










































































































































































































































































XL418 (Exelixis, San Francisco, California, USA), 3-Bromo-4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-piperazin-1-yl}-1H-
pyrazolo[3,4-d]pyrimidine, is a selective, orally active small molecule mostly like a pyrazolopyrimidine. 










References:323 (Li Q (2007) Recent progress in the discovery of AKT inhibitors as anticancer agents. Expert Opinion on Therapeutic Patents 17:1077-
1130.) (http://www.exelixis.com/) 
XL647 
XL647 (Exelixis, San Francisco, California, USA), (3,4-Dichloro-phenyl)-{6-methoxy-7-[5-(4-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-3-ylmethoxy]-
quinazolin-4-yl}-amine, also named as EXEL-647 or EXEL-7647, is small molecule based on a 4-Methyl-quinazoline-6,7-diol backbone structure. 
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References: (Rice KD, Anand NK, Bussenius J, Costanzo S, Kennedy AR, Kim AI, Peto CJ, Tsang TH and Blazey CM (2004) Receptor-type kinase 
modulators and methods of use. United States patent WO2004006846.)324,325 (Paz K and Zhu Z (2007) Development of Angiogenesis Inhibitors to 
Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy. Top Med Chem 1:333-382.). 
XL844 
XL844 (Exelixis, San Francisco, California, USA), 1-[2-(3-Amino-propoxy)-phenyl]-3-pyrazin-2-yl-urea, also named as EXEL9844, is an 










References: (Boyle RG, Imogai HJ and Cherry M (2008) Chk-1 inhibitors. United States Patent 7,202,244.)326-328 
(http://www.exelixis.com/eortc/posters/EORTC08_395_XL844-002.pdf) 
XL880 
XL880 (Exelixis, San Francisco, California, USA), Cyclopropane-1,1-dicarboxylic acid {3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-
quinolin-4-yloxy]-phenyl}-amide (4-fluoro-phenyl)-amide, is also known as EXEL-2880, GSK1363089 or GSK089. 
Structure: 
















659032 (Human Genome Sciences, Rockville, Maryland, USA), 2-[[(2,3-Difluorophenyl)methyl]thio]-N-[1-(2-methoxyethyl)-4-piperidinyl]-4-oxo-N-
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AT13387 
AT13387 (Astex Therapeutics Limited, Cambridge, England) is a selective small molecule of a fragment-based clinical candidate active in lung cancer 
and melanoma models. It is the third product derived from Astex‟s Pyramid™ fragment chemistry platform. Information about AT13387 and related 
compounds can be obtained from United States Patent: 7,385,059. 
References: (Berdini V, O'Brien MA, Carr MG, Early TR, Gill AL, Trewartha G, Woolford AJA, Woodhead AJ and Wyatt PG (2006) 3,4-disubstituted 
1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators. United States patent 7,385,059.)330. 
(http://www.astex-therapeutics.com/products/pipeline.php#AT13387) 
CCX915 
CCX915 (ChemoCentryx, Mountain View, California, USA) is an orally available small molecule implicated in damaging inflammation underlying 
multiple sclerosis. It belongs to new class of synthetic compounds that are chemically distinct from all known inhibitors of CCR2. Information about 
MIV-701 and related compounds can be obtained from United States Patent: 7,435,831. 
References: (Chen W, Zhang P, Aggen JB, Dairaghi DJ, Pennell AMK, Sen S and Wright JJK (2005) Bicyclic and bridged nitrogen heterocycles. 
United States patent 7,435,831.) (http://www.chemocentryx.com/) 
(http://www.redorbit.com/news/health/311395/chemocentryx_to_initiate_clinical_studies_of_ccr2_antagonist_ccx915/index.html) 
MIV-701 
MIV-701 (Medivir, Huddinge, Sweden) is a highly active and selective small molecule inhibitor of cathepsin K currently under Phase I/II clinical trial, 
but Medivir has not disclosed any details of MIV-701 yet. 
References: (Mucke HAM, Norman P, Whelan C, Yeates C (2008) Patent alert. Current Opinion in Investigational Drugs 9:552-561). 
(http://www.medivir.se/v3/en/RnD/projects/miv_701.cfm) 
MSX-122 
MSX-122 (Metastatix Inc., Atlanta, Georgia, USA) is an orally bioavailable inhibitor of CXCR4 with potential antineoplastic and antiviral activities. 
Currently it is under Phase I clinical trial. 
References: (Zhang Y, Liang Z and Wu H (2008) MSX-122, an orally available small molecule targeting CXCR4, inhibits primary tumor growth in an 
orthotopic mouse model of lung cancer and improves the effect of paclitaxel. AACR Annual Meeting 2009 Proceedings 49)331. 
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(http://clinicaltrials.gov/ct2/show/NCT00591682) 
STA-9090 
STA-9090 (Synta Pharmaceuticals, Lexington, Massachusetts, USA) is a new chemical entity which contains a triazolone core structure synthesized 
through a 3-step cGMP process. It is a novel triazolone compound with a unique chemical structure that is distinct from 17-AAG (geldanamycin) and 
other ancamycin derivatives. STA-9090 is developed for treating a variety of cancers. 
References:332 (http://www.syntapharma.com/PrdHsp90.aspx) 
TTP889 
TTP889 (TransTech Pharma Inc., High Point, North Carolina, USA) is an orally available, small molecule that inhibits up to 90% of FIXa activity at 
therapeutic doses, using a clinical model of extended prophylaxis in hip fracture surgery. Information about TTP889 and related compounds can be 
obtained from United States Patent: 7,122,580. 
References: (Mjalli AMM, Andrews RC, Guo XC, Christen DP, Gohimmukkula DR, Huang G, Rothlein R, Tyagi S, Yaramasu T and Behme C (2003) 
Aryl and heteroaryl compounds and methods to modulate coagulation. United States patent 7,122,580.) (Rothlein R, Shen JM, Naser N, Gohimukkula 
DR, Caligan TB, Andrews RC, Schmidt AM, Rose EA and Mjalli AMM (2005) TTP889, a novel orally active partial inhibitor of FIXa inhibits clotting 
in two a/v shunt models without prolonging bleeding times. Blood 106:A1886.)333-335 (http://www.ttpharma.com/pipeline_thrombosis.html) 
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Chapter 6 Identification of promising therapeutic targets 
from influenza genomes 
Influenza viruses are among the most common causes of respiratory infections in humans 
and are associated with high morbidity & mortality
336,337
. Seasonal influenza affects 10% 
of the population annually leading to 44 deaths per 10M population
338
. Antigenically 
novel influenza strains occasionally emerge into pandemics
339
 that may potentially infect 
large populations at high death rates
340
. The widely spreading swine influenza A H1N1 
may potentially develop into such a pandemics
341
. The highly pathogenic avian influenza 
A H5N1 has caused widespread death in poultry, substantial economic loss to farmers, 





 are key lines of defense against novel pandemics as 
well as being used as general treatment options because the well-matched protective 
vaccines would not be available for at least several months
337
. The usefulness of these 
drugs may be severely reduced by the emergence of drug-resistance strains. So far, 98% 
of influenza A H3N2 and some percentage of influenza A H1N1 strains are adamantine-
resistant
345





 are tamiflu-resistant. Tamiflu-resistant strains have also been found in 
influenza A H5N1 and B strains
348
. The use of alternative anti-influenza drugs may be 
limited by additional problems such as short supply and side effects
337
. Moreover, 
existing drugs may not be equally effective again all influenza types (e.g. tamiflu is 
significantly less effective against influenza B)
349
. Therefore, in addition to the tests of 
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several new anti-influenza agents in clinical trials
343,344,350
, there is an urgent need for 
discovering new drugs for more complete coverage of potentially harmful drug-resistant 
strains and different influenza types and subtypes at a time of serious concern about the 
possible emergence of influenza pandemics
337
. 
Intensive efforts have been directed at the development of anti-influenza agents against 
several successful and research targets in influenza genomes
343,344,350,351
. Successful 
targets are targeted by at least one marketed drug. Research targets are targeted only by 
agents not yet approved. Drug development is costly, time consuming (8~20 years)
227
 and 
low in productivity particularly against novel targets
272
. Limited resources may better be 
focused on anti-influenza agents against promising targets (targets that likely lead to 
successful drugs) so as to achieve highest possible development speed and success rates. 
Identification of promising targets in the influenza genomes is thus an important first step 
for facilitating more efficient and faster discovery of new anti-influenza agents. 
Recent studies have shown that promising targets tend to show similar genetic, structural, 
physicochemical and system profiles as successful targets
227
. Comparative investigation 
of these profiles with respect to successful targets can thus be used for identifying 
promising targets, which has been validated by the identification of the targets of positive 
phase III results
240
. In this work, this approach was used to identify promising targets 
from the complete genomes of influenza A H1N1 (Swine, Mexico/InDRE4487/2009), 
H5N1 (Avian, Guangdong/1/96), H2N2 (Korea/426/1968), H3N2 (New York/392/2004), 
and H9N2 (Hong Kong/1073/99), influenza B (Lee/40), and influenza C (Ann Arbor/1/50) 
in the NCBI Entrez Genome database and NCBI Influenza Virus Resource
352
. 
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6.1 Summary on methods applied for target identification 
Each encoded protein in an influenza genome was assessed by four methods for probing 
its sequence, structural, physicochemical and systems profiles with respect those of 
successful targets. Method A measures drug-binding domain sequence similarity
226,227
 
against those of 168 successful targets with identifiable drug-binding domains. Method B 
studies drug-binding domain structural and energetic features
275
 against those of 129 
successful targets with available structures. Method C predicts druggable proteins from 
sequence-derived physicochemical characteristics by a machine learning model trained 
by 348 successful targets
144,227,241
. Method D evaluates whether the systems-level 
druggability rules
227
 are satisfied. A protein is identified as promising if it is selected by 
at least 3 methods
240
, marginally promising if it is selected by 2 methods, and 
unpromising if it is selected by less than 2 methods. The identified promising, marginally 
promising, and unpromising targets were evaluated by drug discovery productivity levels 







 anti-influenza agents and the numbers of US 
patents that (http://patft.uspto.gov/) against each target, which was intended to determine 
if there is a clear trend of higher productivity levels for the identified promising targets 
with respect to those of the identified marginally promising and un-promising targets and 
to whether the identified unpromising targets show low productivity levels. Moreover, 
the reported structural studies were also analyzed to determine if these studies show 
druggable features for the identified promising and marginally promising targets and 
additional undesired properties for the marginally promising targets. 
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6.2 Target identification results from influenza genomes 
Table 06-1 shows the target identification results for all encoded proteins in the genomes 
of the 5 subtypes of influenza A (8 proteins in the swine N1H1 and 9 proteins in the other 
4 subtypes), influenza B (9 proteins) and influenza C (7 proteins). Also included in Table 







 agents targeting each protein and the number of US 
patents (http://patft.uspto.gov/) that target each protein for drug development. Three 
proteins were identified as promising targets, which are neuraminidase of influenza A 
and B, polymerase of influenza A, B and C, and matrix protein 2 of influenza A. 
Moreover, two proteins were identified as marginally promising targets by method B and 
D, which are haemagglutinin of influenza A and B, and hemagglutinin-esterase of 
influenza C. 
These results are highly consistent with the current drug discovery productivity levels. 
For the three identified promising targets, neuraminidase and polymerase are the targets 
of 2 and 0 FDA approved
343







literature-described investigative drugs, and in 36 and 30 US patents for the treatment of 
both influenza A and B infections respectively. Matrix protein 2 is the target of 2 FDA 
approved
343
 and 10 literature-described investigative drugs
344,357
, and in 9 US patents for 
the treatment of influenza A infection. In contrast, there is no approved or clinical trial 
drug for the two identified marginally promising targets. One target, hemagglutinin, is 
targeted by 5 literature-described investigative agents
353,358
 and in 3 US patents. We 
found no literature-described investigative agent or US patent for the second target, 
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hemagglutinin-esterase, probably because this influenza C protein has not been 
sufficiently focused in drug development as flu induced by influenza C is rare compared 
to those of influenza A and B
359
. For the six identified non-promising targets, we found 
no literature-described agent or US patent for all but two of them. One protein, 
nonstructural protein 1, is a target of one literature-described investigative agent
354
. 
Another protein, nucleocapsid protein, is the target of drug development in two US 
patents (US Patent 6,242,478 and 6,316,190). 
It is noted that a hemagglutinin inhibitor, arbidol, has been clinically used in Russia
360
 
and tested in humans in China
361
. This agent has been reported to be effective in 
inhibiting the replication of all influenza A and B in in vitro, in vivo and clinical trials in 
Russia
360,361
. But drug application to FDA has not been approved partly because an 
independent test appears to show that arbidol is effective only at a concentration 
approaching 50% cytotoxic dosage with an estimated selectivity index (SI) of 4, which is 
substantially lower than the minimum safety SI value of 10 (http://arbidol.org/sidwell/). 
We found no report about clinical trial of arbidol in US and Europe. Therefore, 
hemagglutinin is conservatively regarded as a research target with no drug approved by 
FDA or in clinical trial. 
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6.3 Discussion on target identification results 
For a protein to be identified as a promising target, apart from its disease roles and 
systems profiles, its drug-binding site must have certain structural and physicochemical 
features that accommodate the selective binding of drug-like molecules and the 
subsequent modulation of the activities of the protein
227
, and some of these druggable 
features may be similarly and partially reflected from the sequence, structural, and 
physicochemical profiles of other validated targets
240
. For the identified promising targets, 
some of the druggable features have already been revealed from the reported structural 
investigations of these proteins. For the identified marginally promising targets, some 
druggable and undesirable features at their drug-binding sites have also been reported. 
Neuraminidase of influenza A and B was identified as a promising target by all four 
methods. This protein plays critical roles in viral life cycles by facilitating virion progeny 
release and general mobility of the virus in the respiratory
362
. Its active site consists of a 
number of distinct adjoining pockets that are lined by eight highly conserved amino-acid 
residues making direct contact with different inhibitors, and the architecture of the active 
site is further stabilized by ten amino-acid residues invariant in all influenza strains 
within the vicinity
363
. Neuraminidases in different influenza types or subtypes may show 
structurally distinct features near the active sites. For instance, in some subtypes of 
influenza A, there is an additional cavity adjacent to the active sites that closes upon 
ligand binding, and this additional cavity may be explored for developing new anti-
influenza drugs
364
. Structural elucidation of drug-resistant mutants has found an altered 
hydrophobic pocket in the active site that allows effective inhibition of alternative 
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drugs
365
. Molecular dynamics simulation has suggested flexible dynamic features at 
multiple sites that allow the access and binding of drugs
366
. These features make 
neuraminidase a highly attractive target for drug development
362
. 
Polymerase of all influenza types was identified as a promising target by three methods 
(A, B, and D). This protein is responsible for the replication and transcription of the eight 
separate segments of the viral RNA genome in the nuclei of infected cells, and all of its 
three subunits PB1, PB2 and PA are involved in protein activities
367
. PB1 carries a 
polymerase active site
367
, PB2 includes a capped-RNA recognition domain
367
, and PA 
contains an endonuclease active site
368
 and is involved in the assembly of the functional 
complex
367







 are highly conserved in all influenza viruses. Polymerases of different 
influenza types are high in sequence identify (50%~63%) and similarity (E-value < 10
-
100
). Therefore, the 3D structures of the influenza B and C proteins, which are unavailable, 
can be generated from those of influenza A protein by using homology modeling. The C-
terminal RNA-binding domain of PB2 has a unique phi-shaped structure with a highly 
basic groove along the loop
369
. The cap-binding domain of PB2 has a previously 
unknown fold and the ligand binding mode is similar to but distinct from other cap 
binding proteins
370
. The endonuclease domain of PA has a structural core closely 
resembling resolvases and type II restriction endonucleases
368,371
. The carboxy-terminal 
domain of PA forms a novel fold with a deep and highly hydrophobic groove into which 
the amino-terminal residues of PB1 can fit
367
. Based on these observed structural features, 
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Matrix protein 2 of all influenza types (named M2, BM2, and CM2 channel for influenza 
A, B, and C respectively) was identified as a promising target for influenza A H1N1, 
H5N1, and H2N2 by four methods, for influenza A H3N2 and H9N2 by three methods 
(A, C and D), but as a non-promising target for influenza B and C. This protein is a pH-
activated proton channel mediating acidification of the interior of viral particles 
entrapped in endosomes
372
. Structural study of M2 has shown druggable features. In the 
closed state, four tightly packed transmembrane helices define a narrow channel, in 
which a 'tryptophan gate' is locked by intermolecular interactions with aspartic acid. A 
carboxy-terminal, an amphipathic helix oriented nearly perpendicularly to the 
transmembrane helix, forms an inward-facing base
373
. Lowering the pH destabilizes the 
transmembrane helical packing and unlocks the gate. There are four equivalent drug-
binding sites near the gate on the lipid-facing side of the channel and drug binding 
stabilizes the closed conformation of the pore
373
. Drug-resistance mutations may counter 
the effect of drug binding by either increasing the hydrophilicity of the pore or weakening 
helix-helix packing, thus facilitating channel opening
372,373
. BM2 contains a substantially 
higher number of polar residues in the pore than M2, which is a probable reason for the 
insensitivity of BM2 to the known M2 inhibitors such as amantadine and which has led to 
a suggestion to seek more polar compounds as effective inhibitors
374
. The highly polar 
nature of the pore of BM2 was likely recognized as non-druggable by the sequence, 
structure, and physicochemical methods, leading to the identification of BM2 as a non-
promising target. 
Hemagglutinin of influenza A and B was identified as a marginally promising target by 
method B and D. It is a surface glycoprotein responsible for receptor binding and the 
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fusion of virus and cell membranes
353
. Some inhibitors bind in a hydrophobic pocket 
formed at an interface between hemagglutinin monomers to stabilize the neutral pH 
structure through inter-subunit and intra-subunit interactions that presumably inhibit the 
conformational rearrangements required for membrane fusion
353
. The drug-binding site 
has good structural features but appears to be highly hydrophobic. Thus, it has been 
suggested that the development of effective inhibitors with sufficient potency requires an 
improvement of hydrophobic interactions and the creation of additional polar interactions 
towards the membrane distal region of the site
353
. The highly hydrophobic nature at the 
binding-site was likely recognized as non-druggable by the sequence and 
physicochemical methods, leading to the identification of this protein as a non-promising 
target. 
Hemagglutinin-esterase of influenza C was also identified as a marginally promising 
target by method B and D. This influenza C protein plays the dual roles of both 
hemagglutinin and neuraminidase
375
. Alignment of the amino-acid sequences of 
hemagglutinin-esterase and hemagglutinin based on their 3D structures has shown that, in 
spite of the low 12% sequence identity, both the overall structure and the detailed folds of 
individual segments of the two proteins are quite similar
375
. Specifically, the receptor-
binding domain is structurally similar to the sialic acid-binding domain of 
haemagglutinin. The esterase domain is structurally similar to the esterase from 
Streptomyces scabies and a brain acetylhydrolase. The receptor domain is inserted into a 
surface loop of the esterase domain and the esterase domain is inserted into a surface loop 
of the stem. The stem domain is similar to that of haemagglutinin, except that the triple-
stranded alpha-helical bundle diverges at both of its ends, and its amino terminus is 
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partially exposed. Moreover, ligand binding has been found to be a dynamic process that 
involves conformational rearrangement at the esterase active site
376
. The high structural 
similarity to haemagglutinin and the involvement of conformational rearrangement for 
ligand-binding may be possible reasons for the identification of this protein as a 
marginally promising target. 
In conclusion, recent emergence of swine and avian influenza A H1N1 and H5N1 
outbreaks and various drug-resistant influenza strains underscore the urgent need for 
developing new anti-influenza drugs. Drug development is costly and time-consuming. 
Limited resources may better be focused on the development of drugs against promising 
targets. Recent studies have shown that promising targets show genetic, structural, 
physicochemical and systems profiles resembling those of successful targets, which can 
be explored for identifying promising targets. We used this approach to identify 
promising targets from the genomes of influenza A (H1N1, H5N1, H2N2, H3N2, H9N2), 
B and C. The identified promising targets are neuraminidase of influenza A and B, 
polymerase of influenza A, B and C, and matrix protein 2 of influenza A. The identified 
marginally promising targets are haemagglutinin of influenza A and B, and 
hemagglutinin-esterase of influenza C. These are consistent with reported druggable 
structural features for the promising and marginally promising targets and undesired 
properties for the unpromising targets. The promising targets show fair drug discovery 
productivity levels (1~4 FDA approved or clinical trial drug, 7~13 literature-described 
agents, and 9~36 patents for each target) in comparison to the modest levels for the 
marginally promising targets (no FDA approved or clinical trial drug, 5 literature-
described agents and 3 patents for one target) and low levels for the unpromising proteins 
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(only 1 investigative agent for one protein and 2 patents for another protein). These 
results are highly consistent with the current drug discovery productivity levels against 
these proteins. Literature reported drug-binding site structural studies of the identified 
targets also exhibit druggable features or undesirable properties consistent with the 
identification of these proteins as promising or marginally promising targets. These 
suggest that the integrated target analysis method is useful for facilitating the 
identification of promising targets from influenza genomes. This method may be used for 
the identification of promising targets from the genomes of other viruses or viral strains 
for facilitating target discovery and subsequent drug development for the treatment of 
viral infections that are also in urgent need for new drugs. 
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Table 06- 1 Target identification results for all encoded proteins in the genomes of the 5 subtypes of influenza A, B and C* 
Protein 










Literature-described Investigative Agents 









































(Tamiflu ® ) 
Zanamivir 
(Relenza ® ) 





[A, B] 343,350 
A-315675; BCX-1812; BCX-1827; BCX-1898; 
BCX-1923; DANA; FANA; Cyclopentane amide 




















T-705 (Phase II) 
[A, B, C] 343,378 
ANX-201; T-1105; Flutimide; FdG; T-1106; 
Pyrimidinyl acylthiourea; 2,4-dioxo-4-
phenylbutanoic acid; Thiadiazolo[2,3-
a]pyrimidine. [A, B, C] 344,356,379,380 
30 
[A, B, C] 



















(Symmetrel ® ) 
Rimantadine 




isomer 1 & 2; 2-(1-adamantyl) piperidine; 2-(1-
adamantyl) pyrrolidine; 3-(2-adamantyl) 
pyrrolidine; 2-(2-adamantyl) piperidine; 
Spiro[piperidine-2,2’-adamantane]; 
Spiro[cyclopropane-1,2’-adamantan]-2-amine; 
Spiro[pyrrolidine-2,2’-adamantane]. [A] 344,357,381 
9 
[A] 

























Arbidol (Clinically used in Russia, tested in 
China but not in clinical trial in US & western 
Europe up to 2009), TBHQ; BMY-27709; 


























None None None 0 
Nonstructural 






















None None CPSF30 [A] 354,385 0 







































































None None None 0 
Nonstructural 






















None None None 0 























None None None 0 
* Influenza A viruses used here include: H1N1 (Swine, Mexico/InDRE4487/2009), H5N1 (Avian, Guangdong/1/96), H2N2 (Korea/426/1968), H3N2 (New York/392/2004), 
H9N2 (Hong Kong/1073/99), influenza B virus is influenza B (Lee/40) and influenza C virus is influenza C (Ann Arbor/1/50) 
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Chapter 7 Concluding remarks 
This last chapter summarizes the major findings and contributions of this study (Section 
7.1). Limitation of present study and suggestion on possible areas for further studies are 
discussed in Section 7.2. 
7.1 Major findings and contributions 
Although the study described in this thesis has a main focus on the identification of drug 
targets, it is composed of three major findings. In Section 7.1.1, the merits of TTD update 
in facilitating target discovery have been illustrated, then, followed by a discussion on the 
performance of the collective method on target identification in Section 7.1.2. In Section 
7.1.3, the finding on accelerating the development of influenza therapeutics is proposed. 
The contributions for each finding are also discussed in the following sections. 
7.1.1 Merits of TTD in facilitating target discovery 
TTD was a pioneer for providing pharmaceutical information on therapeutic target. After 
progress in the past 8 years on target discovery, TTD still acts as reliable knowledge base 
for established therapeutic target. However, the profile of drugs under clinical developing 
keeps changing in the past decade, and many new drugs have been approved for acting on 
some new targets. Moreover, many drugs in previous TTD did not indicate their primary 
target, and there is no information of drugs in clinical trial provided. TTD 2010 update 
takes these challenges and tries to offer a most comprehensive map of drug targets for the 
modern pharmaceutical era. In this updated version, TTD significantly expanding target 
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data to include 348 successful, 292 clinical trial, and 1,254 research targets, and added 
drug data for 1,514 approved, 1,212 clinical trial and 2,302 experimental drugs linked to 
their primary targets. Other features which add additional credits to TTD 2010 include: (1) 
collection of information of antisense, aptamer and siRNA based drugs; (2) allowance of 
customized target search by disease indications, target biochemical classes, drug mode of 
actions, drug therapeutic classes, and so on; (3) allowance of target search by BLAST; (4) 
allowance of drug search by tanimoto similarity; and (5) user friendly interface and full 
data download. Comprehensive data integrated, primary targets identified, detail clinical 
trial stage for both drugs and targets labeled, and functional features added guarantee this 
version of TTD a reliable, informative, useful, multifunctional and convenient source of 
drug target information. 
Since 2002, TTD has been the primary resource providing comprehensive information on 
drug targets. Its popularity has been reflected by its visit count (near 130,000 times) and 
its citation records (79 times) in Aug 9
th
 2010. In particular, after the update of TTD 2010 
in Jan 2010, we have accumulated near 24,000 visit counts and 4 times of citation, which 
further prove its important role in pharmaceutical research. 
7.1.2 Merits of collective decision made by four in silico systems in target 
identification from clinical trial targets 
In this work, four systems were constructed to facilitate the identification of drug targets, 
which include: (1) statistical classification system established by machine learning; (2) 
homology identification system built by BLAST; (3) drug-binding domain 3-D structural 
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comparison set up by structure fold analysis; and (4) the simple system-level druggability 
rules summarized from established therapeutic target. Statistical analyses have proven the 
reliability and robustness of this collective method. 
The collective predictive performance of the four systems was tested against clinical trial 
and non-clinical trial targets. The best overall performance was produced by combining 
at least three systems. This combination identified 50% of the phase III, 25% of the phase 
II, 10% of the phase I, and 4% of the non-clinical trial targets as promising. Comparing to 
reported drug successful rate, our results of the identified promising clinical trial targets 
are lower than but roughly follow a similar descending trend as the report. The collective 
methods enriched identification rate of phase II & III targets by 4.0~6.0 fold over random 
selection, with the combination of all four methods producing the highest enrichment. On 
the other hand, the 15 identified promising phase III targets include 7 of the 8 targets with 
positive phase III results reported. The only one exception has a positive phase III result 
reported in 2004 and no further news has been released since then. Moreover, a possible 
adverse effects caused by it inhibition has been reported. On the other hand, the difficulty 
in exploring some of the un-promising targets has been reported like MMP and kinases of 
non-tyrosine kinase classes. 
Collective use of multiple in silico methods is capable of identifying high percentages of 
phase III targets including most of the targets of positive III results, and of eliminating 
difficult and un-promising ones. Our study suggests that comparative analysis of multiple 
profiles of successful targets provides useful clues to the identification of promising drug 
targets. 
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7.1.3 Merits of collective decision made by four in silico systems in target 
identification from influenza genome 
The collective prediction method of the four systems was used to identify promising drug 
targets from genomes of influenza A H1N1 (Swine, Mexico/InDRE4487/2009), H5N1 
(Avian, Guangdong/1/96), H2N2 (Korea/426/1968), H3N2 (New York/392/2004), and 
H9N2 (Hong Kong/1073/99), influenza B (Lee/40), and influenza C (Ann Arbor/1/50) in 
the NCBI Entrez Genome database and NCBI Influenza Virus Resource. 3 proteins were 
identified as promising, which are neuraminidase of influenza A and B, polymerase of 
influenza A, B and C, and matrix protein 2 of influenza A. Additionally, 2 proteins were 
identified as marginally promising by two prediction systems, which are haemagglutinin 
of influenza A and B, and hemagglutinin-esterase of influenza C. 
Further study reveals that the promising targets show fair drug discovery productivity 
levels in comparison to the modest levels for the marginally promising targets and low 
levels for the unpromising proteins. These results are highly consistent with the current 
drug discovery productivity levels against these proteins. 
7.2 Limitations and suggestions for future studies 
As a robust classification system, machine learning (especially support vector machine) 
plays a major role in the collective methods used for identifying targets. The performance 
of machine learning methods critically depends on the diversity of protein targets in the 
training dataset and the appropriate representation of these proteins. The dataset used in 
this work are not expected to fully represent all proteins possessing and not possessing a 
 Chapter 7 Concluding remarks  200 
specific property. This is particularly true for proteins not possessing a specific property 
given the vast protein space of several millions of proteins in current protein databases. 
Hence, inadequate representation of proteins from vast protein space to a certain extent 
will affect the performance of the models developed. 
In the construction of the in silico machine learning system, only 320 successful protein 
targets have been used for capturing common features embedded in these targets. Based 
on previous analysis 320 only consist of a very small portion of the whole protein space, 
which makes identification of drug target biased to the non-target data by using diversity-
dependent machine learning methods. Besides the including of more target data, there are 
many in silico ways to increase the diversity, which generally include direct variation on 
protein sequences and indirect variation on protein vectors. Therefore, it is necessary for 
us to try these methods for increasing data diversity, which may increase the prediction 
performance. 
According to Chapter 2 Section 2.3.1.2, only three groups of descriptors were combined 
for generating protein vector, and they are (1) amino acid composition and composition, 
transition and distribution; (2) normalized Moreau-Broto autocorrelation; and (3) pseudo 
amino acid composition. However, there are several other groups of descriptors which are 
popular in representing protein, like: (4) Geary autocorrelation; (5) Moran autocorrelation; 
(6) sequence order, and so on. The reason why we choose the first three groups is because 
they have demonstrated the best performance in predicting protein functional families
386
, 
but this may not be true for therapeutic targets. Moreover, the physicochemical properties 
used in this study are hydrophobicity, polarity, polarizibility, charge, secondary structures, 
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surface tension, and normalized Van der Waals volumes, but we have not sought whether 
there is other property which can be good complementary to them. On the other hand, as 
shown in Table 02-2, all physicochemical properties are classified into only three groups. 
Take the property hydrophobicity as an example, amino acids RKEDQN are grouped in 
polar, GASTPHY in neutral, and CVLUMFW in hydrophobic, but the difference among 
amino acid inside each group has been ignored. Thus, different combination of descriptor 
groups, increasing number of physicochemical properties, and more detail classification 
of amino acids by properties will help to validate the prediction system, and may further 
enhance our model. 
One of the most distinguished features of current TTD is the availability of clinical trial 
information for both drugs and targets. However, the clinical trial status keeps changing 
for our modern pharmacology is a dynamically moving process, the clinical trial status in 
TTD will not change only when manually update is applied onto the original TTD data. 
This kind of manual update is expected to be delayed for even several months after the 
original information is released, which makes TTD data not up-to-date. A solution to this 
may be to integrate automatic information system which helps TTD to search latest data 
update from reliable sources, like reputable journals, famous pharmaceutical companies 
and so on, then latest information can be automatically updated. 
As multi-functional tools in pharmaceutical research, TTD is ambitious for integrating 
more functions. For instance, we can probably extend TTD by add pharmacophore model 
to predict antagonists/agonists for certain target. Similarly, Docking and QSAR model 
can also be added as extensions of TTD functions. 
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